

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 March 2006 (16.03.2006)

PCT

(10) International Publication Number
WO 2006/028290 A1

(51) International Patent Classification:

C07D 413/04 (2006.01) A61K 31/5377 (2006.01)
C07D 413/14 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/JP2005/017080

(22) International Filing Date:

9 September 2005 (09.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2004-296926 9 September 2004 (09.09.2004) JP

(71) Applicants (for all designated States except US): **MITSUBISHI PHARMA CORPORATION** [JP/JP]; 6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, 5410046 (JP). **SANOFI-AVENTIS** [FR/FR]; 174, Avenue de France, Paris, F-75013 (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WATANABE, Kazutoshi** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **UEHARA, Fumiaki** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **HIKI, Shinsuke** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **KOHARA, Toshiyuki** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome,

Chuo-ku, Tokyo, 1038405 (JP). **FUKUNAGA, Kenji** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **YOKOSHIMA, Satoshi** [JP/JP]; I-201, Casa Hiko, 3-12-3, Yanaka, Adachi-ku, Tokyo, 1200006 (JP).

(74) Agent: **SIKS & Co.**; 8th Floor, Kyobashi-Nisshoku Bldg., 8-7, Kyobashi 1-chome, Chuo-ku, Tokyo, 1040031 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-MORPHOLINO-4-PYRIMIDONE COMPOUND



(I)

(57) Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; ¹R represents a C₁-C₁₂ alkyl; ²R represents a hydrogen atom, or the like; R' represents a C₁-C₆ alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C₁-C₆ alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

WO 2006/028290 A1

DESCRIPTION

2-MORPHOLINO-4-PYRIMIDONE COMPOUND

Technical Field

The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases mainly caused by abnormal activity of tau protein kinase 1, such as neurodegenerative diseases (e.g. Alzheimer disease).

Background Art

Alzheimer disease is progressive senile dementia, in which marked cerebral cortical atrophy is observed due to degeneration of nerve cells and decrease of nerve cell number. Pathologically, numerous senile plaques and neurofibrillary tangles are observed in brain. The number of patients has been increased with the increment of aged population, and the disease arises a serious social problem. Although various theories have been proposed, a cause of the disease has not yet been elucidated. Early resolution of the cause has been desired.

It has been known that the degree of appearance of two characteristic pathological changes of Alzheimer disease well correlates to the degree of intellectual dysfunction. Therefore, researches have been conducted from early 1980's to reveal the cause of the disease through molecular level investigations of components of the two pathological changes. Senile plaques accumulate extracellularly, and β amyloid protein has been elucidated as their main component (abbreviated as "A β " hereinafter in the specification: Biochem. Biophys. Res. Commun., 120, 885 (1984); EMBO J., 4, 2757 (1985); Proc. Natl. Acad. Sci. USA, 82, 4245 (1985)). In the other pathological change, i.e., the neurofibrillary tangles, a double-helical filamentous substance called paired helical filament (abbreviated as "PHF" hereinafter in the specification) accumulate intracellularly, and tau protein, which is a kind of microtubule-associated

protein specific for brain, has been revealed as its main component (Proc. Natl. Acad. Sci. USA, 85, 4506 (1988); Neuron, 1, 827 (1988)).

Furthermore, on the basis of genetic investigations, presenilins 1 and 2 were found as causative genes of familial Alzheimer disease (Nature, 375, 754 (1995); Science, 269, 973 (1995); Nature, 376, 775 (1995)), and it has been revealed that presence of mutants of presenilins 1 and 2 promotes the secretion of A β (Neuron, 17, 1005 (1996); Proc. Natl. Acad. Sci. USA, 94, 2025 (1997)). From these results, it is considered that, in Alzheimer disease, A β abnormally accumulates and agglomerates due to a certain reason, which engages with the formation of PHF to cause death of nerve cells. It is also expected that extracellular outflow of glutamic acid and activation of glutamate receptor responding to the outflow may possibly be important factors in an early process of the nerve cell death caused by ischemic cerebrovascular accidents.

It has been reported that kainic acid treatment that stimulates the AMPA receptor, one of glutamate receptor, increases mRNA of the amyloid precursor protein (abbreviated as "APP" hereinafter in the specification) as a precursor of A β (Society for Neuroscience Abstracts, 17, 1445 (1991)), and also promotes metabolism of APP (The Journal of Neuroscience, 10, 2400 (1990)). Therefore, it has been strongly suggested that the accumulation of A β is involved in cellular death due to ischemic cerebrovascular disorders. Other diseases in which abnormal accumulation and agglomeration of A β are observed include, for example, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, Lewy body disease and the like. Furthermore, as diseases showing neurofibrillary tangles due to the PHF accumulation, examples include progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease and the like.

The tau protein is generally composed of a group of related proteins that forms several bands at molecular weights of 48-65 kDa in SDS-polyacrylamide gel electrophoresis, and it promotes the formation of microtubules. It has been verified

that tau protein incorporated in the PHF in the brain suffering from Alzheimer disease is abnormally phosphorylated compared with usual tau protein (J. Biochem., 99, 1807 (1986); Proc. Natl. Acad. Sci. USA, 83, 4913 (1986)). An enzyme catalyzing the abnormal phosphorylation has been isolated. The protein was named as tau protein kinase 1 (abbreviated as "TPK1" hereinafter in the specification), and its physicochemical properties have been elucidated (J. Biol. Chem., 267, 10897 (1992)). Moreover, cDNA of rat TPK1 was cloned from a rat cerebral cortex cDNA library based on a partial amino acid sequence of TPK1, and its nucleotide sequence was determined and an amino acid sequence was deduced. As a result, it has been revealed that the primary structure of the rat TPK1 corresponds to that of the enzyme known as rat GSK-3 β (glycogen synthase kinase 3 β , FEBS Lett., 325, 167 (1993)).

It has been reported that A β , the main component of senile plaques, is neurotoxic (Science, 250, 279 (1990)). However, various theories have been proposed as for the reason why A β causes the cell death, and any authentic theory has not yet been established. Takashima et al. observed that the cell death was caused by A β treatment of fetal rat hippocampus primary culture system, and then found that the TPK1 activity was increased by A β treatment and the cell death by A β was inhibited by antisense of TPK1 (Proc. Natl. Acad. Sci. USA, 90, 7789 (1993); EP616032).

In view of the foregoing, compounds which inhibit the TPK1 activity may possibly suppress the neurotoxicity of A β and the formation of PHF and inhibit the nerve cell death in the Alzheimer disease, thereby cease or defer the progress of the disease. The compounds may also be possibly used as a medicament for therapeutic treatment of ischemic cerebrovascular disorder, Down syndrome, cerebral amyloid angiopathy, cerebral bleeding due to Lewy body disease and the like by suppressing the cytotoxicity of A β . Furthermore, the compounds may possibly be used as a medicament for therapeutic treatment of neurodegenerative diseases such as progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration and

frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, as well as other diseases such as non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors.

As structurally similar compounds to the compounds of the present invention represented by formula (I) described later, the compounds disclosed in the International Publication Nos. WO01/70729, WO03/037888 and WO03/027080 are known. However, these compounds are not enough as medicament in the pharmacokinetics and so on.


Disclosure of the Invention

An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases such as Alzheimer disease. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables radical prevention and/or treatment of the neurodegenerative diseases such as Alzheimer disease by inhibiting the TPK1 activity to suppress the neurotoxicity of $A\beta$ and the formation of the PHF and by inhibiting the death of nerve cells.

In order to achieve the foregoing object, the inventors of the present invention conducted screenings of various compounds having inhibitory activity against the phosphorylation of TPK1. As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases. The present invention was achieved on the basis of these findings.

The present invention thus provides;

1. A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof;



wherein each symbol is as defined below.

X represents CH or N;

R¹ represents a C₁-C₁₂ alkyl which may be substituted;

R² represents a hydrogen atom, a halogen or a C₁-C₆ alkyl which may be substituted;

R' represents a C₁-C₆ alkyl which may be substituted,

a C₂-C₆ alkenyl which may be substituted,

a C₂-C₆ alkynyl which may be substituted,

a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

a heterocyclic group which may be substituted,

a C₁-C₆ alkoxy which may be substituted,

a C₃-C₆ alkenyloxy which may be substituted,

a C₃-C₆ alkynyloxy which may be substituted,

a C₃-C₇ cycloalkyloxy which may be substituted,

a C₃-C₇ cycloalkenyloxy which may be substituted,

a hydroxyl,

an oxo group,

a halogen,

a nitro, or



a cyano;

q represents 0 or an integer of 1 to 3;


Y represents a C₁-C₆ alkyl which may be substituted,

a C₂-C₆ alkenyl which may be substituted,
a C₂-C₆ alkynyl which may be substituted,
a C₃-C₇ cycloalkyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
a C₁-C₆ alkoxy which may be substituted,
a C₃-C₆ alkenyloxy which may be substituted,
a C₃-C₆ alkynyloxy which may be substituted,
a C₃-C₇ cycloalkyloxy which may be substituted,
a C₃-C₇ cycloalkenyloxy which may be substituted,
a halogen,
a nitro,
a cyano,
an amino,
a C₁-C₆ alkylamino which may be substituted,
a C₃-C₆ alkenylamino which may be substituted,
a C₃-C₆ alkynylamino which may be substituted,
a N,N-di-C₁-C₆ alkylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₆ alkenylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₆ alkynylamino which may be substituted,
a N,N-di-C₃-C₆ alkenylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylamino which may be substituted,
or
a N,N-di-C₃-C₆ alkynylamino which may be substituted,
p represents 0 or an integer of 1 to 4;
R represents
a carboxyl group,
a 2,3-dihydroindolyl,
a perhydroindolyl,
a perhydroisindolyl,

a perhydroquinolinyl,
 a perhydroisoquinolinyl, or
 a formula (1) or (2);



In the formula (1), R³ represents a hydrogen atom,
 a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted, or
 a heterocyclic group which may be substituted;
 R⁴ represents an adamantyl,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted,
 a heterocyclic group which may be substituted, or
 a formula (3)



wherein m represents 0 or an integer of 1 to 4,
 Z¹ represents a carbonyl group, a thiocarbonyl group, or a sulfonyl group,
 R²⁰ and R²¹ are the same or different and each represents a hydrogen atom or a C₁-C₆
 alkyl;
 R⁷ represents a C₁-C₆ alkyl which may be substituted,

a C₃-C₆ alkenyl which may be substituted,
a C₃-C₆ alkynyl which may be substituted,
a C₃-C₇ cycloalkyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
a C₆-C₁₀ aryl which may be substituted,
a heterocyclic group which may be substituted,
a C₁-C₆ alkoxy which may be substituted,
a C₃-C₆ alkenyloxy which may be substituted,
a C₃-C₆ alkynyloxy which may be substituted,
a C₃-C₇ cycloalkyloxy which may be substituted,
a C₃-C₇ cycloalkenyloxy which may be substituted,
a C₆-C₁₀ aryloxy which may be substituted,
a heterocycle-oxy which may be substituted, or
a group represented by -NRa Rb;

wherein Ra and Rb are the same or different and each represents a hydrogen atom,

a C₁-C₆ alkyl which may be substituted,
a C₃-C₆ alkenyl which may be substituted,
a C₃-C₆ alkynyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
a C₃-C₇ cycloalkyl which may be substituted,
a C₆-C₁₀ aryl which may be substituted,
a heterocyclic group which may be substituted,
a C₁-C₆ alkylcarbonyl which may be substituted,
a C₂-C₆ alkenylcarbonyl which may be substituted,
a C₂-C₆ alkynylcarbonyl which may be substituted,
a C₃-C₇ cycloalkylcarbonyl which may be substituted,
a C₃-C₇ cycloalkenylcarbonyl which may be substituted,
a C₆-C₁₀ arylcarbonyl which may be substituted,
a heterocycle-carbonyl which may be substituted,

- a C₁-C₆ alkoxy carbonyl which may be substituted,
- a C₃-C₆ alkenyloxy carbonyl which may be substituted,
- a C₃-C₆ alkynyloxy carbonyl which may be substituted,
- a C₃-C₇ cycloalkyloxy carbonyl which may be substituted,
- a C₃-C₇ cycloalkenyloxy carbonyl which may be substituted,
- a C₆-C₁₀ aryloxy carbonyl which may be substituted,
- a C₁-C₆ alkylsulfonyl which may be substituted,
- a C₂-C₆ alkenylsulfonyl which may be substituted,
- a C₂-C₆ alkynylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
- a C₆-C₁₀ arylsulfonyl which may be substituted,
- a heterocycle-sulfonyl which may be substituted,
- an aminocarbonyl,
- a C₁-C₆ alkylaminocarbonyl which may be substituted,
- a C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,


a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted, or
 a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
 a N,N-di-heterocycle-aminocarbonyl which may be substituted;

or Ra and Rb bind to form a nitrogen containing heterocycle which may contain sulfur atom or oxygen atom together with the adjacent nitrogen atom, or R⁷ and R⁸ may bind to form a cycle, and further Ra or Rb may binds R⁸ to form a cycle together with the adjacent nitrogen atom, or R⁷ may form a cycle together with Y;

In the formula (2), Z represents a carbonyl group, a sulfonyl group, or a group represented by -O-W wherein W represents a C₁-C₆ alkylene group which may be substituted;

R⁵ and R⁶ are the same or different and each represents a hydrogen atom,
 a C₁-C₆ alkyl which may be substituted,

a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted, or
 a heterocyclic group which may be substituted;
 or R³ and R⁴, or R⁵ and R⁶ may combine with the adjacent nitrogen atom to form a cyclic amino group represented by the formula (4):




wherein R¹⁰ represents a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted,
 a heterocyclic group which may be substituted,
 a C₁-C₆ alkoxy which may be substituted,
 a C₃-C₆ alkenyloxy which may be substituted,
 a C₃-C₆ alkynyloxy which may be substituted,
 a C₃-C₇ cycloalkyloxy which may be substituted,
 a C₃-C₇ cycloalkenyloxy which may be substituted,
 a C₆-C₁₀ aryloxy which may be substituted,
 a hydroxyl,
 an oxo group,
 a halogen,
 a nitro, or
 a cyano;

r represents 0 or an integer of 1 to n+2;

n represents an integer of 1 to 4;

with the proviso that when n represents 2, then r is not 0;

Q represents a bond, an oxygen atom, sulfur atom or a formula:



wherein R²⁴ represents a hydrogen atom,

a C₁-C₆ alkyl which may be substituted,

a C₃-C₆ alkenyl which may be substituted,

a C₃-C₆ alkynyl which may be substituted,

a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

an C₆-C₁₀ aryl which may be substituted,

a heterocyclic group which may be substituted,

a C₁-C₆ alkylcarbonyl which may be substituted,

a C₂-C₆ alkenylcarbonyl which may be substituted,

a C₂-C₆ alkynylcarbonyl which may be substituted,

a C₃-C₇ cycloalkylcarbonyl which may be substituted,

a C₃-C₇ cycloalkenylcarbonyl which may be substituted,

a C₆-C₁₀ arylcarbonyl which may be substituted,

a heterocycle-carbonyl which may be substituted,

a C₁-C₆ alkoxy carbonyl which may be substituted,

a C₃-C₆ alkenyloxycarbonyl which may be substituted,

a C₃-C₆ alkynyloxycarbonyl which may be substituted,

a C₃-C₇ cycloalkyloxycarbonyl which may be substituted,

a C₃-C₇ cycloalkenyloxycarbonyl which may be substituted,


a C₆-C₁₀ aryloxycarbonyl which may be substituted,

a C₁-C₆ alkylsulfonyl which may be substituted,

a C₂-C₆ alkenylsulfonyl which may be substituted,

- a C₂-C₆ alkynylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
- a C₆-C₁₀ arylsulfonyl which may be substituted,
- an aminocarbonyl,
- a C₁-C₆ alkylaminocarbonyl which may be substituted,
- a C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,

a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
 a N,N-di-heterocycle-aminocarbonyl which may be substituted;
 or Q further represents a formula:



wherein R³⁰ and R³¹ are the same or different and each represents a hydrogen atom,
 a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted,
 a heterocyclic group which may be substituted,
 a C₁-C₆ alkyloxycarbonyl which may be substituted,
 a C₃-C₆ alkenyloxycarbonyl which may be substituted,
 a C₃-C₆ alkynyloxycarbonyl which may be substituted,
 a C₃-C₇ cycloalkyloxycarbonyl which may be substituted,
 a C₃-C₇ cycloalkenyloxycarbonyl which may be substituted,
 a C₆-C₁₀ aryloxycarbonyl which may be substituted,

- a C₁-C₆ alkoxy which may be substituted,
- a C₃-C₆ alkenyloxy which may be substituted,
- a C₃-C₆ alkynyloxy which may be substituted,
- a C₃-C₇ cycloalkyloxy which may be substituted,
- a C₃-C₇ cycloalkenyloxy which may be substituted,
- a C₆-C₁₀ aryloxy which may be substituted,
- a heterocycl-oxy which may be substituted,
- an amino,
- a C₁-C₆ alkylamino which may be substituted,
- a C₃-C₆ alkenylamino which may be substituted,
- a C₃-C₆ alkynylamino which may be substituted,
- a C₃-C₇ cycloalkylamino which may be substituted,
- a C₃-C₇ cycloalkenylamino which may be substituted,
- an C₆-C₁₀ arylamino which may be substituted,
- a heterocycle-amino which may be substituted,
- a N,N-di-C₁-C₆ alkylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₆ alkenylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₆ alkynylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylamino which may be substituted,
- a N-C₁-C₆ alkyl-N-heterocycle-amino which may be substituted,
- a N,N-di-C₃-C₆ alkenylamino which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylamino which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylamino which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylamino which may be substituted,
- a N-C₃-C₆ alkenyl-N-heterocycle-amino which may be substituted,
- a N,N-di-C₃-C₆ alkynylamino which may be substituted,

- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylamino which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylamino which may be substituted,
- a N-C₃-C₆ alkynyl-N-heterocycle-amino which may be substituted,
- a N,N-di-C₃-C₇ cycloalkylamino which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylamino which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-heterocycle-amino which may be substituted,
- a N,N-di-C₃-C₇ cycloalkenylamino which may be substituted,
- a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylamino which may be substituted,
- a N-C₃-C₇ cycloalkenyl-N-heterocycle-amino which may be substituted,
- a N,N-di-C₆-C₁₀ arylamino which may be substituted,
- a N-C₆-C₁₀ aryl-N-heterocycle-amino which may be substituted,
- a N,N-diheterocycle-amino which may be substituted,
- a C₁-C₆ alkylcarbonyl which may be substituted,
- a C₂-C₆ alkenylcarbonyl which may be substituted,
- a C₂-C₆ alkynylcarbonyl which may be substituted,
- a C₃-C₇ cycloalkylcarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylcarbonyl which may be substituted,
- a C₆-C₁₀ arylcarbonyl which may be substituted,
- a heterocycle-carbonyl which may be substituted,
- a C₁-C₆ alkylsulfonyl which may be substituted,
- a C₂-C₆ alkenylsulfonyl which may be substituted,
- a C₂-C₆ alkynylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
- a C₆-C₁₀ arylsulfonyl which may be substituted,
- an aminocarbonyl,
- a C₁-C₆ alkylaminocarbonyl which may be substituted,

- a C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,

a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
a N,N-di-heterocycle-aminocarbonyl which may be substituted.

2. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R² is a hydrogen atom or a halogen.

3. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R² is a hydrogen atom.

4. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R¹ is methyl group.

5. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein q is 0.

6. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein Y is a C₁-C₆ alkyl which may be substituted, a C₁-C₆ alkoxy which may be substituted, a halogen, a nitro, a cyano, an amino, a C₁-C₆ alkylamino which may be substituted or a N,N-di-C₁-C₆ alkylamino which may be substituted.

7. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R represents a formula (1).

8. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R represents a formula (2).

9. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 7, wherein R⁴ represents a formula (3).

10. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to the above 1, wherein R¹ is methyl group, R² is hydrogen atom, and p is 0.

11. A compound according to claim 1 selected from the group consisting of:

2-(2-(4-((4-Pyrrolidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-((4-Piperidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-(N-Cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-((3-Pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-(3-N-acetyl-N-methylaminopyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

2-{2-[4-(3-Hydroxy-azetidin-1-yl)phenyl]morpholin-4-yl}-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

N-(4-(4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,

N-(4-(4-(1,6-Dihydro-1-methyl-6-oxo-4,4'-bipyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,

2-(2-(4-(2-Pyridylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-Tetrahydrofuran-3-ylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-(N-Tetrahydrofuran-3-yl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

N-{4-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl)-1,6-dihydropyrimidin-2-yl]morpholin-

2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,

N-{4-[(2S)-4-(1-Methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,

N2,N2-Dimethyl-N1-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)-morpholin-2-yl]phenyl}glycinamide,

Methyl {4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,

Ethyl {4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,

N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)-morpholin-2-yl]phenyl}acetamide,

N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide, and

N-{3-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide,

an optically active isomer thereof, or a pharmaceutically acceptable salt thereof.

12. A medicament comprising as an active ingredient a substance selected from the group consisting of the compound represented by the formula (I) and an optically active isomer thereof, or a pharmaceutically acceptable salt thereof according to the above 1.

13. A tau protein kinase 1 inhibitor selected from the group consisting of the compound represented by the formula (I) and an optically active isomer thereof, or a pharmaceutically acceptable salt thereof according to the above 1.

14. The medicament according to the above 12 which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity.

15. The medicament according to the above 12 which is used for preventive and/or therapeutic treatment of a neurodegenerative disease.

16. The medicament according to the above 15, wherein the disease is selected from the group consisting of Alzheimer disease, ischemic cerebrovascular

accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

17. The medicament according to the above 12, which is used for preventive and/or therapeutic treatment of a disease selected from the group consisting of non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and a virus-induced tumor.

Mode for Carrying Out the Invention

Unless otherwise indicated, the following definitions are set forth to illustrate and defined the meaning and scope of the various terms used to describe the invention herein.

The term "C₁-C₆ alkyl" means alkyl group having 1 to 6 carbon atoms which may be either linear or branched, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 1,1-dimethylpropyl, n-hexyl, isohexyl.

The term "C₁-C₁₂ alkyl" means alkyl group having 1 to 12 carbon atoms which may be either linear or branched, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 1,1-dimethylpropyl, n-hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl.

The term "C₃-C₇ cycloalkyl" means cycloalkyl having 3 to 7 atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.

The term "C₆-C₁₀ aryl" means a group having 6 to 10 carbon atoms derived from, for example, benzene, naphthalene, indane, indene, tetrahydronaphthalene. The bond position in the cycle is not limited.

The term "heterocyclic group" and "heterocycle" mean cyclic group derived from, for example, furan, dihydrofuran, tetrahydrofuran, pyran, dihydropyran, tetrahydropyran, benzofuran, dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, thiophene, benzothiophene, pyrrole, pyrroline, pyrrolidine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, tetrazole, pyridine, pyridine oxide, piperidine, pyrazine, piperazine, pyrimidine, pyridazine, indole, indoline, isoindole, isoindoline, indazole, benzimidazole, benzotriazole, tetrahydroisoquinoline, benzothiazolinone, benzoxazolinone, purine, quinolizine, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, oxazole, oxazolidine, isoxazole, isoxazolidine, oxadiazole, thiazole, benzothiazole, thiazylidene, isothiazole, isothiazolidine, benzodioxole, dioxane, benzodioxane, dithian, morpholine, thiomorpholine, phthalimide homopiperidinyl, homopiperazinyl. The bond position in the cycle is not limited.

The term "C₁-C₆ alkoxy" means alkoxy group having 1 to 6 carbon atoms which may be either linear or branched, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy isopentyloxy, neopentyloxy, 1,1-dimethylpropoxy, n-hexyloxy, isohexyloxy.

The term "C₂-C₆ alkenyl" means alkenyl group having 2 to 6 carbon atoms, for example, vinyl, propenyl, butenyl, pentenyl, hexenyl.

The term "C₂-C₆ alkynyl" means alkynyl group having 2 to 6 carbon atoms, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl.

The term "C₃-C₇ cycloalkenyl" means cycloalkenyl group having 3 to 7 carbon atoms, for example, cyclopropenyl cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl.

The term "nitrogen containing heterocycle formed by Ra and Rb together with the adjacent nitrogen atom" means, for example, pyrrolidinyl which may be substituted, piperidinyl which may be substituted, morpholino which may be substituted, thiomorpholino which may be substituted, piperazinyl which may be substituted, homopiperazinyl which may be substituted.

The term "which may be substituted" means a group which may have one or more substituents. The substituent in the present specification means, for example, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, C₆-C₁₀ aryl, heterocycles, C₁-C₆ alkoxy, C₃-C₆ alkenyloxy, C₃-C₆ alkynyloxy, C₃-C₇ cycloalkyloxy, C₃-C₇ cycloalkenyloxy, C₆-C₁₀ aryloxy, heterocycleoxy, halogen (chlorine, bromine, fluorine, iodine), nitro, amino, cyano, hydroxyl, oxo, C₁-C₆ alkylcarbonyl, C₂-C₆ alkenylcarbonyl, C₂-C₆ alkynylcarbonyl, C₃-C₇ cycloalkylcarbonyl, C₃-C₇ cycloalkenylcarbonyl, C₆-C₁₀ arylcarbonyl, heterocyclecarbonyl, C₁-C₆ alkylsulfonyl, C₂-C₆ alkenylsulfonyl, C₂-C₆ alkynylsulfonyl, C₃-C₇ cycloalkylsulfonyl, C₃-C₇ cycloalkenyloxy, C₆-C₁₀ arylsulfonyl, heterocyclesulfonyl, C₁-C₆ alkoxy, C₃-C₆ alkenyloxycarbonyl, C₃-C₆ alkynyloxycarbonyl, C₃-C₇ cycloalkyloxycarbonyl, C₃-C₇ cycloalkenyloxycarbonyl, C₆-C₁₀ aryloxycarbonyl, heterocycleoxycarbonyl, amino, C₁-C₆ alkylamino, C₃-C₆ alkenylamino, C₃-C₆ alkynylamino, C₃-C₇ cycloalkylamino, C₃-C₇ cycloalkenylamino, C₆-C₁₀ arylamino, heterocycle-amino, N,N-di-C₁-C₆ alkylamino, aminocarbonyl, C₁-C₆ alkylaminocarbonyl, C₃-C₆ alkenylaminocarbonyl, C₃-C₆ alkynylaminocarbonyl, C₃-C₇ cycloalkylaminocarbonyl, C₃-C₇ cycloalkenylaminocarbonyl, C₆-C₁₀ arylaminocarbonyl, heterocycle-aminocarbonyl, N,N-di-C₁-C₆ dialkylaminocarbonyl. The number of substituents as well as their types and substituting positions are not particularly limited, and when two or more substituents are present, they may be the same or different. In the above substituents, every term expressed by "C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, C₆-C₁₀ aryl, heterocycle or C₁-C₆ alkoxy" represents the same meaning as defined in the above. These substituents may be also substituted by the substituents described above.

R¹ may preferably be a C₁-C₃ alkyl group, more preferably be a methyl group.

R² may preferably be a hydrogen atom.

p may preferably be 0.


R may preferably be the group of formula (1).

The pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I) may include the salt with inorganic acid such as hydrochloric acid, hydrobromic acid and the like and the salt with organic acid such as acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid and the like.

In addition to the compound represented by the aforementioned formula (I), an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, their solvates and hydrates also fall within the scope of the present invention. The compound represented by the formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers of pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention


Examples of preferred compounds of the present invention are shown in the tables set out below. However, the scope of the present invention is not limited by the following compounds.

Table 1



Compound No.	$\begin{matrix} R^3 \\ R^4-N- \end{matrix}$	X
1		N
2		CH
3		N
4		N
5		CH

Table 2



Compound No.	R ³ R ⁴ -N-	X
6		CH
7		N
8		CH
9		N
10		CH
11		N
12		CH
13		N
14		N

Table 2 continued









Compound No.		X
15		CH
16		N
17		CH
18		CH
19		CH
20		CH
21		CH
22		N
23		CH

Table 2 continued










Compound No.	$\begin{array}{c} R^3 \\ \\ R^4-N- \end{array}$	X
24		CH
25		CH
26		CH
27		CH
28		CH
29		N
30		CH
31		N
32		CH

Table 2 continued












Compound No.		X
33		CH
34		CH
35		CH
36		CH
37		CH
38		CH
39		CH
40		N
41		CH
42		CH

Table 2 continued










Compound No.		X
43		N
44		CH
45		N
46		CH
47		N
48		CH
49		N
50		CH
51		CH

Table 2 continued








Compound No.	R^3 R^4 -N-	X
52		CH
53		N
54		CH
55		N
56		CH
57		N
58		CH

Table 2 continued








Compound No.	R^3 R^4 -N-	X
59		N
60		CH
61		N
62		CH
63		N
64		CH
65		N

Table 2 continued









Compound No.		X
66		CH
67		N
68		CH
69		N
70		CH
71		N
72		CH
73		N

Table 2 continued










Compound No.		X
74		CH
75		N
76		CH
77		N
78		CH
79		N
80		CH
81		N
82		CH

Table 2 continued










Compound No.		X
83		N
84		CH
85		N
86		CH
87		N
88		CH
89		N
90		CH
91		N

Table 2 continued























Compound No.	$\begin{matrix} R^3 \\ \\ N- \\ \\ R^4 \end{matrix}$	X
92		N
93		CH
94		N
95		N
96		CH
97		N
98		CH
99		N





Table 2 continued

Compound No.	R^3 N R^4	X
100		CH
101		N





Compound No.	STRUCTURE
201	 <chem>CN1C(=O)N(C2=CC=C(C=C2)C3CCOC4CCCN4)C5=CC=CC=C5C6=CC=CC=N6</chem>
202	 <chem>CN1C(=O)N(C2=CC=NC=C2)C3=CC=C(C=C3)C4CCOC5CCCN5</chem>
203	 <chem>CN1C(=O)N(C2=CC=C(C=C2)C3CCOC4CCN(C4)CC5)C6=CC=CC=N6</chem>
204	 <chem>CN1C(=O)N(C2=CC=NC=C2)C3=CC=C(C=C3)C4CCOC5CCN(C5)CC6</chem>





Compound No.	STRUCTURE
205	 <p>Chemical structure of compound 205: A piperazine ring substituted with a methyl group (H₃C) and a propyl chain ending in an oxygen atom. This oxygen atom is connected to a para-substituted benzene ring. The benzene ring is further substituted at the para position with a morpholine ring. The morpholine ring is substituted at the nitrogen atom with a 2-methyl-4-(pyridin-2-yl)quinoline-3-carbonyl group.</p>
206	 <p>Chemical structure of compound 206: A piperazine ring substituted with a methyl group (H₃C) and a propyl chain ending in an oxygen atom. This oxygen atom is connected to a para-substituted benzene ring. The benzene ring is further substituted at the para position with a morpholine ring. The morpholine ring is substituted at the nitrogen atom with a 2-methyl-4-(pyrimidin-2-yl)quinoline-3-carbonyl group.</p>
207	 <p>Chemical structure of compound 207: A cyclohexane ring substituted with a primary amide group (-NH-). The nitrogen atom of the amide group is connected to a para-substituted benzene ring. The benzene ring is further substituted at the para position with a morpholine ring. The morpholine ring is substituted at the nitrogen atom with a 2-methyl-4-(pyridin-2-yl)quinoline-3-carbonyl group.</p>
208	 <p>Chemical structure of compound 208: A cyclohexane ring substituted with a primary amide group (-NH-). The nitrogen atom of the amide group is connected to a para-substituted benzene ring. The benzene ring is further substituted at the para position with a morpholine ring. The morpholine ring is substituted at the nitrogen atom with a 2-methyl-4-(pyrimidin-2-yl)quinoline-3-carbonyl group.</p>

Compound No.	STRUCTURE
209	 <chem>CN1C=NC(=O)N(C1)c2ccncc2[C@@H]3CCOCC3NC(=O)Cc4ccc(OCC)cc4</chem>
210	 <chem>CN1C=NC(=O)N(C1)c2ccnnc2[C@@H]3CCOCC3NC(=O)Cc4ccc(OCC)cc4</chem>
211	 <chem>CN1C=NC(=O)N(C1)c2ccncc2[C@@H]3CCOCC3NC(=O)Cc4ccc(CN(C)C)cc4</chem>
212	 <chem>CN1C=NC(=O)N(C1)c2ccnnc2[C@@H]3CCOCC3NC(=O)Cc4ccc(CN(C)C)cc4</chem>





Compound No.	STRUCTURE
213	 <chem>CN1C=NC(=O)C=C1N2CCN(C2)C3=CC=C(C=C3)NS(=O)(=O)C</chem>
214	 <chem>CN1C=NC(=O)C=C1N2CCN(C2)C3=CC=NC=N3</chem>
215	 <chem>CN1C=NC(=O)C=C1N2CCN(C2)C3=CC=C(C=C3)NS(=O)(=O)C</chem>
216	 <chem>CN1C=NC(=O)C=C1N2CCN(C2)C3=CC=NC=N3</chem>





Compound No.	STRUCTURE
221	
222	
223	
224	





Compound No.	STRUCTURE
225	 <p>Chemical structure of compound 225: A piperidine ring is connected via its nitrogen atom to a carbonyl group. This carbonyl group is further connected to a para-substituted benzene ring. The benzene ring is linked to a morpholine ring at its 4-position. The nitrogen atom of the morpholine ring is connected to the 2-position of a pyrimidin-2(1H)-one ring. The pyrimidin-2(1H)-one ring has a methyl group (CH₃) at the 1-position and a pyridin-2-yl group at the 4-position.</p>
226	 <p>Chemical structure of compound 226: A benzene ring is connected to a sulfonamide group (-SO₂NH-). The nitrogen atom of the sulfonamide group is connected to a para-substituted benzene ring. This benzene ring is linked to a morpholine ring at its 4-position. The nitrogen atom of the morpholine ring is connected to the 2-position of a pyrimidin-2(1H)-one ring. The pyrimidin-2(1H)-one ring has a methyl group (CH₃) at the 1-position and a pyridin-2-yl group at the 4-position.</p>
227	 <p>Chemical structure of compound 227: A methyl group (CH₃) is attached to a nitrogen atom, which is connected to a carbonyl group (C=O). The carbonyl carbon is also bonded to a sulfur atom (S). The nitrogen atom is further connected to a para-substituted benzene ring. This benzene ring is linked to a morpholine ring at its 4-position. The nitrogen atom of the morpholine ring is connected to the 2-position of a pyrimidin-2(1H)-one ring. The pyrimidin-2(1H)-one ring has a methyl group (CH₃) at the 1-position and a pyridin-2-yl group at the 4-position.</p>
228	 <p>Chemical structure of compound 228: A benzene ring is connected to a nitrogen atom, which is further connected to a carbonyl group (C=O). The carbonyl carbon is also bonded to a sulfur atom (S). The nitrogen atom is further connected to a para-substituted benzene ring. This benzene ring is linked to a morpholine ring at its 4-position. The nitrogen atom of the morpholine ring is connected to the 2-position of a pyrimidin-2(1H)-one ring. The pyrimidin-2(1H)-one ring has a methyl group (CH₃) at the 1-position and a pyridin-2-yl group at the 4-position.</p>





Compound No.	STRUCTURE
229	 <chem>CN(C)C(=S)Nc1ccc(cc1)C2CCN(C2)c3nc(=O)c4c(ncn3C)c5ccncc5</chem>
230	 <chem>CN(C)C(=O)c1cc2c(ncn1C)c3ccncc3n2C4CCN(C4)C5=CC=CC=C5</chem>
231	 <chem>COC(=O)Nc1ccc(cc1)C2CCN(C2)c3nc(=O)c4c(ncn3C)c5ccncc5</chem>
232	 <chem>COC(=O)Nc1ccc(cc1)C2CCN(C2)c3nc(=O)c4c(ncn3C)c5ccncc5</chem>





Compound No.	STRUCTURE
233	
234	
235	
236	





Compound No.	STRUCTURE
237	 <p>Chemical structure of compound 237: A piperazine ring is substituted at the 4-position with a 4-(dimethylamino)benzamide group and at the 1-position with a 2-methyl-4-(pyridin-2-yl)pyrimidin-5(1H)-one group.</p>
238	 <p>Chemical structure of compound 238: A piperazine ring is substituted at the 4-position with a 4-(dimethylamino)benzamide group and at the 1-position with a 2-methyl-4-(pyrimidin-2-yl)pyrimidin-5(1H)-one group.</p>
239	 <p>Chemical structure of compound 239: A piperazine ring is substituted at the 4-position with a 4-(benzenesulfonylamino)benzamide group and at the 1-position with a 2-methyl-4-(pyrimidin-2-yl)pyrimidin-5(1H)-one group.</p>
240	 <p>Chemical structure of compound 240: A piperazine ring is substituted at the 4-position with a 4-(N-methyl-N-(1-methyl-1H-indol-2-yl)benzenesulfonylamino)benzamide group and at the 1-position with a 2-methyl-4-(pyrimidin-2-yl)pyrimidin-5(1H)-one group.</p>





Compound No.	STRUCTURE
241	 <chem>CN1C(=O)N(C2=CC=CC=N2)N1C3CCOCC3c4ccc(cc4)N=C(S)N5C=CC=CN5</chem>
242	 <chem>CN1C(=O)N(C2=CC=CC=N2)N1C3CCOCC3c4ccc(cc4)NS(=O)(=O)c5ccccc5</chem>
243	 <chem>CN1C(=O)N(C2=CC=CC=N2)N1C3CCOCC3c4ccc(cc4)NS(=O)(=O)Cc5ccccc5</chem>
244	 <chem>CN1C(=O)N(C2=CC=CC=N2)N1C3CCOCC3c4ccc(cc4)NS(=O)(=O)c5c6cccc7c5N(C)C7</chem>





Compound No.	STRUCTURE
245	
246	
247	 <p style="text-align: center;">racemate</p>
248	 <p style="text-align: center;">racemate</p>





Compound No.	STRUCTURE
249	 <p style="text-align: center;">racemate</p>
250	 <p style="text-align: center;">racemate</p>
251	
252	 <p style="text-align: center;">racemate</p>





Compound No.	STRUCTURE
253	
254	
255	
256	

Compound No.	STRUCTURE
257	 <chem>CC(=O)Nc1ccc(OC)c(c1)N2CCOCC2N3C(=O)C=C(N3)C4=CN=CN4</chem>
258	 <chem>CC(=O)Nc1ccc(cc1)N2CCOCC2N3C(=O)C=C(N3)C4=CC=NC=C4</chem>
259	 <chem>CC(=O)Nc1ccc(cc1)N2CCOCC2N3C(=O)C=C(N3)C4=CN=CN=C4</chem>
260	 <chem>CCN(CC)C(=O)Nc1ccc(cc1)N2CCOCC2N3C(=O)C=C(N3)C4=CC=NC=C4</chem>





Compound No.	STRUCTURE
261	 <p>Chemical structure of compound 261: A piperazine ring is substituted at the 4-position with a morpholine ring. The morpholine ring is further substituted at the 2-position with a pyridin-2-yl group. The piperazine ring is also substituted at the 1-position with a methylamino group (-NHCH₃) and at the 3-position with a carbonyl group (-C(=O)-). The carbonyl group is further substituted with a dimethylamino group (-N(CH₃)₂).</p>
262	 <p>Chemical structure of compound 262: A piperazine ring is substituted at the 4-position with a morpholine ring. The morpholine ring is further substituted at the 2-position with a pyridin-2-yl group. The piperazine ring is also substituted at the 1-position with a methylamino group (-NHCH₃) and at the 3-position with a carbonyl group (-C(=O)-). The carbonyl group is further substituted with a dimethylamino group (-N(CH₃)₂).</p> <p>racemate</p>
263	 <p>Chemical structure of compound 263: A piperazine ring is substituted at the 4-position with a morpholine ring. The morpholine ring is further substituted at the 2-position with a pyridin-2-yl group. The piperazine ring is also substituted at the 1-position with a methylamino group (-NHCH₃) and at the 3-position with a carbonyl group (-C(=O)-). The carbonyl group is further substituted with a dimethylamino group (-N(CH₃)₂).</p> <p>racemate</p>
264	 <p>Chemical structure of compound 264: A piperazine ring is substituted at the 4-position with a morpholine ring. The morpholine ring is further substituted at the 2-position with a pyridin-2-yl group. The piperazine ring is also substituted at the 1-position with a methylamino group (-NHCH₃) and at the 3-position with a carbonyl group (-C(=O)-). The carbonyl group is further substituted with a dimethylamino group (-N(CH₃)₂).</p>





Compound No.	STRUCTURE
265	 <chem>ClCS(=O)(=O)c1ccc(cc1)C2CCN(C2)c3cnc(=O)c4c3ncc4</chem>
266	 <chem>CN(S(=O)(=O)c1ccc(cc1)C2CCN(C2))c3cnc(=O)c4c3ncc4</chem>
267	 <chem>CN(S(=O)(=O)c1ccc(cc1)C2CCN(C2)c3cnc(=O)c4c3ncc4</chem>
268	 <chem>CN(C)S(=O)(=O)c1ccc(cc1)C2CCN(C2)c3cnc(=O)c4c3ncc4</chem>





Compound No.	STRUCTURE
269	 <p>Chemical structure of compound 269: A 4-(dimethylsulfamoyl)phenyl group is attached to the 4-position of a piperazine ring. The 1-position of the piperazine ring is attached to the 2-position of a 2-methyl-4-(4-pyridin-2-ylphenyl)quinazolin-3(1H)-one. The quinazolinone core has a methyl group on the nitrogen at position 1 and a carbonyl group at position 3. The pyridine ring is attached at its 2-position to the 4-position of the quinazolinone.</p>
270	 <p>Chemical structure of compound 270: A 1-(2-methylcyclopropyl)urea group is attached to the 4-position of a piperazine ring. The 1-position of the piperazine ring is attached to the 2-position of a 2-methyl-4-(4-pyridin-2-ylphenyl)quinazolin-3(1H)-one. The quinazolinone core has a methyl group on the nitrogen at position 1 and a carbonyl group at position 3. The pyridine ring is attached at its 2-position to the 4-position of the quinazolinone.</p>
271	 <p>Chemical structure of compound 271: A 1-(2-methylcyclopropyl)urea group is attached to the 4-position of a piperazine ring. The 1-position of the piperazine ring is attached to the 2-position of a 2-methyl-4-(4-pyridin-2-ylphenyl)quinazolin-3(1H)-one. The quinazolinone core has a methyl group on the nitrogen at position 1 and a carbonyl group at position 3. The pyridine ring is attached at its 2-position to the 4-position of the quinazolinone.</p>
272	 <p>Chemical structure of compound 272: A cyclopentylurea group is attached to the 4-position of a piperazine ring. The 1-position of the piperazine ring is attached to the 2-position of a 2-methyl-4-(4-pyridin-2-ylphenyl)quinazolin-3(1H)-one. The quinazolinone core has a methyl group on the nitrogen at position 1 and a carbonyl group at position 3. The pyridine ring is attached at its 2-position to the 4-position of the quinazolinone.</p>

Compound No.	STRUCTURE
273	 <chem>CC1=NC(=O)C=C(N2CCOCC2c3ccc(cc3)NC(=O)C4CCCC4)N1C</chem>
274	 <chem>CC1=NC(=O)C=C(N2CCOCC2c3ccc(cc3)NC(=O)C4CC4)N1C</chem>
275	 <chem>CC1=NC(=O)C=C(N2CCOCC2c3ccc(cc3)NC(=O)C4CC4)N1C</chem>
276	 <chem>CC(C)(O)C(=O)Nc1ccc(cc1)N2CCOCC2c3ccc(cc3)NC(=O)N4C</chem>

Compound No.	STRUCTURE
277	
278	
279	
280	

Compound No.	STRUCTURE
281	
282	
283	
284	

Compound No.	STRUCTURE
285	 <p>Chemical structure of compound 285: A central piperazine ring is substituted at the 2-position with a cyclopropylacetamide group (-NH-CO-CH₂-cyclopropyl) and at the 4-position with a 4-methoxyphenyl group (-CH₂-C₆H₄-OCH₃). The piperazine nitrogen at the 1-position is substituted with a 2-methyl-4-(pyridin-2-yl)quinoline-3-carboxamide group (-N(CH₃)-C(=O)-C₅H₃(N)-N(CH₃)-C₅H₄N).</p>
286	 <p>Chemical structure of compound 286: A central piperazine ring is substituted at the 2-position with a cyclopropylacetamide group (-NH-CO-CH₂-cyclopropyl) and at the 4-position with a 4-methoxyphenyl group (-CH₂-C₆H₄-OCH₃). The piperazine nitrogen at the 1-position is substituted with a 2-methyl-4-(pyrimidin-2-yl)quinoline-3-carboxamide group (-N(CH₃)-C(=O)-C₅H₃(N₂)-N(CH₃)-C₅H₄N₂).</p>
287	 <p>Chemical structure of compound 287: A central piperazine ring is substituted at the 2-position with a methanesulfonyl group (-NH-SO₂-CH₃) and at the 4-position with a 4-methoxyphenyl group (-CH₂-C₆H₄-OCH₃). The piperazine nitrogen at the 1-position is substituted with a 2-methyl-4-(pyridin-2-yl)quinoline-3-carboxamide group (-N(CH₃)-C(=O)-C₅H₃(N)-N(CH₃)-C₅H₄N).</p>
288	 <p>Chemical structure of compound 288: A central piperazine ring is substituted at the 2-position with a methanesulfonyl group (-NH-SO₂-CH₃) and at the 4-position with a 4-methoxyphenyl group (-CH₂-C₆H₄-OCH₃). The piperazine nitrogen at the 1-position is substituted with a 2-methyl-4-(pyrimidin-2-yl)quinoline-3-carboxamide group (-N(CH₃)-C(=O)-C₅H₃(N₂)-N(CH₃)-C₅H₄N₂).</p>

Compound No.	STRUCTURE
289	 <p style="text-align: center;">racemate</p>
290	 <p style="text-align: center;">racemate</p>
291	
292	


Particularly preferred compounds of the present invention represented by formula (I) include:

- 2-(2-(4-((4-Pyrrolidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-((4-Piperidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-(N-Cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-((3-Pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-(3-N-acetyl-N-methylaminopyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
- 2-{2-[4-(3-Hydroxy-azetidin-1-yl)phenyl]morpholin-4-yl}-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
- N-(4-(4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,
- N-(4-(4-(1,6-Dihydro-1-methyl-6-oxo-4,4'-bipyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,
- 2-(2-(4-(2-Pyridylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-Tetrahydrofuran-3-ylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
- 2-(2-(4-(N-Tetrahydrofuran-3-yl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-

pyrimidin-4-yl-3H-pyrimidin-4-one,
N-{4-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,
N-{4-[(2S)-4-(1-Methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,
N2,N2-Dimethyl-N1-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}glycinamide,
Methyl {4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,
Ethyl {4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,
N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide,
N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide, and
N-{3-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide,
an optically active isomer thereof, or a pharmaceutically acceptable salt thereof.

Salts of the aforementioned preferred compound, and solvates or hydrates of the aforementioned compounds and salts thereof are also preferred.

The compounds represented by the aforementioned formula (I) can be prepared, for example, according to the method explained below.



(In the above scheme, definitions of each symbol are the same as those already described.)

The 2-chloropyrimidone represented by the above formula (II) is prepared easily by the method described in the specification of WO2003/027080 and WO2003/037888.

Then the chloride derivative (II) is allowed to react with the amine (III) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and 1,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0 °C to 200 °C under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (I).

Examples of a solvent for the reactions include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like. Generally, a single solvent or a mixture of two or more solvents may be used so as to be suitable to a base used.

The compounds of the present invention have inhibitory activity against TPK1,

and they inhibit TPK1 activity in neurodegenerative diseases such as Alzheimer disease, thereby suppress the neurotoxicity of A β and the formation of PHF and inhibit the nerve cell death. Accordingly, the compounds of the present invention are useful as an active ingredient of a medicament which radically enables preventive and/or therapeutic treatment of Alzheimer disease. In addition, the compounds of the present invention are also useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitis, postencephalitic parkinsonism, pugilistic encephalosis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors. As the compound of the present invention has good safety and good pharmacokinetics, the compound has preferable characteristics as a medicament.

As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the aforementioned substance may be used in combination.

A type of the pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the

form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like.

Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 3000 mg (the weight of an active ingredient) to an adult.

Examples

The present invention will be explained more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples. The compound number in the examples corresponds to that in the table above.

Example 1:

N-(4-((2S)-4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)-morpholin-2-yl)phenyl)acetamide (Compound No. 39)

2-bromo-(1S)-1-(4-bromophenyl)ethanol

A borane-tetrahydrofuran complex (1.0 M solution in tetrahydrofuran, 270 ml,

270 mmol) was added to the solution of (S)-CBS ((S)-2-Methyl-CBS-oxazaborolidine, 50 ml, 1.0M solution in toluene) at -30 °C over 15 min and the solution was stirred for 15 minutes. 4-Bromophenacyl bromide (75.0g, 270 mmol) in dichloromethane (350 ml) was dropped over 70 minutes keeping the temperature -32 to -28 °C. After one hour stirring, solution was warmed to room temperature, and methanol (10 ml) was added slowly and then 0.5 M hydrochloric acid (300 ml) was dropped over 10 minutes. The solution was filtered after 40 minutes stirring and filtrate was extracted by dichloromethane. The combined organic layer was washed with 0.5 M hydrochloric acid, 0.1M aqueous sodium hydroxide and brine and dried over anhydrous sodium sulfate. Concentration of the organic layer yielded 2-bromo-(1S)-1-(4-bromophenyl)ethanol (77 g) as a pale brown oil.

(2S)-2-(4-bromophenyl) oxirane

Aqueous sodium hydroxide (1M, 400 ml) was added to 2-bromo-(1S)-1-(4-bromophenyl)ethanol (77.0 g) in diethyl ether (400 ml) and stirred at room temperature for 5 hours. The organic layer was separated and water layer was extracted with ether. Combined organic layer was washed with brine and dried over anhydrous sodium sulfate. Removal of the solvent yielded (2S)-2-(4-bromophenyl)oxirane (55.0 g) as a pale brown oil.

(1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino)ethanol

A mixture of (2S)-2-(4-bromophenyl)oxirane (55.0 g) and (R)-1-phenylethylamine (98.2g, 810 mmol) was heated at 80 °C for 6 hours. Addition of isopropyl ether (200 ml) to the residue after distillation of excess phenethylamine and successive filtration yielded (1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino) ethanol (57.0 g) as white crystals. Further crystallization was performed by the concentration of the filtrate in vacuo and cooling the residue in refrigerator. Filtration of the crystal with isopropyl ether (30 ml) yielded additional title compound (5.60 g) as crystals (72.4% yield, 3 steps).

(6S)-6-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholin-3-one

A solution of chloroacetyl chloride (24.3g, 215 mmol) in dichloromethane (100 ml) was dropped into the ice-cooled solution of (1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino)ethanol (62.6 g, 215 mmol) and triethylamine (21.8g, 215 mmol) in dichloromethane (600 ml) over 30 minutes and stirred for one hour at the same temperature. Resulting solution was washed with 0.5 M hydrochloric acid, saturated sodium hydrogen carbonate, brine and dried over anhydrous magnesium sulfate. The solvents were removed under reduced pressure and potassium hydroxide (85%, 16.1g, 244 mmol) was added to a solution of resulting pale brown oil in isopropyl alcohol (600 ml) and stirred for 16 hour. The solvent was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was washed with 0.5 M hydrochloric acid, saturated sodium hydrogen carbonate, brine and dried over anhydrous magnesium sulfate. Removal of the solvent under reduced pressure furnished (6S)-6-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholin-3-one (70.2 g) as a brown oil.

(2S)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine

A borane-tetrahydrofuran complex (1.0M solution in tetrahydrofuran, 510 ml, 510 mm) was added to the ice-cooled solution of (6S)-6-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholin-3-one (70.2 g) in tetrahydrofuran (500 ml) over 45 minutes and the solution was stirred at the same temperature for one hour and room temperature for 30 minutes. After careful addition of methanol (60 ml) to the ice-cooled solution, the solvent was removed under reduced pressure and the residue in methanol (750 ml) and 1M aqueous sodium hydroxide (280 ml) was stirred at 80 °C for one hour with addition of 1M aqueous sodium hydroxide (70 ml) in every 15 minutes. The solvents was removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous magnesium sulfate. Removal of the solvent yielded (2S)-

2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (65.0 g, 96.3% yield, 2 steps) as white crystals.

Melting point; 85-87°C

IR : 1487, 1449, 1117, 1098, 809, 758, 699, 550 cm⁻¹

¹H-NMR(CDC1₃) δ : 1.35(3H,d), 2.10(2H,m), 2.60(1H,m), 3.05(1H,m), 3.35(1H,q), 3.75(1H,m), 3.89(1H,m), 4.55(1H,m), 7.25(7H,m), 7.46(2H,d)

(2S)-2-(4-aminophenyl)-4-((1R)-1-phenylethyl)morpholine

A solution of (2S)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (15.6 g, 45 mmol), benzophenone imine (9 g, 50 mmol), tris(dibenzylideneacetone)-dipalladium(0)-chloroform adduct (0.93 g, 0.9 mmol), sodium tert-butoxide (6.0 g, 63 mmol) and 2-(di-*t*-butylphosphino)biphenyl (0.53 g, 1.8 mmol) in toluene (135 ml) was stirred at 95 °C for 4 hours. The solvent was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. To a solution of the resulting residue in tetrahydrofuran (180 ml) was added 6N hydrochloric acid (180 ml) and the mixture was stirred at room temperature for one hour. The solvent was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated. The resulting residue was purified by column chromatography on silica gel (hexane-AcOEt, 2:1) to give (2S)-2-(4-aminophenyl)-4-((1R)-1-phenylethyl)morpholine (12.2 g, 96%) as an oil.

N-(4-((2S)-4-((1R)-1-Phenylethyl)morpholin-2-yl)phenyl)acetamide

To a solution of (2S)-2-(4-aminophenyl)-4-((1R)-1-phenylethyl)morpholine (7.9 g, 28 mmol) and triethylamine (8.5 g, 84 mmol) in tetrahydrofuran (180 ml) was added acetyl chloride (4.4 g, 56 mmol). The mixture was stirred at room temperature for 2 hours and partitioned between water and chloroform. The organic extract was washed with brine and dried over anhydrous sodium sulfate. The solvent was

removed under reduced pressure and the precipitated crystals were collected by filtration, washed with isopropyl ether to give N-(4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)phenyl)-acetamide (6.47 g, 71%) as yellow crystals.

N-(4-((2S)-morpholin-2-yl)phenyl)acetamide

To a solution of N-(4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)phenyl)acetamide (6.47 g, 20 mmol) and ammonium formate (6.3 g, 100 mmol) in mixture of tetrahydrofuran (136 ml), methanol (270 ml) and water (70 ml) was added 10% palladium on carbon (wet, 270 mg) and the solution was stirred at 95 °C for 3 hours. After filtration, the solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to give N-(4-((2S)-morpholin-2-yl)phenyl)acetamide (5.78 g, quant.) as a yellow oil.

N-(4-((2S)-4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)morpholin-2-yl)phenyl)acetamide

A solution of N-(4-((2S)-morpholin-2-yl)phenyl)acetamide (2.63 g, 11.9 mmol), 2-chloro-1-methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidine (2.60 g, 11.9 mmol), and triethylamine (3.60 g, 35.7 mmol) in tetrahydrofuran (100 ml) was stirred at 95 °C for one hour. The solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel (chloroform-methanol, 10:1) to afford N-(4-((2S)-4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)morpholin-2-yl)phenyl)acetamide (2.8 g, 58%) as pale yellow crystals.

Example 2:

N-(4-((2S)-4-(1,6-Dihydro-1-methyl-6-oxo-4,4'-bipyrimidin-2-yl)-morpholin-2-yl)-phenyl)acetamide (Compound No. 40)

A solution of N-(4-((2S)-morpholin-2-yl)phenyl)acetamide (5.78 g, 26.2 mmol), 2-chloro-1,6-dihydro-1-methyl-6-oxo-4,4'-bipyrimidine (4.00 g, 18 mmol), and triethylamine (6.00 g, 60 mmol) in tetrahydrofuran (100 ml) was stirred at 95 °C for one hour. The solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (chloroform-methanol, 10:1) to afford N-(4-((2S)-4-(1,6-Dihydro-1-methyl-6-oxo-4,4'-bipyrimidin-2-yl)morpholin-2-yl)phenyl)acetamide (5.7 g, 30%) as pale yellow crystals.

Example 3:

(S)-2-(2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (Compound No. 10)

(2S)-2-(4-(cyclohexylamino)phenyl)-4-((1R)-1-phenylethyl)morpholine

To a suspension of (2S)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (7.62 g, 22.0 mmol), palladium acetate (198 mg, 0.88 mmol), 2-(di-*t*-butylphosphino)biphenyl (525 mg, 1.76 mmol), and sodium *tert*-butoxide (2.96 g, 30.8 mmol) in toluene (40 ml) was added cyclohexylamine (3.78 ml, 33.0 mmol) at room temperature. After heating at 90 °C for 2.5 hours, the resulting suspension was passed through a Celite column. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluting 5-25% of ethyl acetate in hexane to afford (S)-2-(4-(cyclohexyl-amino)phenyl)-4-((R)-1-phenylethyl)morpholine (6.95 g, 87%) as white crystals.

(2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)-4-((1R)-1-phenylethyl)morpholine

To a solution of (S)-2-(4-(cyclohexylamino)phenyl)-4-((R)-1-phenylethyl)morpholine (6.95 g, 19.1 mmol) and formalin (35%, 8.18 ml, 95.4 mmol) was added sodium triacetoxyborohydride (12.1 g, 57.2 mmol) at room temperature. After

stirring for 30 minutes, the resulting suspension was partitioned between ethyl acetate and 1 N sodium hydroxide. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-20% ethyl acetate in hexane to furnish (2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)-4-((1R)-1-phenylethyl)morpholine (7.27 g, quant.) as a pale yellow oil.

(2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholine

A 300-ml flask containing a solution of (S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)-4-((R)-1-phenylethyl)morpholine (7.27 g, 19.07 mmol) and 10% palladium on carbon (3.0 g) in ethanol (30 ml) was charged with hydrogen. The reaction mixture was stirred vigorously at 50 °C for 10 hours. The catalyst was filtered off with a Celite pad, and the filtrate was concentrated under reduced pressure to yield (2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholine (4.95 g, 95%) as a clear oil.

2-((2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one

To a solution of (2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholine (4.47 g, 16.30 mmol) and triethylamine (3.1 ml, 22.2 mmol) in tetrahydrofuran (50 ml) was added 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (3.28 g, 14.82 mmol) portionwise. Upon disappearance of the chloropyrimidone, the reaction mixture was condensed under reduced pressure. The residue was partitioned between 1 N sodium hydroxide and dichloromethane. The organic layer was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a pale yellow solid, which was recrystallized from ethanol to afford 2-((2S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (5.15 g, 75.7%) as white crystals.

Example 4:

3-Methyl-2-((2*S*)-2-(4-((pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)-pyrimidin-4(3*H*)-one (Compound No. 48)

N-(4-((2*S*)-4-((1*R*)-1-Phenylethyl)morpholin-2-yl)phenyl)pyridin-2-amine

A solution of (2*S*)-2-(4-aminophenyl)-4-((1*R*)-1-phenylethyl)morpholine (1.5 g, 5.31 mmol), 2-chloropyridine (1.21 g, 10.6 mmol), tris(dibenzylideneacetone)-dipalladium(0) (52.6 mg, 0.05 mmol), potassium tert-butoxide (0.88 g, 7.8 mmol) and 1,3-bis(2,6-di-*i*-propylphenyl)imidazolium chloride (89.6 mg, 0.21 mmol) in dioxane (17 ml) was stirred at 90 °C for 15 hours. The solvent was removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (hexane-ethyl acetate, 1:2) to afford N-(4-((2*S*)-4-((1*R*)-1-Phenylethyl)-morpholin-2-yl)phenyl)pyridin-2-amine (0.68 g, 36%) as red crystals.

N-(4-((2*S*)-Morpholin-2-yl)phenyl)pyridin-2-amine

To a solution of N-(4-((2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl)phenyl)-pyridin-2-amine (0.89 g, 2.5 mmol) and ammonium formate (0.78 g, 12.5 mmol) in tetrahydrofuran (15ml) – methanol (24 ml) – water (18 ml) was added 10% palladium on carbon (wet, 200 mg) and the mixture was stirred at 95 °C for one hour. After filtration, the solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure to yield N-(4-((2*S*)-Morpholin-2-yl)phenyl)pyridin-2-amine (0.60 g, 94%) as a yellow oil.

3-Methyl-2-((2*S*)-2-(4-((pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)-pyrimidin-4(3*H*)-one

A solution of *N*-{4-[(2*S*)-morpholin-2-yl]phenyl}pyridin-2-amine (0.2 g, 0.78 mmol), 2-chloro-1-methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidine (0.13 g, 0.62 mmol), and triethylamine (0.23 g, 2.3 mmol) in tetrahydrofuran (10 ml) was stirred at 95 °C for 3 hours. The solvent was removed under reduced pressure and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (chloroform - methanol, 10:1) to afford 3-Methyl-2-((2*S*)-2-(4-((pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)-pyrimidin-4(3*H*)-one (100 mg, 37%) as a yellow oil.

Example 5:

3-Methyl-2-((2*S*)-2-(4-(methyl(pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)pyrimidin-4(3*H*)-one (Compound No. 72)

N-Methyl-*N*-(4-((2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl)phenyl)pyridin-2-amine

To a solution of *N*-(4-((2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl)phenyl)pyridin-2-amine (0.57 g, 1.5 mmol) and iodomethane (1.6 g, 11.2 mmol) in tetrahydrofuran (50 ml) was added potassium tert-butoxide (1.6 g, 9.45 mmol). After stirring at room temperature for 4 hours, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and evaporated. The crude product was purified by column chromatography on silica gel (hexane - ethyl acetate, 1:1) to afford *N*-Methyl-*N*-(4-((2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl)phenyl)pyridin-2-amine (0.57 g, 81%) as a yellow oil.

N-Methyl-*N*-(4-((2*S*)-morpholin-2-yl)phenyl)pyridin-2-amine

To a solution of *N*-Methyl-*N*-(4-((2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl)phenyl)pyridin-2-amine (0.57 g, 1.5 mmol) and ammonium formate (0.48 g, 7.6 mmol) in tetrahydrofuran (15 ml) - methanol (30 ml) - water (16 ml) was added 10%

palladium on carbon (wet, 200 mg) and stirred at 95°C for one hour. After filtration, the solvent was removed under reduced pressure and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure to give N-Methyl-N-(4-((2S)-morpholin-2-yl)phenyl)pyridin-2-amine (0.38 g, 94%) as a yellow oil.

3-Methyl-2-((2S)-2-(4-(methyl(pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)pyrimidin-4(3H)-one

A solution of N-Methyl-N-(4-((2S)-morpholin-2-yl)phenyl)pyridin-2-amine (0.12 g, 0.46 mmol), 2-chloro-1-methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidine (0.08 g, 0.37 mmol), and triethylamine (0.23 g, 2.3 mmol) in tetrahydrofuran (10 ml) was stirred at 95 °C for 3 hours. The solvent was removed under reduced pressure and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (chloroform-methanol, 10:1) to give 3-Methyl-2-((2S)-2-(4-(methyl (pyridin-2-yl)amino)phenyl)morpholin-4-yl)-6-(pyridin-4-yl)-pyrimidin-4(3H)-one (65 mg, 13%) as a yellow oil.

Example 6:

2-((2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholin-4-yl)-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one (Compound No. 091)

4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)-morpholine

(R)-(+)-3-Aminotetrahydrofuran toluene-4-sulfonate (2.0 g, 7.7 mmol) was added to a suspension of (2S)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (2.4 g, 6.9 mmol), palladium acetate (65 mg, 0.29 mmol), 2-(di-t-butylphosphino)biphenyl

(170 mg, 0.57 mmol), and sodium tert-butoxide (3.4 g, 35.4 mmol) in tert-butanol (50 ml) at room temperature. After heating at 90 °C for 6 hours, the resulting suspension was passed through a Celite column. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to afford 4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholine (1.3 g, 53%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.35 (3H, d, J=6.8 Hz), 2.04-2.16 (4H, m), 2.55-2.62 (1H, m), 3.08-3.12 (1H, m), 3.33-3.38 (1H, m), 3.67-3.93 (5H, m), 3.98-4.02 (1H, m), 4.46-4.58 (2H, m), 6.57 (2H, d, J=7.2 Hz), 6.83 (1H, d, J=9.0 Hz), 7.21-7.33 (7H, m)

4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholine

Sodium triacetoxyborohydride (2.4 g, 11.3 mmol) was added to a solution of 4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholine (1.3 g, 3.69 mmol) and formalin (35%, 1.6 g, 18.6 mmol) in dichloroethane (50 mL) at room temperature. After stirring for 2 hours, the resulting suspension was partitioned between ethyl acetate and 1 N sodium hydroxide. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish 4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholine (1.35 g, 100%) as a pale yellow oil.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.33 (3H, d, J=6.8 Hz), 2.02-2.13(4H,m), 2.53-2.60 (1H, m), 3.00(3H, s), 3.08-3.12 (1H, m), 3.30-3.34 (1H, m), 3.70-3.98 (5H, m), 4.00-4.06 (1H, m), 4.46-4.58 (2H, m), 6.60 (2H, d, J=7.2 Hz), 7.28-7.37 (7H, m)

4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholine hydrochloride

A solution of 10% palladium on carbon (1.0 g) and 4-((1R)-1-phenylethyl)-(2S)-2-(4-(N-methyl-N-

((3R)-tetrahydrofuran-3yl)amino)phenyl)-4-((1R)-1-phenylethyl)morpholine (3.69 mmol) in methanol (10 ml) was stirred under hydrogen atmosphere vigorously at 50 °C for 10 hours. The catalyst was filtered off with a Celite pad, and the filtrate was concentrated under reduced pressure. The residue was treated with 4N hydrogen chloride in ethyl acetate and concentrated under reduced pressure to give a pale yellow solid, which was recrystallized from ethanol to afford (2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3yl)amino)phenyl)morpholine hydrochloride (0.9 g, 73%) as white crystals.

¹H-NMR(DMSO-d₆) δ : 2.99 (3H, s), 3.00-3.12 (2H, m), 3.23-3.28 (1H, m), 3.61-4.02 (9H, m), 4.51-4.53 (1H, m), 4.79 (1H, d, J=10.1 Hz), 7.42-7.48 (4H, m), 9.63 (2H, br)

2-((2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)morpholin-4-yl)-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one

A solution of 2-chloro-3-methyl-6-(4-pyrimidin-4-yl)-3H-pyrimidin-4-one (0.24 g, 1.08 mmol), (2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3yl)amino)phenyl)morpholine hydrochloride (0.4 g, 1.19 mmol) and triethylamine (0.6 g, 5.93 mmol) in tetrahydrofuran (20 ml) was stirred for 15 hours at room temperature. The mixture was partitioned between water and chloroform, and the organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting 5-10% methanol in chloroform to furnish 2-((2S)-2-(4-(N-methyl-N-((3R)-tetrahydrofuran-3-yl)amino)phenyl)-morpholin-4-yl)-3-methyl-6-(pyrimidin-4-yl)-pyrimidin-4-one (0.23 g, 47%) as pale yellow crystals.

Example 7:

2-((2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-yl)-3-methyl-6-(pyrimidin-4-yl)-pyrimidin-4-one (Compound No. 202)

2-Bromo-1-(4-hydroxyphenyl)ethan-1-one

Phenyltrimethylammonium tribromide (276 g, 734 mmol) was added to a

suspension of 4-hydroxyacetophenone (100 g, 734 mmol) in tetrahydrofuran (1000 ml) at room temperature. After stirring for 3 hours, the resulting suspension was filtered, and the filtrate was concentrated under reduced pressure. The residue was washed with diisopropyl ether to afford 2-bromo-1-(4-hydroxyphenyl)-ethan-1-one (85 g, 54%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.84 (1H, br), 4.40 (2H, s), 6.98 (2H, d, $J=7.2$ Hz), 7.91 (2H, d, $J=7.2$ Hz)

4-(2-Bromoacetyl)phenyl methanesulfonate

Methanesulfonyl chloride (50 g, 436 mmol) was added to a solution of 2-bromo-1-(4-hydroxyphenyl)-ethan-1-one (85 g, 395 mmol) and triethylamine (48g, 474 mmol) in tetrahydrofuran (1000 ml) at 0 °C and the mixture was stirred for 30 minutes at room temperature. The mixture was partitioned between water and ethyl acetate, and the organic layer was washed with brine, dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was washed with diisopropyl ether to afford 4-(2-bromoacetyl)phenyl methanesulfonate (96 g, 83%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.22 (3H, s), 4.41 (2H, s), 7.41 (2H, d, $J=7.2$ Hz), 8.06 (2H, d, $J=7.2$ Hz)

4-((2S)-2-Bromo-1-hydroxyethyl)phenyl methanesulfonate

Borane-tetrahydrofuran complex (1.0 M solution in tetrahydrofuran, 330 ml) was added to a solution of (S)-CBS ((S)-2-Methyl-CBS-oxazaborolidine, 50 ml, 1.0 M solution in toluene) at -30 °C over 15 minutes and the solution was stirred for 30 minutes. 4-(2-Bromoacetyl)phenyl methanesulfonate (96 g, 328 mmol) in tetrahydrofuran (500 ml) was dropped over 70 minutes keeping the temperature -32 to -28 °C. After stirring for one hour, the solution was warmed to room temperature, and methanol (10 ml) was added slowly and then 0.5 M hydrochloric acid (300 ml) was dropped over 10 minutes. The solution was filtered after 40 minutes stirring and

filtrate was extracted with ethyl acetate. The combined organic layer was washed with 0.5 M hydrochloric acid, 0.1M aqueous sodium hydroxide, and brine and dried over anhydrous sodium sulfate. Concentration of the organic layer yielded 4-((2S)-2-bromo-1-hydroxyethyl)phenyl methanesulfonate as a pale brown oil.
 $^1\text{H-NMR}(\text{CDCl}_3) \delta$: 2.72 (1H, d, J=1.2 Hz), 3.10 (3H, s), 3.44-3.58 (2H, m), 4.93-4.97 (1H, m), 7.30 (2H, d, J=7.2 Hz), 7.46 (2H, d, J=7.2 Hz)

4-((S)-Oxiranyl)phenyl methanesulfonate

An aqueous sodium hydroxide (1M, 600 ml) was added to 4-((2S)-2-bromo-1-hydroxyethyl)phenyl methanesulfonate (328 mmol) in diethyl ether (400 ml) and the solution was stirred at room temperature for 5 hours. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. Combined organic layer was washed with brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was washed with diisopropyl ether to afford 4-((S)-oxiranyl)phenyl methanesulfonate (69 g, 98%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 2.75 (1H, dd, J=1.2 Hz, 6.8 Hz), 3.14-3.16 (4H, m), 3.88 (1H, dd, J=1.2 Hz, 7.2 Hz), 7.28 (2H, d, J=7.2 Hz), 7.42 (2H, d, J=7.2 Hz)

4-((1S)-2-benzylamino-1-hydroxyethyl)phenyl methanesulfonate

A mixture of 4-((S)-oxiranyl)phenyl methanesulfonate (69 g, 322 mmol) and benzylamine (104 g, 971 mmol) was heated at 80 °C for 3 hours. An excess benzylamine was evaporated under reduced pressure and the residue was washed with diisopropyl ether to afford 4-((1S)-2-benzylamino-1-hydroxyethyl)phenyl methanesulfonate (71.0 g, 69%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 2.68-2.72 (1H, m), 2.96 (1H, dd, J=4.8 Hz, 10.2 Hz), 3.12 (3H, s), 3.84 (2H, d, J=1.2 Hz), 4.72 (1H, dd, J=1.2 Hz, 10.2 Hz), 7.23-7.43 (9H, m)

4-((2S)-4-Benzyl-5-oxo-morpholin-2-yl)phenyl methanesulfonate

Chloroacetyl chloride (27.5 g, 243 mmol) was dropped to a solution of 4-((1S)-2-benzylamino-1-hydroxyethyl)phenyl methanesulfonate (71 g, 221 mmol) in 1N aqueous sodium hydroxide (330 ml) and stirred for one hour at room temperature. Resulting solution was extracted with chloroform, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. Potassium hydroxide (85%, 17.5 g, 265 mmol) was added to a solution of the resulting pale brown oil in 2-propanol (600 ml), and the mixture was stirred for 10 hours. The solvent was removed in vacuo and the residue was partitioned between water and chloroform. The organic layer was washed with 0.5 M hydrochloric acid, saturated sodium hydrogen carbonate, brine and dried over anhydrous magnesium sulfate. Removal of the solvent under reduced pressure furnished 4-((2S)-4-benzyl-5-oxo-morpholin-2-yl)phenyl methanesulfonate (79.8 g, 100%) as a brown oil.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.13 (3H, s), 3.29-3.36 (2H, m), 4.36-4.46 (4H, m), 4.81 (1H, dd, $J=1.2$ Hz, 10 Hz), 7.24-7.42 (9H, m)

(2S)-4-Benzyl-2-(4-hydroxyphenyl)morpholine

Chlorotrimethylsilane (96 g, 884 mmol) was added to a solution of lithium borohydride (9.6 g, 441 mmol) in tetrahydrofuran (500 ml) and stirred for one hour at room temperature. A solution of 4-((2S)-4-benzyl-5-oxo-morpholin-2-yl)phenyl methanesulfonate (79.8 g, 221 mmol) in tetrahydrofuran (200 ml) was added to the solution and stirred at room temperature for one hour. After careful addition of methanol (60 ml) under ice-cooling, the solvent was removed under reduced pressure. Potassium hydroxide (145 g, 2.2 mol) was added to a solution of the residue in ethanol (300 ml) and water (300 ml) and the mixture was stirred at 80 °C for 2 hours. The solvent was removed under reduced pressure and the residue was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. Removal of the solvent yielded (2S)-4-benzyl-2-(4-hydroxyphenyl)morpholine (39.8 g, 67 %) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 2.05-2.31 (2H, m), 2.72-2.89 (2H, m), 3.54 (2H, s), 3.81-3.86 (1H, m), 3.96-4.00 (1H, m), 4.50 (1H, dd, $J=1.2$ Hz, 10.2 Hz), 5.12 (1H, br), 6.75 (2H, d, $J=7.2$ Hz),

7.19-1.32 (7H, m)

tert-Butyl (2S)-2-(4-Hydroxyphenyl)morpholine-4-carboxylate

A solution of 10% palladium on carbon (1.0 g) and (2S)-4-benzyl-2-(4-hydroxyphenyl)morpholine (10g, 37.1 mmol) in methanol (100 ml) was stirred under hydrogen atmosphere vigorously at 50 °C for 10 hours. The catalyst was filtered off with a Celite pad, and the filtrate was concentrated under reduced pressure. Di-tert-butylidicarbonate (9.7 g, 44.4 mmol) was added to a solution of the residue in 1N aqueous sodium hydroxide (200 ml) at 0 °C and the mixture was stirred for one hour at room temperature. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish tert-butyl (2S)-2-(4-hydroxyphenyl)morpholine-4-carboxylate (8.6 g, 83 %) as white crystals. ¹H-NMR(CDCl₃) δ : 1.48 (9H, s), 2.80-3.07 (2H, m), 3.62-3.70 (1H, m), 3.86-4.02 (3H, m), 4.33 (1H, dd, J=1.2 Hz, 10.2 Hz), 5.72 (1H, br), 6.81 (2H, d, J=7.2 Hz), 7.22 (2H, d, J=7.2 Hz)

tert-Butyl (2S)-2-(4-(3-bromopropoxy)phenyl)morpholine-4-carboxylate

Diisopropyl azodicarboxylate (40% in toluene, 13.6 g, 26.9 mmol) was added to a solution of tert-butyl (2S)-2-(4-hydroxyphenyl)morpholine-4-carboxylate (5.0 g, 17.9 mmol), triphenylphosphine (7.1 g, 27.1 mmol) and 3-bromopropanol (3.75 g, 27.0 mmol) in tetrahydrofuran (100 ml) and the solution was stirred for 10 hours at room temperature. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish tert-butyl (2S)-2-(4-(3-bromopropoxy)phenyl)morpholine-4-carboxylate (7.16 g, 100%) as a colorless oil.

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.48 (9H, s), 2.29-2.35 (2H, m), 2.83-3.08 (2H, m), 3.58-3.70 (3H, m), 3.98-4.13 (5H, m), 4.36 (1H, d, $J=1.2$ Hz, 10.2 Hz), 6.90 (2H, d, $J=7.2$ Hz), 7.28 (2H, d, $J=7.2$ Hz)

tert-Butyl (2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-carboxylate

tert-Butyl (2S)-2-(4-(3-bromopropoxy)phenyl)morpholine-4-carboxylate (2.0 g, 5.0 mmol) was added to a solution of sodium hydride (60% in oil, 0.22 g, 5.50 mmol) and pyrrolidine (0.43 g, 6.05 mmol) in tetrahydrofuran (40 ml) at room temperature and the mixture was stirred at 80 °C for 5 hours. The mixture was partitioned between water and chloroform. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting 5-10% methanol in chloroform to furnish tert-butyl (2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-carboxylate (1.13 g, 58%) as a colorless oil.

$^1\text{H-NMR}(\text{CDCl}_3) \delta$: 1.48 (9H, s), 1.78-1.82 (4H, m), 1.99-2.03 (2H, m), 2.53-2.67 (6H, m), 2.80-3.06 (2H, m), 3.62-3.68 (1H, m), 3.97-4.05 (5H, m), 4.36 (1H, dd, $J=1.2$ Hz, 10.2 Hz), 6.88 (2H, d, $J=7.2$ Hz), 7.26 (2H, d, $J=7.2$ Hz)

(2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine hydrochloride

Hydrogen chloride in ethyl acetate solution (4N) was added to a solution of tert-butyl (2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-carboxylate (1.13 g, 2.89 mmol) in methanol. The mixture was stirred for one hour at room temperature and the solvent was evaporated under reduced pressure to give a white solid, which was recrystallized from ethanol to afford (2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine hydrochloride (0.9 g, 86 %) as white crystals.

$^1\text{H-NMR}(\text{DMSO-d}_6) \delta$: 1.88-2.18 (6H, m), 2.96-3.02 (4H, m), 3.01-3.22 (4H, m), 3.51-3.54 (2H, m), 3.91-3.96 (1H, m), 4.05-4.09 (3H, m), 4.74 (1H, dd, $J=1.2$ Hz, 10.2 Hz), 6.94 (2H, d, $J=7.2$ Hz), 7.30 (2H, d, $J=7.2$ Hz), 9.60 (2H, br), 10.94 (1H, br)

2-((2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-yl)-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one

A solution of 2-chloro-3-methyl-6-(4-pyrimidin-4-yl)-3H-pyrimidin-4-one (0.15 g, 0.67 mmol), (2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine hydrochloride (0.25 g, 0.69 mmol) and triethylamine (0.42 g, 4.15 mmol) in tetrahydrofuran (10 ml) was stirred for 15 hours at room temperature. The mixture was partitioned between water and chloroform. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting 5-10% methanol in chloroform to furnish 2-((2S)-2-(4-(3-(pyrrolidin-1-yl)propyloxy)phenyl)morpholine-4-yl)-3-methyl-6-(pyrimidin-4-yl)-pyrimidin-4-one (90 mg, 28%) as white crystals.

Example 8:

N-(2-hydroxy-ethyl)-4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl)-morpholin-2-yl]-benzamide (Compound No. 209)

4-[(2S)-4-((1R)-1-phenylethyl)-morpholin-2-yl]-benzoic acid

To a suspension of (2S)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (3.46 g, 10.0 mmol) in tetrahydrofuran (80 ml) was added n-butyllithium (7.7 ml, 12.0 mmol, 1.56 M in hexane) at -78°C . After stirring the mixture for 10 minutes, excess of dry ice was added to the mixture and the reaction mixture was maintained at -78°C for 1.5 hours and then partitioned between diethyl ether and 0.2 N aqueous sodium hydroxide. The aqueous layer was washed with diethyl ether and neutralized with 1N hydrochloric acid. The resulting aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated in vacuo. Filtration of the precipitate gave 4-[(2S)-4-((1R)-1-phenylethyl)-morpholin-2-yl]-benzoic acid (3.05 g, 98%) as white crystals.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.39(3H, d, J=6.9 Hz), 2.10-2.18(2H,m), 2.63(1H,m), 3.15(1H,m), 3.41(1H, q, J=6.9 Hz), 3.78(1H, m), 3.93(1H, m), 4.55(1H, dd, J=10.2, 2.1 Hz),

7.25-7.39(5H,m), 7.47(2H, d, J=8.4 Hz), 8.07(2H, d, J=8.4 Hz).

N-(2-hydroxy-ethyl)-4-[(2S)-4-((1R)-1-phenyl-ethyl)-morpholin-2-yl]-benzamide

1,1'-Carbonyldiimidazole (540 mg, 3.30 mmol) was added to a solution of 4-[(2S)-4-((1R)-1-phenyl-ethyl)-morpholin-2-yl]-benzoic acid (944 mg, 3.03 mmol) in dichloromethane at 0°C. After stirring for 2 hours, ethanolamine (0.36 ml, 6.0 mmol) was added to the reaction mixture and the mixture was stirred over night. The resulting suspension was concentrated in vacuo and the residue was purified by silica gel chromatography (ethyl acetate-hexane) to afford N-(2-hydroxy-ethyl)-4-[(2S)-4-((1R)-1-phenyl-ethyl)-morpholin-2-yl]-benzamide (789 mg, 73%) as a colorless oil. ¹H-NMR(CDCl₃) δ : 1.36(3H, d, J=6.9 Hz), 2.10-2.15(2H,m), 2.61(1H, dd, J=11.7, 1.5 Hz), 3.11(1H,m), 3.36(1H, q, J=6.9 Hz), 3.59-3.64(2H, m), 3.73-3.77(1H, m), 3.78-3.83(2H, m), 3.84-3.91(1H, m), 4.63(1H, dd, J=10.2, 2.4 Hz), 7.26-7.39(2H,m), 7.41(2H, d, J=8.4 Hz), 7.65(3H,m), 7.75(2H, d, J=8.4 Hz).

N-(2-hydroxy-ethyl)-[(2S)-4-morpholin-2-yl]-benzamide

A solution of N-(2-hydroxy-ethyl)-4-[(2S)-4-((1R)-1-phenyl-ethyl)-morpholin-2-yl]-benzamide (789 mg, 2.20 mmol) and 20% palladium hydroxide on carbon (0.30 g) in ethanol (6.0 ml) was stirred under hydrogen atmosphere for 10 hours at room temperature. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to yield N-(2-hydroxy-ethyl)-[(2S)-4-morpholin-2-yl]-benzamide (550 mg, 100%) as a clear oil. ¹H-NMR(CD₃OD) δ : 2.80(1H, dd, J=12.6, 11.1 Hz), 3.02-3.06(1H,m), 3.16-3.21(1H, m), 3.51(2H, d, J=5.7 Hz), 3.72(2H, d, J=5.7 Hz), 3.80-3.97(1H, m), 4.08-4.12(1H,m), 4.65(1H, dd, J=10.8, 2.4 Hz), 7.46(2H, d, J=8.4 Hz), 7.84(2H, d, J=8.4 Hz).

N-(2-hydroxy-ethyl)-4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl)-morpholin-2-yl]-benzamide

A solution of N-(2-hydroxy-ethyl)-[(2S)-4-morpholin-2-yl]-benzamide (190 mg,

0.76 mmol), 2-chloro-3-methyl-6-(4-pyridyl)-pyrimidine-4-one (111 mg, 0.50 mmol) and triethylamine (0.28 ml, 2.0 mmol) in tetrahydrofuran (6.0 ml) was stirred at room temperature for 6 hours. The reaction mixture was evaporated *in vacuo* and the residue was partitioned between dichloromethane and water. The whole was extracted with dichloromethane. The organic layer was washed with water, dried and concentrated in *vacuo*. Washing the precipitate with diethyl ether and dichloromethane gave N-(2-hydroxy-ethyl)-4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl)-morpholin-2-yl]-benzamide (90.8 mg, 42%) as white crystals.

Example 9:

N-(2-hydroxy-ethyl)-4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-[4,4']bipyrimidinyl-2-yl)-morpholin-2-yl]-benzamide (Compound No. 210)

A solution of N-(2-hydroxy-ethyl)-[(2S)-4-morpholin-2-yl]-benzamide (190 mg, 0.76 mmol), 2-chloro-3-methyl-6-(4-pyrimidyl)-pyrimidine-4-one (111 mg, 0.50 mmol) and triethylamine (0.28 ml, 2.0 mmol) in tetrahydrofuran (6 ml) was stirred at room temperature for 6 hours. The reaction mixture was evaporated *in vacuo* and the residue was partitioned between dichloromethane and water. The whole was extracted with dichloromethane. The organic layer was washed with water, dried and concentrated in *vacuo*. Purification of the residue by preparative high performance liquid chromatography gave N-(2-hydroxy-ethyl)-4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl)-morpholin-2-yl]-benzamide (49.8 mg, 23%) as white crystals.

Example 10:

N²,N²-Dimethyl-N¹-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}glycinamide (Compound No. 220)

2-Chloro-N-{4-[(2S)-4-((1R)-1-phenylethyl)morpholin-2-yl]phenyl}acetamide

To a solution of (2S)-2-(4-aminophenyl)-4-((1R)-1-phenylethyl)morpholine

(2.93 g, 10 mmol) and triethylamine (3.0 g, 30 mmol) in tetrahydrofuran (50 ml) was added chloroacetyl chloride (2.26 g, 20 mmol). The mixture was stirred at room temperature for 2 hours and partitioned between water and chloroform. The organic extract was washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the precipitated crystals were collected by filtration, washed with isopropyl ether to give 2-chloro-*N*'{4-[(2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl]phenyl}acetamide (3.5 g, 97%) as yellow crystals.

¹H-NMR(CDCl₃) δ : 1.35 (3H, d, J=6.6 Hz), 2.02-2.17 (2H, m), 2.60 (1H, d, J=11.1 Hz), 3.08 (1H, d, J=11.1 Hz), 3.36 (1H, q, J=6.9 Hz), 3.75 (1H, td, J=11.4 Hz, 2.4 Hz), 3.91 (1H, dd, J=9.9 Hz, 1.5 Hz), 4.19 (2H, s), 4.57 (1H, dd, J=10.2 Hz, 2.1Hz), 7.23-7.32 (5H, m), 7.36 (2H, d, J=8.4 Hz), 7.51 (2H, d, J=8.1 Hz), 8.21 (1H, br.s).

N²,N²-Dimethyl-N¹'{4-[(2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl]phenyl}glycinamide

A solution of 2-chloro-*N*'{4-[(2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl]phenyl}acetamide (0.9 g, 2.5 mmol), potassium carbonate (1.72 g, 12.5 mmol), and dimethylamine hydrochloride (1.00 g, 12.5 mmol) in tetrahydrofuran (40 ml) and acetonitrile (80 ml) was stirred at 95 °C for 10 hours. After filtration, the solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to give N²,N²-dimethyl-N¹'{4-[(2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl] phenyl}glycinamide (1.15 g, quant.) as a yellow oil.

¹H-NMR(CDCl₃) δ : 1.35 (3H, d, J=6.6 Hz), 2.05-2.13 (2H, m), 2.38 (6H, s), 2.57 (1H, m), 3.07 (2H, s), 3.10 (1H, m), 3.35 (1H, q, J=6.6 Hz), 3.72 (1H, m), 3.90 (1H, m), 4.56 (1H, dd, J=10.2Hz, 2.1Hz), 7.20-7.39 (7H, m), 7.56 (2H, d, J=8.4 Hz), 9.90 (1H, br.s).

N²,N²-Dimethyl-N¹'{4-[(2*S*)-morpholin-2-yl]phenyl}glycinamide

To a solution of N²,N²-dimethyl-N¹'{4-[(2*S*)-4-((1*R*)-1-phenylethyl)morpholin-2-yl] phenyl}glycinamide (0.91 g, 2.5 mmol) and ammonium formate (0.79 g, 12.5 mmol) in tetrahydrofuran (20 ml), methanol (40 ml) and water (7

ml) was added 10% palladium on carbon (wet, 300 mg) and the mixture was stirred at 95 °C for 3 hours. After filtration, the solvent was removed in vacuo and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to give N²,N²-dimethyl-N¹-{4-[(2S)-morpholin-2-yl]phenyl}glycinamide (0.63 g, 96%) as a colorless oil.

¹H-NMR(CDCl₃) δ : 2.05-2.13 (2H, m), 2.38 (6H, s), 2.57 (1H, m), 3.07 (2H, s), 3.10 (1H, m), 3.72 (1H, m), 3.90 (1H, m), 4.56 (1H, dd, J=10.2 Hz, 2.1 Hz), 7.35 (2H, d, J=8.4 Hz), 7.56 (2H, d, J=8.4 Hz), 9.90 (1H, br.s).

N²,N²-Dimethyl-N¹-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}glycinamide

A solution of N²,N²-dimethyl-N¹-{4-[(2S)-morpholin-2-yl]phenyl}glycinamide (0.21 g, 0.8 mmol), 2-chloro-1,6-dihydro-1-methyl-6-oxo-4,4'-bipyrimidine (0.14 g, 0.64 mmol), and triethylamine (0.40 g, 4 mmol) in tetrahydrofuran (10 ml) was stirred at 95 °C for one hour. The solvent was removed in *vacuo* and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel (chloroform/methanol = 10/1) to afford N²,N²-dimethyl-N¹-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}glycinamide (0.17 g, 47%) as white crystals.

Example 11:

Methyl (4-((2S)-4-(3-methyl-4-oxo-6-(pyridin-4-yl)-3H-pyrimidin-2-yl)morpholin-2-yl)-phenyl)carbamate (Compound No. 231)

4-((2S)-Morpholin-2-yl)phenylamine

To a solution of (2S)-2-(4-aminophenyl)-4-((1R)-1-phenylethyl)morpholine (17.45 g, 61.8 mmol) and ammonium formate (11.7 g, 185.4 mmol) in mixture of tetrahydrofuran (180 ml), methanol (180 ml) and water (45 ml) was added 10%

palladium on carbon (wet, 1.8 g) and the mixture was stirred at 95 °C for 3 hours. After filtration, the solvent was removed in *vacuo* and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to give 4-((2*S*)-morpholin-2-yl)phenylamine (10.45 g, 95 %) as pale yellow crystals.

¹H-NMR(CDCl₃) δ : 2.46-2.50 (2H, m), 2.68 (2H, d, J=5.8 Hz), 2.76 (1H, d, J=12.2 Hz), 3.52 (1H, m), 3.79 (1H, d, J=10.9 Hz), 4.13 (1H, d, J=9.7 Hz), 4.95 (2H, br.s), 6.49 (2H, d, J=8.1 Hz), 6.94 (2H, d, J=8.1 Hz).

2-[(2*S*)-2-(4-Aminophenyl)morpholin-4-yl]-3-methyl-6-(pyridin-4-yl)-pyrimidin-4(3*H*)-one

A solution of 4-((2*S*)-morpholin-2-yl)phenylamine (0.17 g, 0.95 mmol), 2-chloro-3-methyl-4-oxo-6-(pyridin-4-yl)-3,4-dihydropyrimidine (0.17 g, 0.76 mmol), and triethylamine (0.25 g, 2.85 mmol) in tetrahydrofuran (10 ml) was stirred at 95 °C for one hour. The solvent was removed in *vacuo* and the residue was partitioned between water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol = 10/1) to afford 2-[(2*S*)-2-(4-aminophenyl)morpholin-4-yl]-3-methyl-6-(pyridin-4-yl)-pyrimidin-4(3*H*)-one (0.15 g, 54%) as pale yellow crystals.

Methyl chloroformate (0.13 g, 1.38 mmol) was added to a solution of 2-((2*S*)-2-(4-aminophenyl)morpholine-4-yl)-3-methyl-6-(pyridin-4-yl)-3*H*-pyrimidin-4-one (0.45 g, 1.24 mmol) and triethylamine (0.25 g, 2.47 mmol) in tetrahydrofuran (20 ml) and stirred for one hour at room temperature. The mixture was partitioned between water and chloroform. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in *vacuo*. The residue was purified by silica gel column chromatography eluting 5-10% methanol in chloroform to furnish methyl (4-((2*S*)-4-(3-methyl-4-oxo-6-(pyridin-4-yl)-3*H*-pyrimidin-2-yl)morpholin-2-yl)phenyl) carbamate (0.35 g, 67%) as white crystals.

Example 12:

1,1-Dimethyl-3-{4-[4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl)-morpholin-2-yl]-phenyl}-urea (Compound No. 237)

N,N-Dimethylcarbamoyl chloride (0.24 g, 2.23 mmol) was added to a solution of 2-[(2S)-2-(4-aminophenyl)morpholin-4-yl]-3-methyl-6-(pyridin-4-yl)-pyrimidin-4(3H)-one (0.40 g, 1.10 mmol) and triethylamine (1.1 g, 10.9 mmol) in tetrahydrofuran (20 ml) and the solution was stirred at 50 °C for 48 hours. The mixture was partitioned between water and chloroform. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish 1,1-Dimethyl-3-{4-[4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydro-pyrimidin-2-yl) morpholin-2-yl]-phenyl}-urea (0.14 g, 30 %) as white crystals.

The compounds in the following table were prepared in the same manner as the methods described above. The compound numbers in the following table correspond to those shown in the above-described table of preferred compounds.

Table 4

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
1	1.48(9H, s), 3.09-3.17(5H, m), 3.30(1H, m), 3.57-3.62(9H, m), 3.98(1H, td, J=2.4, 10.8Hz), 4.14(1H, dd, J=1.8, 10.8Hz), 4.65(1H, dd, J=2.4, 10.8Hz), 6.94(2H, d, J=9.0Hz), 7.26-7.41(3H, m), 8.14(1H, dd, J=1.2, 4.8Hz), 8.85(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz) (CDCl ₃)	534
2	2.19 (2H, quintet, J = 7.1 Hz), 2.64 (2H, t, J = 7.1 Hz), 3.11 (1H, dd, J = 10.5, 12.9 Hz), 3.30 (1H, td, J = 11.6, 2.1 Hz), 3.55 (1H, d, J = 11.6 Hz), 3.58 (3H, s), 3.64 (1H, d, J = 12.9 Hz), 3.89 (2H, t, J = 7.1 Hz), 4.00 (1H, td, J = 11.6, 2.1 Hz), 4.19 (1H, dd, J = 11.6, 2.1 Hz), 4.73 (1H, dd, J = 10.5, 2.1 Hz), 6.71 (1H, s), 7.42 (2H, d, J = 8.4 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 5.1 Hz), 8.74 (2H, br s) (CDCl ₃)	
3	2.19 (2H, quintet, J = 7.0 Hz), 2.63 (2H, t, J = 7.0 Hz), 3.10 (1H, dd, J = 13.0, 10.8 Hz), 3.27 (1H, td, J = 12.7, 2.3 Hz), 3.53 (1H, d, J = 12.7 Hz), 3.58 (3H, s), 3.63 (1H, d, J = 13.0 Hz), 3.88 (2H, t, J = 7.0 Hz), 4.00 (1H, td, J = 12.7, 2.3 Hz), 4.18 (1H, d, J = 12.7 Hz), 4.72 (1H, d, J = 10.8 Hz), 7.35 (1H, s), 7.43 (2H, d, J = 8.6 Hz), 7.66 (2H, d, J = 8.6 Hz), 8.14 (1H, d, J = 5.1 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.27 (1H, s) (CDCl ₃)	
4	2.29(3H, s), 3.01-3.05(4H, m), 3.12(1H, dd, J=10.8, 12.9Hz), 3.21-3.23(5H, m), 3.58(3H, s), 3.52-3.61(2H, m), 3.99(1H, m), 4.13(1H, m), 4.64(1H, d, J=9.0Hz), 5.74(1H, s), 6.92(1H, d, J=4.2Hz), 6.95(1H, s), 7.26-7.30(5H, m), 7.41(1H, dd, J=7.5, 8.1Hz), 7.80(2H, d, J=7.5Hz), 8.14(1H, d, J=5.4Hz), 8.86(1H, d, J=5.1Hz), 9.28(1H, d, J=1.25Hz) (CDCl ₃)	590
5	2.29(3H, s), 3.01-3.05(4H, m), 3.12(1H, dd, J=10.8, 12.9Hz), 3.21-3.23(5H, m), 3.58(3H, s), 3.52-3.61(2H, m), 3.99(1H, m), 4.13(1H, m), 4.64(1H, d, J=9.0Hz), 5.73(1H, s), 6.69(1H, s), 6.93(2H, d, J=8.8Hz), 7.26-7.32(4H, m), 7.41(1H, dd, J=7.5, 8.1Hz), 7.77-7.81(4H, m), 8.71(2H, d, J=5.9Hz) (CDCl ₃)	589

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
6	1.67-2.18(9H, m), 2.62-2.83(6H, m), 3.09-3.17(1H, m), 3.26-3.33(1H, m), 3.53-3.74(7H, m), 3.93-4.00(1H, m), 4.13-4.17(1H, m), 4.62(1H, dd, J=1.2, 10.2Hz), 6.69(1H, s), 6.93(2H, d, J=7.3Hz), 7.26(2H, d, J=7.3Hz), 7.79(2H, d, J=4.2Hz), 8.71(2H, d, J=4.2Hz) (CDCl ₃)	501
7	1.64-2.15(9H, m), 2.61-2.83(6H, m), 3.09-3.17(1H, m), 3.26-3.33(1H, m), 3.51-3.70(7H, m), 3.93-4.00(1H, m), 4.13-4.17(1H, m), 4.61(1H, dd, J=1.2, 10.2Hz), 6.94(2H, d, J=7.3Hz), 7.28(2H, d, J=7.3Hz), 7.34(1H, s), 8.14(1H, d, J=4.2Hz), 8.86(1H, d, J=4.2Hz), 9.27(1H, s) (CDCl ₃)	502
8	1.44-1.89(10H, m), 2.30-2.38(1H, m), 2.51-2.55(4H, m), 2.70-2.76(2H, m), 3.13-3.17(1H, m), 3.26-3.32(1H, m), 3.53-3.59(5H, m), 3.75-3.79(2H, m), 3.92-4.00(1H, m), 4.12-4.16(1H, m), 4.62(1H, dd, J=1.2, 10.2Hz), 6.69(1H, s), 6.92(2H, d, J=7.3Hz), 7.29(2H, d, J=7.3Hz), 7.78(2H, d, J=4.2Hz), 8.71(2H, d, J=4.2Hz) (CDCl ₃)	515
9	1.46-1.97(10H, m), 2.59-2.78(7H, m), 3.08-3.16(1H, m), 3.26-3.32(1H, m), 3.51-3.62(5H, m), 3.75-3.79(2H, m), 3.92-4.00(1H, m), 4.12-4.16(1H, m), 4.64(1H, dd, J=1.2, 10.2Hz), 6.93(2H, d, J=7.3Hz), 7.26-7.33(3H, m), 8.13(1H, d, J=4.2Hz), 8.86(1H, d, J=4.2Hz), 9.27(1H, s) (CDCl ₃)	516
10	1.14 (1H, m), 1.40 (4H, m), 1.66 (2H, m), 1.81 (3H, m), 2.79 (3H, s), 3.16 (1H, dd, J = 12.9, 10.8 Hz), 3.29 (1H, td, J = 11.4, 1.5 Hz), 3.53 (3H, s), 3.54 (3H, m), 3.95 (1H, td, J = 11.4, 1.5 Hz), 4.14 (1H, td, J = 11.4, 1.5 Hz), 4.61 (1H, dd, J = 10.8, 2.4 Hz), 6.69 (1H, s), 6.77 (2H, d, J = 8.9 Hz), 7.25 (2H, d, J = 8.9 Hz), 7.80 (2H, J = 4.8, 1.5 Hz, 2H), 8.71 (2H, dd, J = 4.8, 1.5 Hz) (CDCl ₃)	460

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
11	1.10-1.18 (1H, m), 1.35-1.49 (4H, m), 1.62-1.80 (5H, m), 2.71 (3H, s), 2.98-3.06 (2H, m), 3.46 (3H, s), 3.59-3.76 (3H, m), 3.83-3.89 (1H, m), 4.01-4.04 (1H, m), 4.60 (1H, d, 10.2Hz), 6.75 (2H, d, J=7.2Hz), 6.88 (1H, s), 7.23 (2H, d, J=7.3Hz), 8.19 (1H, d, J=4.2Hz), 9.00 (1H, d, J=4.2Hz), 9.29 (1H, s) (CDCl ₃)	461
12	1.62 (1H, br. s), 2.62 (1H, t, J=5.3Hz), 2.68 (4H, t, J=4.9Hz), 3.14 (1H, dd, J=10.8, 12.9Hz), 3.23 (4H, t, J=4.7Hz), 3.31 (1H, m), 3.53-3.69 (5H, m), 3.57 (3H, s), 3.98 (1H, m), 4.14 (1H, m), 4.64 (1H, dd, J=1.9, 10.4Hz), 6.70 (1H, s), 6.95 (2H, d, J=8.7Hz), 7.31 (2H, d, J=8.6Hz), 7.79 (2H, d, J=6.0Hz), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	477
13	1.61 (1H, br. s), 2.61 (1H, t, J=5.3Hz), 2.68 (4H, t, J=4.9Hz), 3.13 (1H, dd, J=10.8, 12.9Hz), 3.24 (4H, t, J=4.7Hz), 3.31 (1H, m), 3.53-3.69 (5H, m), 3.57 (3H, s), 3.98 (1H, m), 4.16 (1H, m), 4.63 (1H, dd, J=1.9, 10.4Hz), 6.97 (2H, d, J=8.7Hz), 7.30 (1H, s), 8.14 (2H, d, J=5.4Hz), 8.86 (2H, d, J=5.1Hz), 9.28 (1H, s) (CDCl ₃)	478
14	1.50 (8H, m), 2.20 (1H, m), 2.55 (3H, m), 3.00 (1H, m), 3.15 (1H, dd, J=10.8, 12.9Hz), 3.28-3.31 (3H, m), 3.45-3.60 (4H, m), 3.57 (3H, s), 3.98 (1H, m), 4.16 (1H, m), 4.60 (1H, dd, J=1.9, 10.4Hz), 6.97 (2H, d, J=8.7Hz), 7.30 (1H, s), 8.14 (2H, d, J=5.4Hz), 8.86 (2H, d, J=5.1Hz), 9.28 (1H, s) (CDCl ₃)	502
15	1.47-1.65 (8H, m), 2.20 (1H, m), 2.55 (3H, m), 3.00 (1H, m), 3.15 (1H, dd, J=10.8, 12.9Hz), 3.28-3.31 (3H, m), 3.45-3.60 (4H, m), 3.57 (3H, s), 3.98 (1H, m), 4.16 (1H, m), 4.60 (1H, dd, J=1.9, 10.4Hz), 6.55 (2H, d, J=8.7Hz), 6.68 (1H, s), 7.31 (2H, d, J=8.6Hz), 7.79 (2H, d, J=6.0Hz), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	501
16	1.94 (1H, m), 2.20 (1H, m), 2.54 (4H, m), 3.00 (1H, m), 3.16-3.62 (8H, m), 3.56 (3H, s), 3.74 (4H, t, J=4.6Hz), 3.97 (1H, m), 4.16 (1H, m), 4.61 (1H, dd, J=1.9, 10.4Hz), 6.55 (2H, d, J=8.7Hz), 7.27 (2H, d, J=8.7Hz), 7.35 (1H, s), 8.15 (1H, d, J=5.4Hz), 8.85 (1H, d, J=5.1Hz), 9.27 (1H, s) (CDCl ₃)	504
17	1.90 (1H, m), 2.20 (1H, m), 2.54 (4H, m), 3.00 (1H, m), 3.14-3.60 (8H, m), 3.57 (3H, s), 3.76 (4H, t, J=4.6Hz), 3.97 (1H, m), 4.17 (1H, m), 4.61 (1H, dd, J=1.9, 10.4Hz), 6.55 (2H, d, J=8.7Hz), 6.69 (1H, s), 7.27 (2H, d, J=8.6Hz), 7.79 (2H, d, J=6.0Hz), 8.70 (2H, d, J=6.0Hz) (CDCl ₃)	503

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
18	1.83-2.05(5H, m), 2.20(1H, m), 2.55(4H, m), 3.00(1H, m), 3.15-3.63(8H, m), 3.56(3H, s), 3.97(1H, m), 4.16(1H, m), 4.61(1H, dd, J=1.9, 10.4Hz), 6.56(2H, d, J=8.7Hz), 6.69(1H, s), 7.31(2H, d, J=8.6Hz), 7.80(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl ₃)	486
19	1.47-1.94(7H, m), 2.20(1H, m), 2.55(4H, m), 3.00(1H, m), 3.15-3.63(8H, m), 3.56(3H, s), 3.97(1H, m), 4.16(1H, m), 4.61(1H, dd, J=1.9, 10.4Hz), 6.55(2H, d, J=8.7Hz), 6.69(1H, s), 7.31(2H, d, J=8.6Hz), 7.80(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl ₃)	500
20	1.94(1H, m), 2.20(1H, m), 2.54(4H, m), 3.00(1H, m), 3.16-3.62(8H, m), 3.56(3H, s), 3.74(4H, t, J=4.6Hz), 3.97(1H, m), 4.16(1H, m), 4.61(1H, dd, J=1.9, 10.4Hz), 6.55(2H, d, J=8.7Hz), 6.69(1H, s), 7.27(2H, d, J=8.6Hz), 7.79(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl ₃)	502
21	1.68-1.73(4H, m), 1.80-1.86(1H, m), 2.12-2.18(1H, m), 2.81-3.26(10H, m), 3.44(3H, s), 3.63-3.66(3H, m), 3.84-4.00(2H, m), 4.58(1H, dd, J=1.2Hz, 10.2Hz), 6.51(2H, d, J=7.2Hz), 6.82(1H, s), 7.21(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6)	487
22	1.68-1.72(4H, m), 1.87-1.91(1H, m), 2.07-2.11(1H, m), 2.98-3.18(10H, m), 3.42(3H, s), 3.45-3.60(3H, m), 3.86-4.02(2H, m), 4.57(1H, dd, J=1.2Hz, 10.2Hz), 6.51(2H, d, J=7.2Hz), 7.00(1H, s), 7.23(2H, d, J=7.2Hz), 8.19(1H, dd, J=1.2Hz, 4.2Hz), 9.00(1H, d, J=4.2Hz), 9.29(1H, d, J=1.2Hz) (DMSO-d6)	488
23	1.97-2.20(2H, m), 1.98(3H, s), 3.13-3.62(9H, m), 3.58(3H, s), 3.97(1H, m), 4.60-4.64(2H, m), 6.58(2H, d, J=8.7 Hz), 6.69(1H, s), 7.32(2H, d, J=9.0 Hz), 7.79(2H, d, J=6.0 Hz), 8.71(2H, d, J=6.0 Hz) (CDCl ₃)	475
24	2.04-2.23(2H, m), 2.12(3H, s), 2.94(3H, s), 3.15(1H, dd, J=10.8, 12.8Hz), 3.25-3.35(3H, m), 3.47-3.63(4H, m), 3.56(3H, s), 3.98(1H, t, J=4.6Hz), 4.12(1H, m), 4.16(1H, m), 4.62(1H, d, J=10.5Hz), 5.40(1H, m), 6.59(2H, d, J=8.7Hz), 6.69(1H, s), 7.29(2H, d, J=8.6Hz), 7.80(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl ₃)	488

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
25	1.48 (9H, s), 2.04-2.23 (2H, m), 2.80 (3H, s), 3.15 (1H, dd, J=10.8, 12.8 Hz), 3.25-3.35 (3H, m), 3.47-3.63 (4H, m), 3.56 (3H, s), 3.98 (1H, t, J=4.6 Hz), 4.13 (1H, m), 4.62 (1H, dd, J=1.7, 10.3 Hz), 4.91 (1H, m), 6.59 (2H, d, J=8.7 Hz), 6.68 (1H, s), 7.29 (2H, d, J=8.6 Hz), 7.80 (2H, d, J=6.0 Hz), 8.70 (2H, d, J=6.0 Hz) (CDCl ₃)	546
26	1.48 (9H, s), 2.10-2.20 (2H, m), 2.81 (3H, s), 3.14-4.62 (9H, m), 3.98 (1H, m), 6.58 (2H, d, J=8.7 Hz), 6.69 (1H, s), 7.28 (2H, d, J=8.7 Hz), 7.79 (2H, dd, J=4.8, 1.5 Hz), 8.71 (2H, dd, J=4.5, 1.2 Hz) (CDCl ₃)	547
27	2.04-2.21 (2H, m), 2.07 (3H, s), 2.94 (3H, s), 3.15-3.58 (7H, m), 3.56 (3H, s), 3.98-4.15 (2H, m), 4.61-4.64 (2H, m), 5.44 (1H, m), 6.59 (2H, m), 6.70 (1H, s), 7.30 (2H, m), 7.80 (2H, d, J=5.4 Hz), 8.71 (2H, d, J=5.4 Hz) (CDCl ₃)	489
28	1.60 (4H, m), 1.72 (2H, m), 1.86 (2H, m), 2.80 (3H, s), 3.16 (1H, dd, J = 12.8, 10.8 Hz), 3.30 (1H, dd, J = 11.4, 2.0 Hz), 3.56 (3H, s), 3.57 (2H, m), 3.97 (1H, td, J = 11.4, 2.0 Hz), 3.56 (3H, s), 3.57 (2H, m), 3.97 (1H, td, J = 11.4, 2.4 Hz), 4.18 (2H, m), 4.61 (1H, dd, J = 10.4, 2.2 Hz), 6.68 (1H, s), 6.82 (2H, d, J = 8.0 Hz), 7.25 (2H, d, J = 8.0 Hz), 7.80 (2H, dd, J = 4.8, 1.2 Hz), 8.71 (2H, dd, J = 4.8, 1.2 Hz) (CDCl ₃)	446
29	1.59 (4H, m), 1.72 (2H, m), 1.88 (2H, m), 2.80 (3H, s), 3.15 (1H, dd, J = 12.7, 10.5 Hz), 3.30 (1H, td, J = 11.4, 2.0 Hz), 3.56 (2H, m), 3.57 (3H, s), 3.97 (1H, td, J = 11.4, 2.0 Hz), 4.17 (2H, m), 4.61 (1H, dd, J = 10.6, 2.1 Hz), 6.82 (2H, d, J = 8.7 Hz), 7.25 (2H, d, J = 8.7 Hz), 7.32 (1H, s), 8.15 (1H, d, J = 5.2 Hz), 8.86 (1H, d, J = 5.2 Hz), 9.27 (1H, s) (CDCl ₃)	447
30	1.51 (4H, m), 1.62 (4H, m), 1.72 (2H, m), 1.82 (2H, m), 2.77 (3H, s), 3.16 (1H, dd, J = 12.8, 10.4 Hz), 3.13 (1H, td, J = 11.4, 2.0 Hz), 3.56 (3H, s), 3.60 (2H, m), 3.77 (1H, m), 3.97 (1H, td, J = 11.4, 2.0 Hz), 4.14 (1H, dd, J = 11.4, 2.0 Hz), 4.60 (1H, dd, J = 10.4, 2.0 Hz), 6.68 (1H, s), 6.75 (2H, d, J = 9.2 Hz), 7.25 (2H, d, J = 9.2 Hz), 7.80 (2H, dd, J = 4.4, 1.6 Hz), 8.71 (2H, dd, J = 4.4, 1.6 Hz) (CDCl ₃)	474

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
31	1.52 (4H, m), 1.64 (4H, m), 1.72 (2H, m), 1.83 (2H, m), 2.77 (3H, s), 3.16 (1H, dd, J = 13.2, 10.8 Hz), 3.29 (1H, td, J = 11.4, 2.0 Hz), 3.56 (2H, m), 3.57 (3H, s), 3.97 (1H, td, J = 11.4, 2.0 Hz), 4.17 (1H, dd, J = 11.4, 2.0 Hz), 4.60 (1H, dd, J = 10.8, 2.0 Hz), 6.75 (2H, d, J = 8.4 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.34 (1H, s), 8.15 (1H, dd, J = 5.2, 1.2 Hz), 8.86 (1H, d, J = 5.2 Hz), 9.27 (1H, d, J = 1.2 Hz) (CDCl ₃)	475
32	1.17 (3H, m), 1.36 (2H, m), 1.62 (1H, m), 1.75 (2H, m), 2.03 (2H, m), 3.14 (1H, dd, J = 12.9, 10.8 Hz), 3.29 (2H, m), 3.56 (3H, s), 3.57 (3H, m), 3.97 (1H, t, J = 11.7 Hz), 4.14 (1H, d, J = 11.7 Hz), 4.58 (1H, dd, J = 10.5, 1.8 Hz), 6.59 (2H, d, J = 8.4 Hz), 6.69 (1H, s), 7.19 (2H, d, J = 8.4 Hz), 7.80 (2H, dd, J = 4.5, 1.8 Hz), 8.71 (2H, dd, J = 4.5, 1.8 Hz) (CDCl ₃)	446
33	1.44 (2H, m), 1.62 (2H, m), 1.74 (2H, m), 2.02 (2H, m), 3.14 (1H, dd, J = 12.8, 10.8 Hz), 3.30 (1H, td, J = 11.4, 2.8 Hz), 3.56 (3H, s), 3.58 (2H, m), 3.71 (br s, 1H), 3.79 (1H, m), 3.96 (1H, td, J = 11.4, 2.0 Hz), 4.13 (1H, td, 11.4, 2.0 Hz), 4.58 (1H, dd, J = 10.4, 2.0 Hz), 6.60 (2H, d, J = 8.4 Hz), 6.68 (1H, s), 7.20 (2H, d, J = 8.4 Hz), 7.80 (2H, dd, J = 6.0, 1.2 Hz), 8.71 (2H, dd, J = 6.0, 1.2 Hz) (CDCl ₃)	432
34	3.13 (1H, dd, J=10.8, 12.9Hz), 3.30 (1H, m), 3.56 (3H, s), 3.50-3.72 (4H, m), 3.97-4.22 (5H, m), 4.60 (1H, dd, J=1.9, 10.4Hz), 4.80 (1H, m), 6.49 (2H, d, J=8.7Hz), 6.69 (1H, s), 7.26 (2H, d, J=8.6Hz), 7.79 (2H, d, J=6.0Hz), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	420
35	1.16 (3H, t, J = 6.9 Hz), 1.16 (1H, m), 1.39 (4H, m), 1.69 (1H, m), 1.85 (4H, m), 3.18 (1H, dd, J = 12.9, 10.8 Hz), 3.30 (3H, m), 3.56 (3H, s), 3.57 (3H, m), 3.97 (1H, t, J = 12.9 Hz), 4.15 (1H, d, J = 12.9 Hz), 4.59 (1H, dd, J = 10.8, 2.1 Hz), 6.69 (1H, s), 6.72 (2H, d, J = 8.7 Hz), 7.24 (2H, d, J = 8.7 Hz), 7.81 (2H, dd, J = 6.4, 2.0 Hz), 8.72 (2H, dd, J = 6.4, 2.0 Hz) (CDCl ₃)	474

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
36	0.92 (3H, t, J = 8.0 Hz), 1.17 (1H, m), 1.38 (4H, m), 1.54 (2H, m), 1.70 (1H, d, J = 13.3 Hz), 1.83 (4H, m), 3.11 (2H, t, J = 8.0 Hz), 3.17 (1H, dd, J = 12.8, 10.8 Hz), 3.30 (1H, td, J = 11.4, 2.0 Hz), 3.59 (3H, s), 3.61 (2H, m), 3.96 (1H, td, J = 11.4, 1.2 Hz), 4.16 (1H, d, J = 11.4 Hz), 4.59 (1H, dd, J = 19.4, 2.0 Hz), 6.68 (1H, s), 6.70 (2H, d, J = 8.8 Hz), 7.23 (2H, d, J = 8.8 Hz), 7.79 (2H, d, J = 6.0 Hz), 8.71 (2H, d, J = 6.0 Hz) (CDCl ₃)	488
37	1.43 (2H, m), 1.58 (2H, m), 1.79 (2H, m), 2.08 (2H, m), 2.77 (3H, s), 3.15 (1H, dd, J = 13.2, 11.2 Hz), 3.30 (1H, td, J = 11.4, 2.0 Hz), 3.59 (4H, m), 3.97 (1H, td, J = 11.4, 1.2 Hz), 4.14 (1H, d, J = 11.4 Hz), 4.61 (1H, dd, J = 10.8, 2.4 Hz), 6.68 (1H, s), 6.78 (2H, d, J = 8.8 Hz), 7.26 (2H, d, J = 8.8 Hz), 7.80 (2H, d, J = 4.8 Hz), 8.71 (2H, d, J = 4.8 Hz) (CDCl ₃)	476
38	1.45 (2H, m), 2.03 (2H, d, J = 12.8 Hz), 3.13 (1H, dd, J = 13.2, 10.8 Hz), 3.30 (1H, t, J = 11.4 Hz), 3.54 (6H, m), 4.00 (3H, m), 4.12 (1H, d, J = 11.4 Hz), 4.59 (1H, d, J = 11.4 Hz), 6.62 (2H, d, J = 8.4 Hz), 6.68 (1H, s), 7.21 (2H, d, J = 8.4 Hz), 7.79 (2H, dd, J = 4.8, 1.6 Hz), 8.71 (2H, dd, J = 4.8, 1.6 Hz) (CDCl ₃)	448
39	2.20 (3H, s), 3.15 (1H, dd, J=10.8, 12.9Hz), 3.29 (1H, m), 3.525-3.65 (2H, m), 3.58 (3H, s), 3.98 (1H, m), 4.16 (1H, m), 4.70 (1H, dd, J=1.9, 10.4Hz), 6.70 (1H, s), 6.91 (1H, s), 7.38 (2H, d, J=8.4Hz), 7.54 (2H, d, J=8.4Hz), 7.79 (2H, d, J=6.0Hz), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	406
40	2.20 (3H, s), 3.15 (1H, dd, J=10.8, 12.9Hz), 3.29 (1H, m), 3.52-3.65 (2H, m), 3.63 (3H, s), 3.98 (1H, m), 4.16 (1H, m), 4.70 (1H, dd, J=1.9, 10.4Hz), 7.26 (1H, s), 7.36 (2H, d, J=8.7Hz), 7.39 (1H, s), 7.55 (2H, d, J=8.7Hz), 8.14 (1H, d, J=5.4Hz), 8.87 (1H, d, J=5.1Hz), 9.27 (1H, s) (CDCl ₃)	407

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
41	1.88(3H, s), 3.15(1H, dd, J=10.8, 12.9Hz), 3.28(3H, s), 3.34(1H, m), 3.55-3.71(2H, m), 3.59(3H, s), 4.01(1H, m), 4.16(1H, m), 4.77(1H, dd, J=1.9, 10.4Hz), 6.71(1H, s), 7.22(2H, d, J=8.4Hz), 7.48(2H, d, J=8.4Hz), 7.79(2H, d, J=6.0Hz), 8.72(2H, d, J=6.0Hz) (CDCl ₃)	420
42	1.68 (2H, dd, J = 11.2, 4.4 Hz), 1.84 (2H, qd, J = 11.2, 4.4 Hz), 2.81 (3H, s), 3.15 (1H, dd, J = 12.8, 10.4 Hz), 3.29 (1H, td, J = 11.4, 2.0 Hz), 3.51 (3H, m), 3.56 (3H, s), 3.62 (1H, d, J = 13.2 Hz), 3.83 (1H, m), 3.97 (1H, td, J = 11.4, 2.4 Hz), 4.07 (2H, dd, J = 11.2, 4.4 Hz), 4.14 (1H, dd, J = 11.4, 2.4 Hz), 4.62 (1H, dd, J = 10.8, 2.4 Hz), 6.68 (1H, s), 6.82 (2H, d, J = 9.2 Hz), 7.27 (2H, d, J = 9.2 Hz), 7.79 (2H, d, J = 6.0 Hz), 8.71 (2H, d, J = 6.0 Hz) (CDCl ₃)	462
43	1.68 (2H, dd, J = 11.2, 4.4 Hz), 1.85 (2H, qd, J = 11.2, 4.4 Hz), 3.14 (1H, dd, J = 12.8, 10.8 Hz), 3.28 (1H, td, J = 11.4, 2.0 Hz), 3.45 (2H, t, J = 11.8 Hz), 3.57 (3H, s), 3.58 (2H, m), 3.82 (1H, m), 3.98 (1H, td, J = 11.4, 2.4 Hz), 4.07 (2H, dd, J = 11.2, 4.4 Hz), 4.16 (1H, dd, J = 11.2, 4.4 Hz), 4.62 (1H, dd, J = 10.4, 2.0 Hz), 6.82 (2H, d, J = 11.6 Hz), 7.27 (2H, d, J = 11.6 Hz), 7.34 (1H, s), 8.14 (1H, dd, J = 4.8, 1.2 Hz), 8.85 (1H, d, J = 4.8 Hz), 9.27 (1H, d, J = 1.2 Hz) (CDCl ₃)	463
44	2.38(2H, t, J=7.3Hz), 3.13(1H, dd, J=10.8, 12.9Hz), 3.30(1H, m), 3.56(3H, s), 3.50-3.59(2H, m), 3.88(4H, t, J=7.3Hz), 3.96(1H, td, J=2.2, 11.6Hz), 4.14(1H, d, J=11.8Hz), 4.61(1H, dd, J=2.1, 10.4Hz), 6.45(2H, d, J=8.6Hz), 6.68(1H, s), 7.24(2H, d, J=8.6Hz), 7.96(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl ₃)	404
45	2.38(2H, t, J=7.3Hz), 3.13(1H, dd, J=10.8, 12.9Hz), 3.30(1H, m), 3.56(3H, s), 3.50-3.59(2H, m), 3.88(4H, t, J=7.3Hz), 3.96(1H, td, J=2.2, 11.6Hz), 4.14(1H, d, J=11.8Hz), 4.61(1H, dd, J=2.1, 10.4Hz), 6.47(2H, d, J=8.7Hz), 7.26(2H, d, J=8.7Hz), 7.34(1H, s), 8.14(1H, d, J=5.4Hz), 8.87(1H, d, J=5.1Hz), 9.27(1H, s) (CDCl ₃)	405

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
46	0.82 (1H, m), 1.00 (2H, m), 1.39 (2H, m), 1.68 (1H, m), 1.71 (2H, m), 1.73 (3H, s), 1.81 (2H, m), 3.14 (1H, dd, J = 13.1, 10.6 Hz), 3.36 (1H, td, J = 11.4, 2.4 Hz), 3.57 (1H, d, J = 11.4 Hz), 3.60 (3H, s), 3.72 (1H, d, J = 13.1 Hz), 4.01 (1H, td, J = 11.4, 2.4 Hz), 4.20 (1H, dd, J = 11.4, 1.8 Hz), 4.59 (1H, m), 4.79 (1H, dd, J = 10.6, 1.8 Hz), 6.70 (1H, s), 7.13 (2H, d, J = 8.3 Hz), 7.46 (2H, d, J = 8.3 Hz), 7.79 (2H, dd, J = 4.8, 1.4 Hz), 8.72 (2H, dd, J = 4.8, 1.4 Hz) (CDCl ₃)	488
47	0.88 (1H, m), 1.01 (2H, m), 1.39 (2H, m), 1.68 (1H, m), 1.70 (2H, m), 1.73 (3H, s), 1.81 (2H, m), 3.14 (1H, dd, J = 12.8, 10.6 Hz), 3.33 (1H, td, J = 12.0, 2.4 Hz), 3.56 (1H, d, J = 12.0), 3.61 (3H, s), 3.69 (1H, d, J = 12.8 Hz), 4.03 (1H, td, J = 12.0, 2.4 Hz), 4.21 (1H, td, J = 12.0, 2.4 Hz), 4.60 (1H, m), 4.79 (1H, dd, J = 10.6, 1.6 Hz), 7.14 (2H, d, J = 8.4 Hz), 7.36 (1H, s), 7.47 (2H, d, J = 8.4 Hz), 8.14 (1H, dd, J = 4.8, 1.2 Hz), 8.88 (1H, d, J = 4.8 Hz), 9.28 (1H, d, J = 1.2 Hz) (CDCl ₃)	489
48	3.14 (1H, dd, J = 10.8, 12.9 Hz), 3.31 (1H, m), 3.52-3.65 (2H, m), 3.61 (3H, s), 3.99 (1H, m), 4.16 (1H, m), 4.69 (1H, dd, J = 1.9, 10.4 Hz), 6.58 (1H, br. s), 6.69-6.77 (1H, m), 6.87 (1H, d, J = 8.4 Hz), 7.19 (1H, m), 7.38 (4H, m), 7.49-7.51 (1H, m), 7.80 (2H, d, J = 6.2 Hz), 8.21 (1H, d, J = 6.0 Hz), 8.72 (2H, d, J = 6.2 Hz) (CDCl ₃)	441
49	3.14 (1H, dd, J = 10.8, 12.9 Hz), 3.31 (1H, m), 3.52-3.65 (2H, m), 3.61 (3H, s), 3.99 (1H, m), 4.16 (1H, m), 4.69 (1H, dd, J = 1.9, 10.4 Hz), 6.58 (1H, br. s), 6.69-6.77 (1H, m), 6.87 (1H, d, J = 8.4 Hz), 7.38 (4H, m), 7.49-7.51 (1H, m), 8.21 (1H, d, J = 6.0 Hz), 8.14 (1H, dd, J = 1.2, 4.8 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.28 (1H, d, J = 1.2 Hz) (CDCl ₃)	442
50	3.14 (1H, dd, J = 10.8, 12.9 Hz), 3.30 (1H, m), 3.58-3.67 (2H, m), 3.59 (3H, s), 4.00 (1H, m), 4.16 (1H, m), 4.70 (1H, dd, J = 1.9, 10.4 Hz), 6.70 (1H, s), 7.23 (1H, s), 7.38 (2H, d, J = 8.3 Hz), 7.55 (2H, d, J = 8.3 Hz), 7.80 (4H, m), 8.72 (4H, m) (CDCl ₃)	441

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
51	3.15 (1H, dd, J = 10.8, 13.2 Hz), 3.32 (1H, m), 3.54-3.67 (2H, m), 3.58 (3H, m), 4.00-4.16 (3H, m), 4.68 (1H, dd, J = 2.4, 10.8 Hz), 5.78 (1H, s), 6.70 (1H, s), 7.10 (2H, d, J = 8.4 Hz), 7.20-7.22 (1H, m), 7.35 (2H, d, J = 8.7 Hz), 7.36 (1H, m), 7.80 (2H, d, J = 6.0 Hz), 8.20 (1H, dd, J = 1.5, 4.5 Hz), 8.41 (1H, d, J = 2.7 Hz), 8.72 (2H, d, J = 6.0 Hz) (CDCl ₃)	441
52	0.85 (1H, m), 1.27 (2H, m), 1.37 (2H, m), 1.58 (1H, m), 1.78 (2H, m), 1.97 (2H, m), 2.97 (3H, s), 3.14 (1H, dd, J = 13.2, 10.8 Hz), 3.32 (1H, td, J = 11.2, 2.0 Hz), 3.56 (1H, d, J = 11.2 Hz), 3.59 (3H, s), 3.71 (1H, d, J = 13.2 Hz), 4.01 (1H, td, J = 11.2, 2.0 Hz), 4.08 (1H, m), 4.19 (1H, dd, J = 11.2, 2.0 Hz), 4.78 (1H, dd, J = 10.8, 2.4 Hz), 6.71 (1H, s), 7.29 (2H, d, J = 8.4 Hz), 7.46 (2H, d, J = 8.4 Hz), 7.80 (2H, dd, J = 4.8, 1.2 Hz), 8.73 (2H, dd, J = 4.8, 1.2 Hz) (CDCl ₃)	524
53	0.87 (1H, m), 1.18 (2H, m), 1.39 (2H, m), 1.69 (1H, m), 1.78 (2H, m), 1.97 (2H, m), 2.98 (3H, m), 3.28 (1H, td, J = 11.2, 2.2 Hz), 3.55 (1H, d, J = 11.2 Hz), 3.60 (3H, s), 3.69 (1H, d, J = 13.2 Hz), 4.00 (1H, td, J = 11.2, 2.2 Hz), 4.07 (1H, m), 4.20 (1H, dd, J = 11.2, 2.2 Hz), 4.77 (1H, dd, J = 10.4, 2.0 Hz), 7.30 (2H, d, J = 8.0 Hz), 7.37 (1H, s), 7.47 (2H, d, J = 8.0 Hz), 8.16 (1H, dd, J = 4.8, 1.2 Hz), 8.89 (1H, d, J = 4.8 Hz), 9.28 (1H, d, J = 1.2 Hz) (CDCl ₃)	525
54	0.97 (1H, m), 1.22 (2H, m), 1.42 (2H, m), 1.60 (1H, m), 1.76 (2H, m), 1.95 (2H, m), 3.01 (1H, dd, J = 12.8, 10.8 Hz), 3.30 (1H, td, J = 11.2, 2.4 Hz), 3.52 (1H, d, J = 11.2 Hz), 3.56 (3H, s), 3.57 (1H, d, J = 12.8 Hz), 3.95 (1H, td, J = 11.2, 2.4 Hz), 4.16 (1H, dd, J = 11.2, 2.4 Hz), 4.66 (1H, m), 4.67 (1H, d, J = 10.8 Hz), 6.69 (1H, s), 7.05 (2H, d, J = 8.0 Hz), 7.15 (1H, t, J = 8.0 Hz), 7.25 (2H, t, J = 8.0 Hz), 7.78 (2H, dd, J = 5.2, 1.2 Hz), 8.72 (2H, dd, J = 5.2, 1.2 Hz) (CDCl ₃)	550

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
55	0.96 (1H, m), 1.20 (2H, m), 1.40 (2H, m), 1.60 (1H, m), 1.78 (2H, m), 1.95 (2H, m), 3.01 (1H, t, J = 11.7 Hz), 3.29 (1H, td, J = 11.6, 2.4 Hz), 3.51 (2H, m), 3.57 (3H, s), 3.96 (1H, t, J = 11.6 Hz), 4.16 (1H, d, J = 11.6 Hz), 4.66 (1H, m), 4.67 (1H, d, J = 9.0 Hz), 7.06 (2H, d, J = 8.0 Hz), 7.15 (1H, t, J = 8.0 Hz), 7.26 (2H, t, J = 8.0 Hz), 7.35 (1H, s), 8.11 (1H, d, J = 5.1 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.28 (1H, s) (CDCl ₃)	551
56	0.57 (2H, m), 0.90 (1H, m), 0.99 (2H, m), 1.07 (2H, m), 1.39 (2H, m), 1.59 (1H, m), 1.74 (2H, m), 1.83 (2H, m), 3.16 (1H, dd, J = 12.8, 10.4 Hz), 3.38 (1H, td, J = 13.2, 2.4 Hz), 3.57 (1H, d, J = 13.2 Hz), 3.60 (3H, s), 3.71 (1H, d, J = 13.2 Hz), 4.02 (1H, td, J = 13.2, 2.4 Hz), 4.21 (1H, dd, J = 13.2, 2.4 Hz), 4.60 (1H, m), 4.79 (1H, dd, J = 10.4, 2.0 Hz), 6.70 (1H, s), 7.22 (2H, d, J = 8.4 Hz), 7.47 (2H, d, J = 8.4 Hz), 7.80 (2H, dd, J = 5.2, 1.2 Hz), 8.73 (2H, dd, J = 5.2, 1.2 Hz) (CDCl ₃)	514
57	0.50 (2H, m), 0.90 (1H, m), 0.99 (2H, m), 1.08 (2H, m), 1.40 (2H, m), 1.57 (1H, m), 1.73 (2H, m), 1.82 (2H, m), 3.15 (1H, dd, J = 12.8, 10.8 Hz), 3.37 (1H, td, J = 13.2, 2.4 Hz), 3.57 (1H, d, J = 13.2 Hz), 3.61 (3H, s), 3.70 (1H, d, J = 12.8 Hz), 4.03 (1H, td, J = 13.2, 2.4 Hz), 4.21 (1H, dd, J = 13.2, 2.4 Hz), 4.60 (1H, m), 4.79 (1H, dd, J = 10.8, 2.0 Hz), 7.23 (2H, d, J = 8.0 Hz), 7.36 (1H, s), 7.48 (2H, d, J = 8.0 Hz), 8.15 (1H, d, J = 5.2 Hz), 8.88 (1H, d, J = 5.2 Hz), 9.29 (1H, s) (CDCl ₃)	515
58	0.82 (1H, m), 1.05 (2H, m), 1.37 (2H, m), 1.65 (1H, m), 1.70 (2H, m), 1.82 (2H, m), 3.13 (1H, dd, J = 13.2, 10.6 Hz), 3.33 (1H, td, J = 13.6, 2.4 Hz), 3.55 (1H, d, J = 13.6 Hz), 3.59 (3H, s), 3.70 (1H, d, J = 13.2 Hz), 4.00 (1H, td, J = 13.6, 2.4 Hz), 4.17 (2H, m), 4.75 (1H, dd, J = 10.6, 2.0 Hz), 6.71 (1H, s), 7.07 (2H, d, J = 8.4 Hz), 7.38 (2H, d, J = 8.4 Hz), 7.47 (2H, t, J = 7.6 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.76 (2H, d, J = 7.6 Hz), 7.81 (2H, dd, J = 4.4, 1.6 Hz), 8.74 (2H, dd, J = 4.4, 1.6 Hz) (CDCl ₃)	586

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
59	0.81 (1H, m), 1.05 (2H, m), 1.36 (2H, m), 1.63 (1H, m), 1.70 (2H, m), 1.81 (2H, m), 3.13 (1H, dd, J = 12.2, 10.8 Hz), 3.30 (1H, td, J = 13.2, 2.4 Hz), 3.54 (1H, d, J = 13.2 Hz), 3.60 (3H, s), 3.68 (1H, d, J = 12.2 Hz), 4.01 (1H, td, J = 13.2, 2.4 Hz), 4.15 (2H, m), 4.75 (1H, dd, J = 10.8, 2.0 Hz), 7.07 (2H, d, J = 7.6 Hz), 7.37 (1H, s), 7.38 (2H, d, J = 7.6 Hz), 7.48 (2H, t, J = 7.6 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.77 (2H, d, J = 8.0 Hz), 8.18 (1H, dd, J = 5.2, 1.2 Hz), 8.90 (1H, d, J = 5.2 Hz), 9.29 (1H, d, J = 1.2 Hz) (CDCl ₃)	587
60	1.13 (1H, m), 1.39 (4H, m), 1.67 (1H, m), 1.82 (4H, m), 3.15 (1H, dd, J = 13.2, 10.8 Hz), 3.30 (1H, m), 3.39 (2H, t, J = 6.2 Hz), 3.52 (2H, m), 3.56 (3H, s), 3.62 (1H, d, J = 12.8 Hz), 3.69 (2H, br s), 3.97 (1H, td, J = 11.4, 2.4 Hz), 4.15 (1H, d, J = 11.4 Hz), 4.62 (1H, dd, J = 10.8, 2.4 Hz), 6.69 (1H, s), 6.87 (2H, d, J = 8.8 Hz), 7.27 (2H, d, J = 8.8 Hz), 7.80 (2H, dd, J = 4.8, 1.6 Hz), 8.71 (2H, dd, J = 4.8, 1.6 Hz) (CDCl ₃)	490
61	1.12 (1H, m), 1.38 (4H, m), 1.71 (1H, m), 1.83 (4H, m), 3.15 (1H, dd, J = 12.8, 10.4 Hz), 3.30 (1H, m), 3.39 (1H, t, J = 6.2 Hz), 3.51 (1H, m), 3.58 (3H, s), 3.62 (1H, m), 3.69 (1H, q, J = 6.2 Hz), 3.74 (1H, m), 3.98 (1H, td, J = 11.4, 2.0 Hz), 4.16 (1H, d, J = 11.4 Hz), 4.62 (1H, dd, J = 10.4, 2.0 Hz), 6.88 (2H, d, J = 8.4 Hz), 7.27 (2H, d, J = 8.4 Hz), 7.34 (1H, s), 8.15 (1H, dd, J = 5.2, 0.8 Hz), 8.87 (1H, d, J = 5.2 Hz), 9.27 (1H, d, J = 0.8 Hz) (CDCl ₃)	491
62	3.07-3.12 (2H, m), 3.62 (3H, s), 3.62-3.63 (1H, m), 3.76-3.80 (2H, m), 3.90-4.09 (5H, m), 4.38 (2H, br), 4.70 (1H, dd, J = 1.2 Hz, 4.2 Hz), 6.72 (1H, dd, J = 7.2 Hz, 7.3 Hz), 7.05-7.44 (4H, m), 8.31 (2H, d, J = 7.2 Hz), 8.48 (2H, d, J = 7.2 Hz), 8.90-8.96 (4H, m) (DMSO-d ₆).	466

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
63	3.02-3.12(4H, m), 3.51(3H, s), 3.69-3.76(2H, m), 3.90-4.07(4H, m), 4.70(1H, dd, J=1.2Hz, 10.2Hz), 6.73(1H, dd, J=7.2Hz, 7.3Hz), 7.01-7.26(6H, m), 7.43(2H, d, J=7.2Hz), 8.21(1H, dd, J=1.2Hz, 4.2Hz), 9.00(1H, d, J=4.2Hz), 9.30(1H, d, J=1.2Hz) (DMSO-d6).	467
64	0.86-1.24(6H, m), 1.52-1.63(7H, m), 2.33-2.36(1H, m), 2.62-2.72(1H, m), 2.96-3.04(2H, m), 3.12-3.20(1H, m), 3.46(3H, s), 3.65-3.74(2H, m), 3.83-3.86(1H, m), 4.03-4.06(1H, m), 4.69(1H, dd, J=1.2Hz, 10.2Hz), 6.83(1H, s), 7.10(2H, d, J=7.2Hz), 7.35(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.70(2H, d, J=4.2Hz) (DMSO-d6).	486
65	0.82-1.35(7H, m), 1.59-1.66(7H, m), 2.33-2.36(1H, m), 2.60-2.66(1H, m), 2.98-3.00(2H, m), 3.04-3.18(1H, m), 3.47(3H, s), 3.67-4.03(4H, m), 4.68(1H, dd, J=1.2Hz, 10.2Hz), 6.87(1H, s), 7.10(2H, d, J=7.2Hz), 7.38(2H, d, J=7.2Hz), 8.20(1H, dd, J=1.2Hz, 4.2Hz), 9.02(1H, d, J=4.2Hz), 9.29(1H, d, J=1.2Hz) (DMSO-d6).	487
66	1.05-1.95(10H, m), 3.16(1H, dd, J = 12.8, 10.4 Hz), 3.31(1H, m), 3.37(3H, s), 3.45(4H, m), 3.54(2H, m), 3.56(3H, s), 3.57(1H, d, J = 13.2 Hz), 3.97(1H, td, J = 13.3, 2.4 Hz), 4.13(1H, dd, J = 13.3, 2.4 Hz), 4.60(1H, dd, J = 10.4, 2.0 Hz), 6.69(1H, s), 6.78(2H, d, J = 8.8 Hz), 7.24(2H, d, J = 8.8 Hz), 7.80(2H, d, J = 4.8 Hz), 8.71(2H, d, J = 4.8 Hz) (CDCl ₃)	504

Compound No.	$^1\text{H-NMR } \delta$:	LC-MS (M+1)
67	1.18 (1H, m), 1.40 (4H, m), 1.70 (1H, m), 1.83 (4H, m), 3.16 (1H, dd, J = 13.2, 10.8 Hz), 3.31 (1H, m), 3.38 (3H, s), 3.45 (4H, m), 3.56 (4H, m), 3.57 (3H, s), 3.97 (1H, m), 4.13 (1H, m), 4.60 (1H, dd, J = 10.8, 2.4 Hz), 6.78 (2H, d, J = 8.8 Hz), 7.25 (2H, d, J = 8.8 Hz), 7.26 (1H, s), 8.15 (1H, d, J = 5.6 Hz), 8.86 (1H, d, J = 5.6 Hz), 9.27 (1H, s) (CDCl_3)	505
68	1.27-1.98 (10H, m), 2.24 (1H, m), 3.09 (1H, dd, J = 10.8, 12.9 Hz), 3.30 (1H, m), 3.53-3.65 (2H, m), 3.57 (3H, m), 3.99 (1H, td, J = 2.1, 13.5 Hz), 4.16 (1H, dd, J = 2.1, 11.8 Hz), 4.69 (1H, dd, J = 2.4, 10.8 Hz), 6.70 (1H, s), 7.25 (1H, br. s), 7.37 (2H, d, J = 8.7 Hz), 7.56 (2H, d, J = 8.7 Hz), 7.78 (2H, d, J = 6.3 Hz), 8.71 (2H, d, J = 6.3 Hz) (CDCl_3)	474
69	1.27-1.99 (10H, m), 2.20 (1H, t), 3.09 (1H, dd, J = 10.8, 12.9 Hz), 3.30 (1H, m), 3.51-3.67 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J = 2.1, 13.5 Hz), 4.16 (1H, dd, J = 2.1, 11.8 Hz), 4.70 (1H, dd, J = 2.4, 10.8 Hz), 7.20 (1H, br. s), 7.35 (1H, s), 7.36 (2H, d, J = 8.4 Hz), 7.56 (2H, d, J = 8.4 Hz), 8.13 (1H, d, J = 5.1 Hz), 8.86 (1H, d, J = 5.4 Hz), 9.27 (1H, s) (CDCl_3)	475
70	3.12 (1H, dd, J = 10.5, 12.9 Hz), 3.31 (1H, td, J = 3.0, 12.0 Hz), 3.54-3.68 (2H, m), 3.58 (3H, s), 4.01 (1H, td, J = 2.1, 11.4 Hz), 4.18 (1H, dd, J = 1.8, 11.7 Hz), 4.73 (1H, dd, J = 2.1, 10.5 Hz), 6.70 (1H, s), 7.42-7.57 (5H, m), 7.70 (2H, d, J = 8.1 Hz), 7.79 (2H, d, J = 6.0 Hz), 7.88 (2H, d, J = 8.1 Hz), 7.92 (1H, br. s), 8.71 (2H, d, J = 6.3 Hz) (CDCl_3)	468
71	3.12 (1H, dd, J = 10.4, 12.9 Hz), 3.29 (1H, td, J = 3.0, 12.0 Hz), 3.52-3.66 (2H, m), 3.59 (3H, s), 4.01 (1H, td, J = 2.1, 11.4 Hz), 4.20 (1H, dd, J = 1.2, 11.1 Hz), 4.74 (1H, dd, J = 2.1, 10.5 Hz), 7.36 (1H, s), 7.43-7.55 (5H, m), 7.70 (2H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.4 Hz), 7.92 (1H, br. s), 8.14 (1H, d, J = 5.4 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.27 (1H, d, J = 1.2 Hz) (CDCl_3)	469

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
72	3.17 (1H, dd, J = 10.4, 12.9 Hz), 3.37 (1H, t, J = 11.4 Hz), 3.49 (3H, s), 3.60 (3H, s), 3.58-3.72 (2H, m), 4.01-4.20 (2H, m), 4.74 (1H, d, J = 10.5 Hz), 6.60-6.67 (2H, m), 6.71 (1H, s), 7.25-7.37 (1H, m), 7.31 (2H, d, J = 8.4 Hz), 7.45 (2H, d, J = 8.4 Hz), 7.81 (2H, d, J = 6.0 Hz), 8.24 (1H, d, J = 3.6 Hz), 8.72 (2H, d, J = 6.0 Hz) (CDCl ₃)	455
73	3.17 (1H, dd, J = 10.8, 12.9 Hz), 3.32 (1H, td, J = 2.8, 11.4 Hz), 3.49 (3H, s), 3.61 (3H, s), 3.54-3.71 (2H, m), 4.02 (1H, td, J = 2.4, 11.4 Hz), 4.18 (1H, dd, J = 11.7, 18.0 Hz), 4.74 (1H, dd, J = 2.3, 10.6 Hz), 6.61 (1H, d, J = 8.8 Hz), 6.65 (1H, d, J = 1.9 Hz), 7.26-7.36 (4H, m), 7.45 (2H, d, J = 8.4 Hz), 8.17 (1H, d, J = 6.5 Hz), 8.24 (1H, d, J = 3.5 Hz), 8.88 (1H, d, J = 5.1 Hz), 9.28 (1H, d, J = 1.1 Hz) (CDCl ₃)	456
74	0.84-0.89 (2H, m), 1.08-1.13 (2H, m), 1.51 (1H, m), 3.09 (1H, dd, J = 10.6, 13.0 Hz), 3.30 (1H, td, J = 2.9, 13.0 Hz), 3.52-3.65 (2H, m), 3.57 (3H, s), 3.98 (1H, td, J = 2.1, 11.4 Hz), 4.16 (1H, dd, J = 11.7, 18.0 Hz), 4.70 (1H, dd, J = 1.9, 10.3 Hz), 6.69 (1H, s), 7.36 (2H, d, J = 8.3 Hz), 7.50 (1H, br.s), 7.55 (2H, d, J = 8.3 Hz), 7.79 (2H, d, J = 6.0 Hz), 8.71 (2H, d, J = 6.0 Hz) (CDCl ₃)	432
75	0.86-0.90 (2H, m), 1.09-1.13 (2H, m), 1.51 (1H, m), 3.19 (1H, dd, J = 10.6, 13.0 Hz), 3.28 (1H, t, J = 9.9 Hz), 3.52-3.65 (2H, m), 3.59 (3H, s), 3.98 (1H, td, J = 2.1, 11.4 Hz), 4.16 (1H, dd, J = 11.7, 18.0 Hz), 4.70 (1H, dd, J = 1.9, 10.3 Hz), 7.24-7.44 (3H, m), 7.43 (1H, br.s), 7.56 (2H, d, J = 8.4 Hz), 8.13 (1H, d, J = 5.4 Hz), 8.86 (1H, d, J = 5.4 Hz), 9.27 (1H, s) (CDCl ₃)	433
76	1.05 (6H, d, J = 6.9 Hz), 1.74 (3H, s), 3.14 (1H, dd, J = 10.8, 13.2 Hz), 3.40 (1H, td, J = 2.9, 13.0 Hz), 3.55-3.74 (2H, m), 3.60 (3H, s), 4.02 (1H, td, J = 2.1, 11.4 Hz), 4.20 (1H, dd, J = 11.7, 18.0 Hz), 4.80 (1H, dd, J = 2.1, 10.5 Hz), 5.02 (1H, q, J = 6.9 Hz), 6.71 (1H, s), 7.15 (2H, d, J = 8.4 Hz), 7.48 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 6.0 Hz), 8.73 (2H, d, J = 6.0 Hz) (CDCl ₃)	448

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
77	1.05 (6H, d, J = 6.8 Hz), 1.74 (3H, s), 3.14 (1H, dd, J = 10.6, 12.8 Hz), 3.35 (1H, td, J = 2.9, 11.4 Hz), 3.54-3.71 (2H, m), 3.61 (3H, s), 4.03 (1H, td, J = 2.4, 11.6 Hz), 4.20 (1H, dd, J = 11.7, 18.0 Hz), 4.80 (1H, dd, J = 2.1, 10.6 Hz), 5.03 (1H, q, J = 6.8 Hz), 7.15 (2H, d, J = 8.3 Hz), 7.27 (1H, s), 7.48 (2H, d, J = 8.3 Hz), 8.15 (1H, dd, J = 1.1, 5.2 Hz), 8.88 (1H, d, J = 5.1 Hz), 9.28 (1H, d, J = 1.2 Hz) (CDCl ₃)	449
78	1.23 (9H, s), 3.09 (1H, dd, J = 10.5, 12.9 Hz), 3.27 (1H, td, J = 3.0, 12.0 Hz), 3.51-3.64 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J = 2.1, 11.4 Hz), 4.18 (1H, dd, J = 11.7, 18.0 Hz), 4.70 (1H, dd, J = 2.1, 10.5 Hz), 6.70 (1H, s), 7.33 (1H, br. s), 7.38 (2H, d, J = 8.4 Hz), 7.57 (2H, d, J = 8.4 Hz), 7.78 (2H, d, J = 6.0 Hz), 8.70 (2H, d, J = 5.7 Hz) (CDCl ₃)	448
79	1.23 (9H, s), 3.09 (1H, dd, J = 10.5, 12.9 Hz), 3.27 (1H, td, J = 3.0, 12.0 Hz), 3.51-3.64 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J = 2.1, 11.4 Hz), 4.18 (1H, dd, J = 11.7, 18.0 Hz), 4.70 (1H, dd, J = 2.1, 10.5 Hz), 7.34 (1H, s), 7.40 (2H, d, J = 12.3 Hz), 7.43 (1H, br. s), 7.59 (2H, d, J = 12.3 Hz), 8.13 (1H, d, J = 5.4 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.27 (1H, d, J = 1.5 Hz) (CDCl ₃)	449
80	1.62-1.68 (5H, m), 1.89 (6H, m), 2.04-2.11 (3H, m), 3.10-3.73 (6H, m), 3.56 (3H, s), 3.96 (1H, t, J = 12.6 Hz), 4.14 (1H, d, J = 11.7 Hz), 4.60 (1H, d, J = 9.9 Hz), 6.69 (1H, s), 6.79 (2H, d, J = 6.6 Hz), 7.17 (2H, d, J = 7.0 Hz), 7.80 (2H, br. d), 8.71 (2H, br. d) (CDCl ₃)	498
81	1.63-1.67 (5H, m), 1.84-1.90 (6H, m), 2.12 (3H, m), 3.14 (1H, dd, J = 10.5, 12.9 Hz), 3.29 (1H, td, J = 3.0, 12.0 Hz), 3.40 (1H, br. s), 3.51-3.62 (2H, m), 3.57 (3H, s), 3.74 (1H, m), 3.97 (1H, td, J = 2.4, 11.8 Hz), 4.13 (1H, dd, J = 2.4, 11.7 Hz), 4.60 (1H, dd, J = 2.1, 10.5 Hz), 6.78 (2H, d, J = 10.8 Hz), 7.18 (2H, d, J = 10.8 Hz), 7.35 (1H, s), 8.16 (1H, dd, J = 1.2, 5.1 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.27 (1H, s) (CDCl ₃)	499

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
82	1.35-1.67 (12H, m), 2.07 (3H, m), 2.79 (3H, s), 3.14 (1H, dd, J = 10.5, 12.9 Hz), 3.29 (1H, td, J = 3.0, 12.0 Hz), 3.54-3.69 (1H, td, J = 3.0, 12.0 Hz), 3.54-3.69 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J = 2.4, 11.8 Hz), 4.17 (1H, dd, J = 2.4, 11.7 Hz), 4.70 (1H, dd, J = 2.1, 10.5 Hz), 6.70 (1H, s), 7.16 (2H, d, J = 8.1 Hz), 7.30 (2H, d, J = 8.1 Hz), 7.80 (1H, d, J = 6.3 Hz), 8.72 (1H, d, J = 6.3 Hz) (CDCl ₃)	512
83	1.52-1.73 (12H, m), 2.06 (3H, m), 2.78 (3H, s), 3.14 (1H, dd, J = 10.5, 12.9 Hz), 3.29 (1H, td, J = 3.0, 12.0 Hz), 3.53-3.68 (2H, m), 3.59 (3H, s), 3.99 (1H, td, J = 2.4, 11.7 Hz), 4.17 (1H, dd, J = 2.4, 11.7 Hz), 4.68 (1H, dd, J = 2.1, 10.5 Hz), 7.16 (2H, d, J = 8.2 Hz), 7.31 (2H, d, J = 8.2 Hz), 7.35 (1H, s), 8.16 (1H, d, J = 5.3 Hz), 8.88 (1H, d, J = 5.2 Hz), 9.28 (1H, d, J = 1.1 Hz) (CDCl ₃)	513
84	1.58-2.05 (14H, m), 3.15 (1H, dd, J = 10.5, 12.9 Hz), 3.30 (1H, td, J = 3.3, 12.0 Hz), 3.53-3.62 (3H, m), 3.56 (3H, s), 3.97 (1H, td, J = 2.1, 11.8 Hz), 4.00 (1H, m), 4.14 (1H, td, J = 2.1, 4.4 Hz), 4.58 (1H, dd, J = 2.1, 10.5 Hz), 6.59 (2H, d, J = 8.0 Hz), 6.69 (1H, s), 7.19 (2H, d, J = 8.0 Hz), 7.80 (2H, d, J = 6.3 Hz), 8.70 (2H, d, J = 6.3 Hz) (CDCl ₃)	498
85	1.58-2.04 (14H, m), 3.14 (1H, dd, J = 10.8, 12.9 Hz), 3.28 (1H, td, J = 3.0, 12.0 Hz), 3.57-3.61 (3H, m), 3.57 (3H, s), 4.00 (1H, td, J = 2.1, 11.7 Hz), 4.07 (1H, m), 4.14 (1H, td, J = 2.1, 11.4 Hz), 4.57 (1H, dd, J = 1.8, 10.5 Hz), 6.60 (2H, d, J = 8.7 Hz), 7.19 (2H, d, J = 8.7 Hz), 7.34 (1H, s), 8.15 (2H, dd, J = 0.9, 3.1 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.27 (1H, s) (CDCl ₃)	499
86	1.40-1.85 (10H, m), 2.06-2.11 (4H, m), 2.78 (1H, dd, J = 10.5, 12.9 Hz), 3.30 (1H, td, J = 3.3, 12.0 Hz), 3.53-3.62 (3H, m), 3.56 (3H, s), 3.97 (1H, td, J = 2.1, 11.8 Hz), 4.00 (1H, m), 4.14 (1H, td, J = 2.1, 4.4 Hz), 4.58 (1H, dd, J = 2.1, 10.5 Hz), 6.59 (2H, d, J = 8.0 Hz), 6.69 (1H, s), 7.19 (2H, d, J = 8.0 Hz), 7.80 (2H, d, J = 6.3 Hz), 8.70 (2H, d, J = 6.3 Hz) (CDCl ₃)	512

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
87	1.26-1.86 (10H, m), 2.06-2.11 (4H, m), 2.78 (3H, s), 3.14 (1H, dd, J = 10.8, 13.2 Hz), 3.20 (1H, s), 3.30 (1H, td, J = 3.0, 12.0 Hz), 3.51-3.65 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J = 2.7, 11.4 Hz), 4.14 (1H, td, J = 11.7, 18.0 Hz), 4.60 (1H, dd, J = 2.1, 10.5 Hz), 7.07 (2H, d, J = 11.0 Hz), 7.29 (2H, d, J = 11.0 Hz), 7.35 (1H, s), 8.16 (1H, dd, J = 1.5, 5.4 Hz), 8.87 (1H, d, J = 5.4 Hz), 9.27 (1H, s) (CDCl ₃)	513
88	1.90 (1H, s), 2.24-2.28 (1H, m), 3.14 (1H, dd, J = 10.5, 12.9 Hz), 3.30 (1H, td, J = 3.0, 12.0 Hz), 3.53-3.58 (2H, m), 3.56 (3H, s), 3.84-4.13 (8H, m), 4.60 (1H, dd, J = 2.1, 10.5 Hz), 6.60 (2H, J = 8.7 Hz), 6.69 (1H, s), 7.20 (2H, d, J = 8.7 Hz), 7.79 (2H, d, J = 6.3 Hz), 8.70 (2H, d, J = 6.3 Hz) (CDCl ₃)	434
89	1.90 (1H, s), 2.24-2.28 (1H, m), 3.14 (1H, dd, J = 10.5, 12.9 Hz), 3.30 (1H, td, J = 3.0, 12.0 Hz), 3.53-3.58 (2H, m), 3.56 (3H, s), 3.84-4.13 (8H, m), 4.60 (1H, dd, J = 2.1, 10.5 Hz), 6.62 (2H, J = 8.7 Hz), 7.32 (2H, d, J = 8.4 Hz), 7.36 (1H, s), 8.15 (1H, d, J = 4.8 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.28 (1H, s) (CDCl ₃)	435
90	1.90-1.96 (1H, m), 2.20-2.25 (1H, m), 2.88 (3H, s), 3.15 (1H, dd, J = 10.8, 12.9 Hz), 3.30 (1H, td, J = 3.0, 12.0 Hz), 3.53-3.64 (2H, m), 3.57 (3H, s), 3.75-4.13 (6H, m), 4.48 (1H, m), 4.63 (1H, dd, J = 1.8, 10.5 Hz), 6.89 (1H, s), 6.83 (2H, J = 8.7 Hz), 7.27 (2H, d, J = 8.7 Hz), 7.80 (2H, d, J = 6.3 Hz), 8.71 (2H, d, J = 6.3 Hz) (CDCl ₃)	448
91	1.90-1.97 (1H, m), 2.20-2.25 (1H, m), 2.88 (3H, s), 3.15 (1H, dd, J = 10.5, 12.9 Hz), 3.51-3.62 (2H, m), 3.58 (3H, s), 3.75-4.13 (7H, m), 4.44 (1H, m), 4.62 (1H, dd, J = 2.1, 10.5 Hz), 6.83 (2H, J = 8.7 Hz), 7.29 (2H, d, J = 8.7 Hz), 7.34 (1H, s), 8.15 (1H, dd, J = 1.2, 5.1 Hz), 8.85 (1H, d, J = 5.1 Hz), 9.27 (1H, d, J = 1.2 Hz) (CDCl ₃)	449

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
92	1.89 (3H, s), 3.12 (1H, dd, J = 10.8, 13.2 Hz), 3.28 (3H, s), 3.30 (1H, td, J = 10.5, 12.9 Hz), 3.54-3.74 (2H, m), 3.60 (3H, s), 4.02 (1H, td, J = 2.7, 11.4 Hz), 4.19 (1H, dd, J = 11.7, 18.0 Hz), 4.76 (1H, dd, J = 1.8, 10.5 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.36 (1H, s), 7.48 (2H, d, J = 8.4 Hz), 8.13 (1H, d, J = 5.1 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.28 (1H, s) (CDCl ₃)	421
93	1.90 (1H, m), 2.85 (1H, m), 2.90-2.93 (2H, m), 3.16 (1H, dd, J = 10.8, 12.9 Hz), 3.54-3.64 (2H, m), 3.57 (3H, s), 4.00 (2H, td, J = 2.1, 11.8 Hz), 4.14 (1H, dd, J = 2.1, 10.5 Hz), 4.62 (1H, dd, J = 2.1, 10.5 Hz), 5.00 (1H, m), 6.69 (1H, s), 6.72 (2H, d, J = 5.5 Hz), 7.25 (2H, d, J = 5.5 Hz), 7.20-7.37 (4H, m), 7.80 (2H, d, J = 6.0 Hz), 8.72 (2H, d, J = 6.0 Hz) (CDCl ₃)	480
94	1.92 (1H, m), 2.59 (1H, m), 2.88-3.03 (2H, m), 3.12-3.29 (2H, m), 3.34-3.63 (2H, m), 3.59 (3H, s), 4.01 (1H, t, J = 8.7 Hz), 4.16 (1H, d, J = 12.7 Hz), 4.61 (1H, d, J = 10.5 Hz), 5.03 (1H, m), 6.74 (2H, d, J = 8.4 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.24-7.37 (6H, m), 8.16 (1H, d, J = 5.1 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.28 (1H, s) (CDCl ₃)	481
95	2.04-2.31 (2H, m), 2.13 (3H, s), 2.94 (3H, s), 3.10-3.61 (7H, m), 3.57 (3H, s), 3.94-4.18 (2H, m), 4.62 (1H, m), 5.43 (1H, m), 6.58 (2H, m), 7.28 (2H, m), 7.34 (1H, s), 8.14 (1H, d, J = 4.8 Hz), 8.85 (1H, d, J = 5.1 Hz), 9.27 (1H, s) (CDCl ₃)	490
96	2.64 (4H, t, J = 4.5 Hz), 3.10 (1H, dd, J = 10.5, 12.9 Hz), 3.16 (2H, s), 3.30 (1H, td, J = 10.5, 12.9 Hz), 3.53-3.66 (2H, m), 3.58 (3H, s), 3.79 (4H, t, J = 4.5 Hz), 3.99 (1H, t, J = 11.7 Hz), 4.18 (1H, d, J = 9.3 Hz), 4.72 (1H, d, J = 10.5 Hz), 6.71 (1H, s), 7.32 (2H, d, J = 8.7 Hz), 7.40 (2H, d, J = 8.7 Hz), 7.79 (2H, d, J = 6.0 Hz), 8.71 (2H, d, J = 6.0 Hz), 9.11 (1H, br. s) (CDCl ₃)	491

Compound No.	¹ H-NMR δ :	LC-MS (M+1)
97	2.66 (4H, t, J = 4.5 Hz), 3.11 (1H, dd, J = 10.0, 12.7 Hz), 3.15 (2H, s), 3.32 (1H, td, J = 10.5, 12.9 Hz), 3.50-3.66 (2H, m), 3.60 (3H, s), 3.79 (4H, t, J = 4.5 Hz), 3.99 (1H, t, J = 11.7 Hz), 4.18 (1H, d, J = 9.0 Hz), 4.72 (1H, d, J = 10.5 Hz), 6.71 (1H, s), 7.32 (2H, d, J = 8.7 Hz), 7.40 (2H, d, J = 8.7 Hz), 8.13 (1H, d, J = 5.1 Hz), 8.87 (1H, d, J = 5.1 Hz), 9.28 (1H, s) (CDCl ₃)	492
98	2.36 (3H, s), 2.53-2.67 (8H, s), 3.11 (1H, dd, J = 10.0, 12.7 Hz), 3.16 (2H, s), 3.34 (1H, t, J = 9.0 Hz), 3.47-3.61 (2H, m), 3.57 (3H, s), 3.99 (1H, t, J = 11.8 Hz), 4.17 (1H, d, J = 11.8 Hz), 4.72 (1H, d, J = 8.3 Hz), 6.70 (1H, s), 7.39 (2H, d, J = 8.5 Hz), 7.61 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 6.2 Hz), 8.71 (2H, d, J = 6.2 Hz), 9.18 (1H, br. s) (CDCl ₃)	504
99	2.34 (3H, s), 2.52-2.67 (8H, s), 3.12 (1H, dd, J = 10.0, 12.7 Hz), 3.16 (2H, s), 3.29 (1H, td, J = 12.3, 2.7 Hz), 3.52-3.71 (2H, m), 3.59 (3H, s), 4.00 (1H, t, J = 9.6 Hz), 4.18 (1H, d, J = 11.4 Hz), 4.72 (1H, d, J = 8.7 Hz), 7.32 (1H, s), 7.38 (2H, d, J = 8.3 Hz), 7.61 (2H, d, J = 8.3 Hz), 8.14 (1H, d, J = 4.8 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.19 (1H, br. s), 9.28 (1H, s) (CDCl ₃)	505
100	2.81 (4H, t, J = 5.1 Hz), 3.10 (1H, dd, J = 10.8, 13.2 Hz), 3.23 (2H, s), 3.28 (4H, t, J = 5.1 Hz), 3.40 (1H, m), 3.52-3.66 (2H, m), 3.57 (3H, s), 3.99 (1H, td, J = 2.1, 11.8 Hz), 4.15 (1H, d, J = 11.4 Hz), 4.72 (1H, dd, J = 2.1, 10.5 Hz), 6.70 (1H, s), 6.90-6.98 (4H, m), 7.30 (1H, d, J = 7.8 Hz), 7.40 (2H, d, J = 8.7 Hz), 7.62 (2H, d, J = 8.4 Hz), 7.79 (2H, d, J = 6.3 Hz), 8.71 (2H, d, J = 6.3 Hz), 9.19 (1H, br. s) (CDCl ₃)	566
101	2.81 (4H, t, J = 4.9 Hz), 3.10 (1H, dd, J = 10.2, 12.8 Hz), 3.23 (2H, s), 3.28 (4H, t, J = 4.9 Hz), 3.30 (1H, m), 3.51-3.67 (2H, m), 3.59 (3H, s), 3.99 (1H, td, J = 2.1, 11.8 Hz), 4.15 (1H, d, J = 11.4 Hz), 4.72 (1H, dd, J = 2.1, 10.5 Hz), 6.91-6.98 (4H, m), 7.26-7.41 (4H, m), 7.61 (2H, d, J = 8.6 Hz), 8.14 (1H, d, J = 6.2 Hz), 8.86 (1H, d, J = 5.1 Hz), 9.20 (1H, br. s), 9.27 (1H, br. s) (CDCl ₃)	567

Compound No.	¹ H-NMR δ	MS(M+1)
201	1.90-2.14 (6H, m), 2.95-3.18 (8H, m), 3.46 (3H, s), 3.65-3.69 (2H, m), 3.87-3.91(1H, m), 4.03-4.07(3H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.84 (1H, s), 6.96 (2H, d, J=7.2Hz), 7.38 (2H, d, J=7.2Hz), 7.96 (2H, d, J=4.2Hz), 8.68 (2H, d, J=4.2Hz) (CDCl ₃)	476
202	1.94-2.17 (6H, m), 2.97-3.18 (8H, m), 3.50 (3H, s), 3.67-3.72 (2H, m), 3.86-3.90 (1H, m), 4.03-4.09 (3H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.96 (2H, d, J=7.2Hz), 7.00 (1H, s), 7.38 (2H, d, J=7.2Hz), 8.19 (1H, dd, J=1.2Hz, 4.2Hz), 8.99 (1H, d, J=4.2Hz), 9.30 (1H, d, J=1.2Hz) (CDCl ₃)	477
203	1.41-1.44 (2H, m), 1.48-1.58 (4H, m), 1.82-1.87 (2H, m), 2.32-2.39 (6H, m), 2.97-3.05 (1H, m), 3.17-3.20 (1H, m), 3.45 (3H, s), 3.64-3.69 (2H, m), 3.86-3.90 (1H, m), 3.97-4.01 (3H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.84 (1H, s), 6.93 (2H, d, J=7.2Hz), 7.35 (2H, d, J=7.2Hz), 7.96 (2H, d, J=4.2Hz), 8.69 (2H, d, J=4.2Hz) (CDCl ₃)	490
204	1.41-1.44 (2H, m), 1.52-1.60 (4H, m), 1.92-1.96 (2H, m), 2.52-2.83 (6H, m), 2.97-3.05 (1H, m), 3.17-3.20 (1H, m), 3.49 (3H, s), 3.67-3.72 (2H, m), 3.86-3.90 (1H, m), 3.97-4.07 (3H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.93 (2H, d, J=7.2Hz), 7.00 (1H, s), 7.36 (2H, d, J=7.2Hz), 8.20 (1H, dd, J=1.2Hz, 4.2Hz), 8.99 (1H, d, J=4.2Hz), 9.29 (1H, d, J=1.2Hz) (CDCl ₃)	491
205	1.83-1.88 (2H, m), 2.14 (3H, s), 2.31-2.45 (9H, m), 2.98-3.05 (1H, m), 3.13-3.20 (1H, m), 3.26-3.30 (1H, m), 3.45 (3H, s), 3.67-3.69 (2H, m), 3.86-3.88 (1H, m), 3.97-4.02 (3H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.84 (1H, s), 6.93 (2H, d, J=7.2Hz), 7.35 (2H, d, J=7.2Hz), 7.96 (2H, d, J=4.2Hz), 8.68 (2H, d, J=4.2Hz) (CDCl ₃)	505
206	1.83-1.88 (2H, m), 2.14 (3H, s), 2.31-2.45 (9H, m), 2.98-3.05 (1H, m), 3.14-3.20 (1H, m), 3.26-3.30 (1H, m), 3.47 (3H, s), 3.67-3.72 (2H, m), 3.86-3.90 (1H, m), 3.97-4.02 (3H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.93 (2H, d, J=7.2Hz), 7.00 (1H, s), 7.36 (2H, d, J=7.2Hz), 8.20 (1H, dd, J=1.2Hz, 4.2Hz), 8.99 (1H, d, J=4.2Hz), 9.29 (1H, d, J=1.2Hz) (CDCl ₃)	506
207	1.19-1.50 (5H, m), 1.57-1.79 (3H, m), 2.03-2.06 (2H, m), 3.08 (1H, dd, J=12.9, 10.5Hz), 3.16 (1H, m), 3.53-3.58 (1H, m), 3.58 (3H, s), 3.65-3.69 (1H, m), 3.97-4.04 (2H, m), 4.18-4.21 (1H, m), 4.80 (1H, d, J=10.5Hz), 5.95 (1H, d, J=8.4Hz), 6.71 (1H, s), 7.48 (2H, d, J=8.1Hz), 7.77-7.80 (4H, m), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	474

Compound No.	¹ H-NMR δ	MS(M+1)
208	1.22-1.47 (5H, m), 1.63-1.79 (3H, m), 2.03-2.06 (2H, m), 3.07 (1H, dd, J=12.9, 10.5Hz), 3.16 (1H, m), 3.52-3.59(1H, m), 3.59 (3H, s), 3.61-3.67 (1H, m), 3.96-4.01 (2H, m), 4.18-4.21 (1H, m), 4.79 (1H, dd, J=10.5, 2.1Hz), 5.95 (1H, d, J=7.8Hz), 7.36 (1H, s), 7.48 (2H, d, J=8.4Hz), 7.79 (2H, d, J=8.4Hz), 8.11 (1H, dd, J=5.1, 1.2Hz), 8.86 (1H, d, J=5.4Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	475
209	3.09 (1H, dd, J=12.9, 10.8Hz), 3.31 (1H, m), 3.46-3.53 (1H, m), 3.58 (3H, s), 3.65-3.70 (3H, m), 3.84-3.87 (2H, m), 4.00 (1H, m), 4.18-4.21 (1H, m), 4.81 (1H, d, J=8.4Hz), 6.61 (1H, m), 6.71 (1H, s), 7.50 (2H, d, J=8.4Hz), 7.75 (2H, d, J=6.0Hz), 7.84 (2H, d, J=8.4Hz), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	436
210	3.08 (1H, dd, J=12.9, 10.8Hz), 3.29 (1H, m), 3.52-3.56 (1H, m), 3.59 (3H, s), 3.63-3.68 (3H, m), 3.83-3.88 (2H, m), 4.01 (1H, m), 4.18-4.21 (1H, m), 4.81 (1H, dd, J=12.9, 2.4Hz), 6.65 (1H, m), 7.36 (1H, s), 7.51 (2H, d, J=8.4Hz), 7.84 (2H, d, J=8.4Hz), 8.10 (1H, dd, J=5.7, 1.5Hz), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	437
211	2.99-3.14 (7H, m), 3.31 (1H, m), 3.54-3.58 (1H, m), 3.58 (3H, s), 3.64-3.69 (1H, m), 4.00 (1H, m), 4.17-4.22 (1H, m), 4.81 (1H, d, J=10.5, 2.1Hz), 6.71 (1H, s), 7.46 (4H, s), 7.79 (2H, dd, J=4.8Hz, 1.5Hz), 8.71 (2H, dd, J=4.8Hz, 1.5Hz) (CDCl ₃)	420
212	2.99-3.14 (7H, m), 3.28 (1H, m), 3.53-3.57 (1H, m), 3.59 (3H, s), 3.61-3.66 (1H, m), 4.01 (1H, m), 4.17-4.22 (1H, m), 4.77 (1H, d, J=10.5Hz, 2.4Hz), 7.37 (1H, s), 7.47 (4H, s), 8.14 (1H, dd, J=5.4Hz, 1.5Hz), 8.88 (1H, d, J=5.1Hz), 9.28(1H, s). (CDCl ₃)	421
213	2.99 (3H, s), 3.09 (1H, t, J=11.9Hz), 3.38 (2H, m), 3.59 (3H, s), 3.67 (1H, d, J=11.7Hz), 4.01 (1H, t, J=11.6Hz), 4.19 (1H, d, J=11.7Hz), 4.73 (1H, d, J=10.2Hz), 5.32 (1H, s), 6.72 (1H, s), 7.28 (2H, d, J=8.4Hz), 7.40 (2H, d, J=8.4Hz), 7.86 (2H, d, J=4.8Hz), 8.66 (2H, d, J=4.8Hz) (CDCl ₃)	442
214	3.04 (3H, s), 3.10 (1H, dd, J=10.8Hz, 12.8Hz), 3.29 (1H, td, J=3.0Hz, 12.0Hz), 3.52-3.65 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=2.4Hz, 11.0Hz), 4.18 (1H, dd, J=1.8Hz, 11.4Hz), 4.73 (1H, dd, J=2.1Hz, 10.5Hz), 6.67 (1H, br.s), 7.26-7.29 (3H, m), 7.42 (2H, d, J=8.4Hz), 8.14 (1H, dd, J=1.2Hz, 5.1Hz), 8.87 (1H, d, J=5.1Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	443

Compound No.	¹ H-NMR δ	MS(M+1)
215	1.50 (2H, m), 1.67 (4H, t, J=5.7Hz), 2.54 (4H, m), 3.08 (2H, s), 3.11 (1H, dd, J=2.4Hz, 13.2Hz), 3.30 (1H, td, J=3.0Hz, 11.9Hz), 3.53-3.66 (2H, m), 3.58 (3H, s), 3.99 (1H, t, J=2.4Hz, 11.6Hz), 4.16 (1H, dd, J=1.5Hz, 11.7Hz), 4.71 (1H, dd, J=1.8Hz, 10.2Hz), 6.70 (1H, s), 7.39 (2H, d, J=8.7Hz), 7.62 (2H, d, J=8.4Hz), 7.79 (2H, d, J=6.0Hz), 8.71 (2H, d, J=6.3Hz), 9.33 (1H, br.s) (CDCl ₃)	489
216	1.51 (2H, m), 1.60-1.67 (4H, m), 2.55 (4H, m), 3.04 (2H, s), 3.11 (1H, dd, J=2.4Hz, 13.2Hz), 3.29 (1H, td, J=3.0Hz, 11.9Hz), 3.51-3.63 (2H, m), 3.58 (3H, s), 3.99 (1H, t, J=2.4Hz, 11.6Hz), 4.17 (1H, dd, J=1.5Hz, 11.7Hz), 4.71 (1H, dd, J=1.8Hz, 10.2Hz), 6.89 (1H, s), 7.38 (2H, d, J=8.7Hz), 7.61 (2H, d, J=8.7Hz), 7.95 (1H, d, J=5.1Hz), 8.51 (1H, d, J=4.8Hz), 8.55 (1H, d, J=3.0Hz), 9.34 (1H, br.s) (CDCl ₃)	490
217	1.85 (4H, m), 2.27 (4H, m), 3.10 (1H, dd, J=10.8Hz, 12.9Hz), 3.29 (2H, s), 3.33 (1H, m), 3.53-3.66 (2H, m), 3.62 (3H, s), 3.99 (1H, td, J=2.1Hz, 11.7Hz), 4.18 (1H, dd, J=2.4Hz, 12.0Hz), 4.71 (1H, dd, J=2.1Hz, 10.5Hz), 6.70 (1H, s), 7.38 (2H, d, J=8.4Hz), 7.62 (2H, d, J=6.0Hz), 7.79 (2H, d, J=3.0Hz), 8.71 (2H, d, J=6.3Hz), 9.16 (1H, br.s) (CDCl ₃)	475
218	1.87 (4H, m), 2.70 (4H, m), 3.09 (1H, dd, J=10.8Hz, 12.9Hz), 3.28 (1H, m), 3.30 (2H, s), 3.58-3.67 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=2.1Hz, 11.7Hz), 4.16 (1H, dd, J=2.4Hz, 12.0Hz), 4.71 (1H, dd, J=2.1Hz, 10.5Hz), 7.26 (1H, s), 7.35 (2H, d, J=8.7Hz), 7.62 (2H, d, J=8.7Hz), 8.13 (1H, d, J=6.3Hz), 8.86 (1H, d, J=5.1Hz), 9.16 (1H, br.s), 9.28 (1H, s) (CDCl ₃)	476
219	2.39 (6H, s), 3.06-3.14 (1H, m), 3.09 (2H, s), 3.31 (1H, td, J=3.0Hz, 12.0Hz), 3.53-3.66 (2H, m), 3.57 (3H, s), 3.96 (1H, td, J=2.0Hz, 11.3Hz), 4.17 (1H, d, J=9.7Hz), 4.71 (1H, dd, J=2.6Hz, 10.5Hz), 6.70 (1H, s), 7.39 (2H, d, J=8.4Hz), 7.63 (2H, d, J=8.5Hz), 7.79 (2H, d, J=6.1Hz), 8.71 (2H, d, J=6.0Hz), 9.16 (1H, br.s) (CDCl ₃)	449
220	2.39 (6H, s), 3.07-3.14 (1H, m), 3.09 (2H, s), 3.28 (1H, td, J=3Hz, 12Hz), 3.52-3.64 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=3.2Hz, 11.3Hz), 4.17 (1H, d, J=9.7Hz), 4.71 (1H, dd, J=2.1Hz, 10.5Hz), 7.26 (1H, s), 7.39 (2H, d, J=8.4Hz), 7.63 (2H, d, J=8.5Hz), 8.14 (1H, dd, J=1.4Hz, 5.4Hz), 8.86 (1H, d, J=5.1Hz), 9.17 (1H, br.s), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	450
221	3.09 (1H, dd, J=12.9, 10.5Hz), 3.31 (1H, m), 3.53-3.58 (1H, m), 3.58 (3H, s), 3.67-3.71 (1H, m), 4.01 (1H, ddd, J=11.7Hz, 11.7Hz, 2.4Hz), 4.18-4.22 (1H, m), 4.82 (1H, dd, J=10.5Hz, 2.1Hz), 6.71 (1H, s), 7.52 (2H, d, J=8.1Hz), 7.79 (2H, dd, J=4.5Hz, 1.5Hz), 7.86 (2H, d, J=8.1Hz), 8.72 (2H, d, J=4.5, 1.5Hz) (CDCl ₃)	392

Compound No.	¹ H-NMR δ	MS(M+1)
222	3.09(1H, dd, J=12.8Hz, 10.7Hz), 3.29(1H, ddd, J=12.3Hz, 12.3Hz, 3.1Hz), 3.53-3.57(1H, m), 3.60(3H, s), 3.64-3.69(1H, m), 4.02(1H, ddd, J=11.7Hz, 11.7Hz, 2.3Hz), 4.21(1H, dd, J=12.6Hz, 2.0Hz), 4.81(1H, dd, J=10.4Hz, 1.9Hz), 7.36(1H, s), 7.52(2H, d, J=8.1Hz), 7.87(2H, d, J=8.1Hz), 8.12(1H, d, J=5.3Hz), 8.86(1H, d, J=5.1Hz), 9.28(1H, s) (CDCl ₃)	393
223	2.30 (3H, s) , 2.64-2.80 (8H, m) , 2.82 (2H, t, J=7.2Hz) , 3.11-3.15 (1H, m) , 3.26-3.32 (1H, m) , 3.53-3.63 (2H, m) , 3.59 (3H, s) , 3.98-4.02 (1H, m) , 4.10-4.18 (3H, m) , 4.67 (1H, dd, J=1.2Hz, 10.2Hz) , 6.93 (1H, s) , 6.94 (2H, d, J=7.2Hz) , 7.31 (2H, d, J=7.2Hz) , 7.78 (2H, d, J=4.2Hz) , 8.71 (2H, d, J=4.2Hz) (CDCl ₃)	491
224	1.52-1.93 (6H, m), 3.11 (1H, dd, J=12.9, 10.5Hz), 3.30-3.37 (3H, m), 3.54-3.58 (1H, m), 3.58 (3H, s), 3.65-3.74 (3H, m), 4.00 (1H, m), 4.19 (1H, dd, J=11.7, 2.1Hz), 4.78 (1H, dd, J=10.5, 2.1Hz), 6.71 (1H, s), 7.38-7.45 (4H, m), 7.79 (2H, d, J=5.4Hz), 8.72 (2H, m) (CDCl ₃)	460
225	1.60-1.69 (6H, m), 3.10 (1H, dd, J=12.9, 10.5Hz), 3.27-3.35 (3H, m), 3.52-3.57 (1H, m), 3.59 (3H, s), 3.61-3.67 (3H, m), 4.01 (1H, m), 4.17-4.19 (1H, m), 4.78 (1H, dd, J=10.5, 2.4Hz), 7.36 (1H, s), 7.41-7.48 (4H, m), 8.13 (1H, dd, J=5.1, 1.2Hz), 8.88 (1H, d, J=5.1Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	461
226	3.04 (1H, dd, J=10.5Hz, 12.6Hz), 3.27 (1H, td, J=11.7Hz, 2.4Hz), 3.48-3.58 (2H, m), 3.50 (3H, s), 3.97 (1H, td, J=2.1Hz, 11.7Hz), 4.18 (1H, dd, J=11.8Hz, 2.1Hz), 4.67 (1H, d, J=10.5Hz), 7.11 (1H, br.s), 7.13 (2H, d, J=8.4Hz), 7.27-7.55 (6H, m), 7.80 (2H, d, J=7.2Hz), 8.12 (1H, dd, J=1.2Hz, 5.1Hz), 8.87 (1H, d, J=5.1Hz), 9.27 (1H, d, J=0.9Hz) (CDCl ₃)	505
227	3.07 (1H, m), 3.14 (3H, d, J=4.4Hz), 3.30 (1H, t, J=11.8Hz), 3.48-3.58 (2H, m), 3.50 (3H, s), 4.00 (1H, t, J=11.6Hz), 4.18 (1H, d, J=11.6Hz), 4.75 (1H, d, J=10.4Hz), 6.09 (1H, br.s), 6.71 (1H, s), 7.26 (2H, d, J=7.5Hz), 7.49 (2H, d, J=8.1Hz), 7.78 (2H, d, J=5.5Hz), 7.93 (1H, br.s), 8.71 (2H, d, J=5.7Hz) (CDCl ₃).	437
228	3.11 (1H, dd, J=12.9Hz, 10.8Hz), 3.32 (1H, td, J=3.0Hz, 12.0Hz), 3.52-3.67 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J=2.1Hz, 11.7Hz), 4.17 (1H, d, J=11.7Hz), 4.73 (1H, dd, J=1.5Hz, 9.9Hz), 6.71 (1H, s), 7.25-7.47 (8H, m), 7.72 (1H, br.s), 7.78 (2H, d, J=6.0Hz), 8.70 (2H, d, J=6.0Hz) (CDCl ₃).	499

Compound No.	¹ H-NMR δ	MS(M+1)
229	3.11 (1H, dd, J=12.9Hz, 10.5Hz), 3.14 (3H, d, J=4.5Hz), 3.30 (1H, td, J=12.0Hz, 3.0Hz), 3.53-3.67 (2H, m), 3.59 (3H, s), 4.01 (1H, td, J=2.4Hz, 12.0Hz), 4.18 (1H, dd, J=2.1Hz, 11.7Hz), 4.75 (1H, dd, J=2.1Hz, 10.5Hz), 6.11 (1H, br.s), 7.28 (2H, d, J=8.4Hz), 7.35 (1H, s), 7.50 (2H, d, J=8.4Hz), 8.00 (1H, d, J=6.6Hz), 8.12 (1H, d, J=5.4Hz), 8.87 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃).	438
230	3.11 (1H, dd, J=12.9Hz, 10.5Hz), 3.30 (1H, td, J=12.0Hz, 3.0Hz), 3.33-3.67 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=2.4Hz, 12.0Hz), 4.18 (1H, dd, J=2.1Hz, 11.7Hz), 4.75 (1H, dd, J=2.1Hz, 10.5Hz), 7.26-7.48 (10H, m), 8.15 (1H, d, J=5.4Hz), 8.87 (1H, d, J=5.1Hz), 9.27 (1H, s) (CDCl ₃)	500
231	3.07-3.14 (1H, m), 3.30-3.34 (1H, m), 3.53-3.65 (5H, m), 3.79 (3H, s), 3.96-4.02 (1H, m), 4.15-4.19 (1H, m), 4.71 (1H, dd, J=1.2Hz, 10.2Hz), 6.70 (1H, s), 6.73 (1H, br.s), 7.26-7.38 (4H, m), 7.79 (2H, d, J=4.2Hz), 8.71 (2H, d, J=4.2Hz) (DMSO-d ₆)	422
232	3.06-3.10 (1H, m), 3.25-3.31 (1H, m), 3.51-3.63 (5H, m), 3.79 (3H, s), 3.96-4.00 (1H, m), 4.16-4.20 (1H, m), 4.69 (1H, dd, J=1.2Hz, 10.2Hz), 6.68 (1H, br), 7.33-7.44 (5H, m), 8.13 (1H, dd, J=1.2Hz, 4.2Hz), 8.86 (1H, d, J=4.2Hz), 9.27 (1H, d, J=1.2Hz) (DMSO-d ₆)	423
233	1.84-1.88 (4H, m), 2.49-2.55 (3H, m), 2.69-2.71 (2H, m), 2.78-2.82 (1H, m), 3.08-3.15 (1H, m), 3.24-3.32 (1H, m), 3.53-3.64 (2H, m), 3.57 (3H, s), 3.99-4.14 (5H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.95 (1H, s), 6.95 (2H, d, J=6.8Hz), 7.33 (2H, d, J=6.8Hz), 7.78 (2H, d, J=4.2Hz), 8.71 (2H, d, J=4.2Hz) (CDCl ₃)	492
234	1.78-1.85 (4H, m), 2.50-2.55 (3H, m), 2.70-2.72 (2H, m), 2.79-2.82 (1H, m), 3.08-3.12 (1H, m), 3.23-3.28 (1H, m), 3.52-5.62 (2H, m), 3.58 (3H, s), 4.00-4.15 (5H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.97 (2H, d, J=6.8Hz), 7.32 (2H, d, J=6.8Hz), 8.13 (1H, dd, J=1.2Hz, 4.2Hz), 8.86 (1H, d, J=4.2Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	493
235	3.06-3.10 (1H, m), 3.24-3.32 (1H, m), 3.48-3.65 (9H, m), 3.73-3.77 (4H, m), 3.96-4.02 (1H, m), 4.12-4.18 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.40 (1H, br), 6.97 (1H, s), 7.34-7.41 (4H, m), 7.78 (2H, d, J=4.2Hz), 8.71 (2H, d, J=4.2Hz) (CDCl ₃)	477

Compound No.	¹ H-NMR δ	MS(M+1)
236	3.06-3.10 (1H, m), 3.18-3.28 (1H, m), 3.48-3.62 (9H, m), 3.74-3.77 (4H, m), 3.92-4.00 (1H, m), 4.15-4.20 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.43 (1H, br.s), 7.34-7.41 (5H, m), 8.14 (1H, dd, J=1.2Hz, 4.2Hz), 8.86 (1H, d, J=4.2Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	478
237	3.04 (6H, s), 3.14-3.18 (1H, m), 3.26-3.34 (1H, m), 3.52-3.64 (5H, m), 3.95-4.01 (1H, m), 4.14-4.18 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.38 (1H, br.s), 6.97 (1H, s), 7.33 (2H, d, J=7.2Hz), 7.42 (2H, d, J=7.2Hz), 7.80 (2H, d, J=4.2Hz), 8.71 (2H, d, J=4.2Hz) (CDCl ₃)	435
238	3.05 (6H, s), 3.10-3.14 (1H, m), 3.27-3.34 (1H, m), 3.51-3.62 (5H, m), 3.96-4.02 (1H, m), 4.15-4.20 (1H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 6.37 (1H, br.s), 7.28-7.43 (5H, m), 8.15 (1H, dd, J=1.2Hz, 4.2Hz), 8.87 (1H, d, J=4.2Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	436
239	3.11 (1H, dd, J=10.8Hz, 13.2Hz), 3.31 (1H, td, J=12.1Hz, 3.0Hz), 3.54-3.67 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=11.7Hz, 1.8Hz), 4.20 (1H, d, J=11.7Hz), 4.34 (2H, s), 4.73 (1H, dd, J=1.8Hz, 10.5Hz), 6.72 (1H, br.s), 7.19-7.42 (10H, m), 8.14 (1H, dd, J=0.9Hz, 5.1Hz), 8.86 (1H, d, J=5.1Hz), 9.26 (1H, s) (CDCl ₃)	519
240	2.87 (6H, s), 2.99 (1H, dd, J=10.6Hz, 13.3Hz), 3.21 (1H, td, J=12.1Hz, 3.0Hz), 3.47-3.50 (3H, m), 3.55 (3H, s), 3.92 (1H, td, J=2.1Hz, 11.7Hz), 4.11-4.16 (1H, m), 4.59 (1H, dd, J=1.9Hz, 10.4Hz), 7.02 (2H, m), 7.19-7.42 (10H, m), 8.14 (1H, dd, J=0.9Hz, 5.1Hz), 8.86 (1H, d, J=5.1Hz), 9.26 (1H, s) (CDCl ₃)	598
241	3.09 (1H, dd, J=10.6Hz, 12.8Hz), 3.28 (1H, td, J=12.1Hz, 3.0Hz), 3.52-3.67 (2H, m), 3.58 (3H, s), 3.92 (1H, td, J=2.1Hz, 11.7Hz), 4.17 (1H, m), 4.75 (1H, dd, J=2.4Hz, 10.8Hz), 7.34 (2H, m), 7.43 (2H, d, J=8.7Hz), 7.51 (1H, d, J=8.7Hz), 8.05 (1H, m), 8.10 (1H, br.s), 8.13 (1H, dd, J=1.2Hz, 5.1Hz), 8.43-8.45 (2H, m), 8.51 (2H, dd), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	501
242	3.05 (1H, dd, J=10.7Hz, 12.9Hz), 3.30 (1H, td, J=12.2Hz, 3.0Hz), 3.51-3.62 (2H, m), 3.56 (3H, s), 3.96 (1H, td, J=11.4Hz, 2.0Hz), 4.00-4.17 (1H, m), 4.67 (1H, dd, J=1.9Hz, 10.4Hz), 6.71 (1H, s), 7.13 (2H, d, J=8.6Hz), 7.27 (2H, d, J=8.6Hz), 7.41-7.46 (3H, m), 7.54 (1H, t, J=7.4Hz), 7.78-7.80 (4H, m), 8.71 (2H, d, J=6.0Hz) (CDCl ₃)	504

Compound No.	¹ H-NMR δ	MS(M+1)
243	3.11 (1H, dd, J=10.8Hz, 13.2Hz), 3.31 (1H, td, J=12.1Hz, 3.0Hz), 3.54-3.67 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=11.7Hz, 7.8Hz), 4.20 (1H, d, J=11.7Hz), 4.34 (2H, s), 4.73 (1H, dd, J=9.8Hz, 10.5Hz), 6.68 (1H, s), 6.94 (1H, br.s), 7.19-7.41 (9H, m), 7.83 (2H, dd, J=1.5Hz, 4.5Hz), 8.69 (2H, dd, J=1.2Hz, 4.5Hz) (CDCl ₃)	518
244	2.87 (6H, s), 2.97 (1H, dd, J=10.6Hz, 13.3Hz), 3.14 (1H, td, J=12.1Hz, 3.0Hz), 3.46-3.60 (2H, m), 3.53 (3H, s), 3.90 (1H, m), 4.08-4.16 (1H, m), 4.57 (1H, dd, J=1.9Hz, 10.4Hz), 6.70 (1H, s), 7.01 (2H, d, J=8.7Hz), 7.17-7.20 (3H, m), 7.45 (1H, t, J=8.1Hz), 7.57 (1H, d), 7.76 (2H, dd, J=1.5Hz, 4.5Hz), 8.21 (1H, d, J=7.8Hz), 8.33 (1H, d, J=8.6Hz), 8.48 (1H, d, J=7.8Hz), 8.71 (1H, dd, J=1.5Hz, 4.5Hz) (CDCl ₃)	597
245	3.09 (1H, dd, J=10.8Hz, 12.8Hz), 3.28 (1H, td, J=7.0Hz, 12.0Hz), 3.52-3.67 (2H, m), 3.58 (3H, s), 4.00 (1H, td, J=12.0Hz, 3.1Hz), 4.18 (1H, d, J=12.0Hz), 4.75 (1H, dd, J=2.4Hz, 10.8Hz), 6.71 (1H, s), 7.36-7.54 (5H, m), 7.78 (2H, d, J=4.8Hz), 7.90 (1H, br.s), 8.10 (1H, d), 8.20 (1H, br.s), 8.47 (1H, d, J=5.1Hz), 8.61 (1H, d, J=2.7Hz), 8.70 (2H, d, J=4.8Hz) (CDCl ₃)	500
246	3.06-3.11 (1H, m), 3.26-3.32 (1H, m), 3.53-3.65 (5H, m), 3.95-3.99 (1H, m), 4.15-4.18 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 5.21 (2H, s), 6.70 (1H, s), 6.79 (1H, br), 7.35-7.45 (9H, m), 7.80 (2H, d, J=7.2Hz), 8.71 (2H, d, J=7.2Hz) (CDCl ₃)	498
247	2.63-2.68 (2H, m), 2.97-3.12 (3H, m), 3.22-3.32 (1H, m), 3.54-3.64 (5H, m), 3.98-4.04 (1H, m), 4.14-4.18 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 4.68 (1H, s), 6.78 (1H, d, J=7.2Hz), 7.20-7.26 (2H, m), 7.79 (2H, d, J=4.2Hz), 7.97 (1H, br.s), 8.72 (2H, d, J=4.2Hz) (CDCl ₃)	418
248	2.63-2.68 (2H, m), 2.98-3.15 (3H, m), 3.21-3.32 (1H, m), 3.53-3.63 (5H, m), 3.96-4.01 (1H, m), 4.15-4.20 (1H, m), 4.66 (1H, dd, J=1.2Hz, 10.2Hz), 6.78 (1H, d, J=7.2Hz), 7.21-7.26 (2H, m), 7.36 (1H, s), 7.59 (1H, br.s), 8.13 (1H, dd, J=1.2Hz, 4.2Hz), 8.57 (1H, d, J=4.2Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	419
249	1.36 (6H, s), 2.50 (2H, s), 3.09-3.16 (1H, m), 3.34-3.39 (1H, m), 3.55-3.67 (5H, m), 3.99-4.05 (1H, m), 4.16-4.20 (1H, m), 4.70 (1H, dd, J=1.2Hz, 10.2Hz), 6.71 (1H, s), 6.79 (1H, d, J=7.2Hz), 7.21 (1H, dd, J=1.2Hz, 7.2Hz), 7.34 (1H, d, J=1.2Hz), 7.73 (1H, br), 7.78 (2H, d, J=4.2Hz), 8.72 (2H, d, J=4.2Hz) (CDCl ₃)	446

Compound No.	¹ H-NMR δ	MS(M+1)
250	1.36 (6H, s), 2.50 (2H, s), 3.08-3.16 (1H, m), 3.32-3.36 (1H, m), 3.51-3.62 (5H, m), 3.97-4.05 (1H, m), 4.17-4.21 (1H, m), 4.71 (1H, dd, J=1.2Hz, 10.2Hz), 6.78 (1H, d, J=7.2Hz), 7.22-7.26 (2H, m), 7.35 (1H, s), 7.83 (1H, br.s), 8.13 (1H, dd, J=1.2Hz, 4.2Hz), 8.87 (1H, d, J=4.2Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	447
251	3.06-3.11 (1H, m), 3.24-3.31 (1H, m), 3.51-3.62 (5H, m), 3.96-4.02 (1H, m), 4.16-4.20 (1H, m), 4.67 (1H, dd, J=1.2Hz, 10.2Hz), 5.22 (2H, s), 6.74 (1H, br), 7.26 (1H, s), 7.36-7.45 (9H, m), 8.14 (1H, dd, J=1.2Hz, 4.2Hz), 8.87 (1H, d, J=4.2Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	499
252	1.31 (3H, t, J=7.2Hz), 3.07-3.11 (1H, m), 3.28-3.33 (1H, m), 3.53-3.65 (5H, m), 3.96-4.00 (1H, m), 4.15-4.26 (3H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.70 (1H, s), 6.72 (1H, br.s), 7.36 (2H, d, J=7.2Hz), 7.40 (2H, d, J=7.2Hz), 7.78 (2H, d, J=4.2Hz), 8.72 (2H, d, J=4.2Hz) (CDCl ₃)	436
253	1.32 (3H, t, J=7.2Hz), 3.07-3.10 (1H, m), 3.27-3.31 (1H, m), 3.52-3.63 (5H, m), 3.96-4.02 (1H, m), 4.16-4.27 (3H, m), 4.69 (1H, dd, J=1.2Hz, 10.2Hz), 6.65 (1H, br.s), 7.33-7.44 (5H, m), 8.14 (1H, dd, J=1.2Hz, 4.2Hz), 8.87 (1H, d, J=4.2Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	437
254	3.11 (1H, dd, J=12.9Hz, 10.5Hz), 3.30-3.43 (1H, m), 3.54-3.58 (1H, m), 3.64 (3H, s), 3.64-3.75 (9H, m), 4.01 (1H, m), 4.17 (1H, m), 4.78 (1H, dd, J=10.5Hz, 2.1Hz), 6.71 (1H, s), 7.44-7.50 (4H, m), 7.79 (2H, dd, J=5.1Hz, 1.5Hz), 8.71 (2H, dd, J=4.8Hz, 1.5Hz) (CDCl ₃)	461
255	3.09 (1H, dd, J=12.9Hz, 10.5Hz), 3.28 (1H, m), 3.56-3.58 (1H, m), 3.59 (3H, s), 3.61-3.75 (9H, m), 4.02 (1H, m), 4.17 (1H, m), 4.78 (1H, dd, J=10.5Hz, 2.1Hz), 7.36 (1H, s), 7.43-7.51 (4H, m), 8.13 (1H, dd, J=5.1Hz, 1.2Hz), 8.87 (1H, dd, J=5.1Hz, 2.1Hz), 9.28 (1H, d, J=0.9Hz) (CDCl ₃)	462
256	2.16 (3H, s), 2.79 (1H, dd, J=12.6Hz, 9.9Hz), 3.28-3.36 (1H, m), 3.54-3.61 (1H, m), 3.61 (3H, s), 3.81-3.84 (1H, m), 3.84 (3H, s), 4.00 (1H, m), 4.18-4.22 (1H, m), 5.02 (1H, dd, J=9.6Hz, 1.8Hz), 6.69 (1H, s), 6.86 (1H, d, J=9.0Hz), 7.09 (1H, m), 7.46 (1H, d, J=2.4Hz), 7.60 (1H, dd, J=8.7Hz, 2.7Hz), 7.82 (2H, dd, J=4.5Hz, 1.5Hz), 8.71 (2H, dd, J=4.8Hz, 1.5Hz) (CDCl ₃)	436

Compound No.	¹ H-NMR δ	MS(M+1)
257	2.17 (3H, s), 2.80 (1H, dd, J=12.9Hz, 10.2Hz), 3.29-3.34 (1H, m), 3.52-3.57 (1H, m), 3.63 (3H, s), 3.79-3.83 (1H, m), 3.85 (3H, s), 4.00 (1H, ddd, J=12.0Hz, 12.0Hz, 2.4Hz), 4.18 (1H, dd, J=11.7Hz, 2.4Hz), 5.02 (1H, d, J=14.1Hz), 6.69 (1H, s), 6.86 (1H, d, J=8.7Hz), 7.15 (1H, s), 7.35 (1H, s), 7.48(1H, d, J=2.4Hz), 7.58(1H, dd, J=8.7z, 2.7Hz), 8.20(1H, dd, J=5.1, 1.2Hz), 8.87 (1H, d, J=5.4Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	437
258	2.19 (3H, s), 3.07-3.14 (1H, m), 3.27-3.46 (1H, m), 3.52-3.57 (1H, m), 3.58 (3H, s), 3.66-3.71 (1H, m), 3.94-4.02 (1H, m), 4.15-4.19 (1H, m), 4.74 (1H, d, J=9.6Hz), 6.70 (1H, s), 7.16 (1H, m), 7.31-7.40 (3H, m), 7.71 (1H, s), 7.80 (2H, d, J=3.9Hz), 8.72 (2H, d, J=3.9Hz) (CDCl ₃)	406
259	2.20 (3H, s), 3.10 (1H, dd, J=13.2Hz, 10.5Hz), 3.29-3.34 (1H, m), 3.50-3.54 (1H, m), 3.62 (3H, s), 3.72-3.79 (1H, m), 3.98 (1H, ddd, J=11.7Hz, 11.7Hz, 2.4Hz), 4.11 (1H, m), 4.76 (1H, dd, J=10.5, 2.1Hz), 7.16-7.21 (2H, m), 7.35-7.38 (3H, m), 7.76 (1H, s), 8.18 (1H, d, J=5.4Hz), 8.91 (1H, d, J=5.4Hz), 9.28 (1H, d, J=0.9Hz) (CDCl ₃)	407
260	1.23 (6H, t, J=7.2Hz), 3.06-3.13 (1H, m), 3.28-3.42 (5H, m), 3.52-3.63 (5H, m), 3.94-4.00 (1H, m), 4.14-4.18 (1H, m), 4.70 (1H, dd, J=1.2Hz, 10.2Hz), 6.38 (1H, br.s), 6.70 (1H, s), 7.30 (2H, d, J=7.2Hz), 7.41 (2H, d, J=7.2Hz), 7.79 (2H, d, J=4.2Hz), 8.71 (2H, d, J=4.2Hz) (CDCl ₃)	463
261	1.24 (6H, t, J=7.3Hz), 3.06-3.13 (1H, m), 3.26-3.42 (5H, m), 3.51-3.62 (5H, m), 3.96-4.00 (1H, m), 4.14-4.17 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.31 (1H, br.s), 7.32-7.38 (3H, m), 7.43 (2H, d, J=7.2Hz), 8.14 (1H, dd, J=1.2Hz, 4.2Hz), 8.87 (1H, d, J=4.2Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	464
262	3.08-3.13 (1H, m), 3.28-3.33 (1H, m), 3.54-3.64 (7H, m), 3.96-4.03 (1H, m), 4.15-4.20 (1H, m), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.71 (1H, s), 6.90 (1H, d, J=7.2Hz), 7.26 (1H, dd, J=1.2Hz, 7.2Hz), 7.33 (1H, d, J=1.2Hz), 7.78 (2H, d, J=4.2Hz), 8.00 (1H, br.s), 8.72 (2H, d, J=4.2Hz) (CDCl ₃)	404
263	3.08-3.13 (1H, m), 3.28-3.32 (1H, m), 3.52-3.62 (7H, m), 3.96-4.02 (1H, m), 4.16-4.20 (1H, m), 4.69 (1H, dd, J=1.2Hz, 10.2Hz), 6.89 (1H, d, J=7.2Hz), 7.25-7.35 (3H, m), 7.84 (1H, br), 8.12 (1H, dd, J=1.2Hz, 4.2Hz), 8.86 (1H, d, J=4.2Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	405

Compound No.	¹ H-NMR δ	MS(M+1)
264	3.10 (1H, dd, J=10.6Hz, 12.8Hz), 3.29 (1H, td, J=12.1Hz, 2.5Hz), 3.52-3.66 (2H, m), 3.60 (3H, s), 4.03 (1H, td, J=11.7Hz, 7.2Hz), 4.20 (1H, d, J=11.6Hz), 4.48 (2H, s), 4.73 (1H, dd, J=10.5Hz, 2.1Hz), 7.34 (2H, d, J=6.4Hz), 7.36 (1H, br.s), 7.45 (2H, d, J=5.6Hz), 8.13 (1H, d, J=5.6Hz), 8.88 (1H, d, J=5.2Hz), 9.28 (1H, d, J=1.3Hz) (CDCl ₃).	477
265	3.12 (1H, dd, J=10.5Hz, 12.9Hz), 3.33 (1H, m), 3.57-3.69 (2H, m), 3.58 (3H, s), 4.00 (1H, td, J=11.7Hz, 2.4Hz), 4.19 (1H, dd, J=11.7Hz, 2.1Hz), 4.48 (2H, s), 4.73 (1H, dd, J=10.8Hz, 2.4Hz), 6.72 (1H, s), 7.34 (2H, d, J=6.3Hz), 7.42 (2H, d, J=6.3Hz), 7.85 (2H, d, J=6.0Hz), 8.66 (2H, d, J=6.3Hz) (CDCl ₃).	476
266	3.03 (3H, s), 3.10 (1H, dd, J=13.2Hz, 10.5Hz), 3.24 (1H, m), 3.53-3.57 (1H, m), 3.58 (3H, s), 3.66-3.71 (1H, m), 4.00 (1H, m), 4.15-4.19 (1H, m), 4.75 (1H, dd, J=10.5Hz, 2.1Hz), 6.71 (1H, s), 6.92 (1H, s), 7.20-7.42 (4H, m), 7.80 (2H, dd, J=4.5Hz, 1.5Hz), 8.72 (2H, dd, J=4.8Hz, 1.5Hz). (CDCl ₃)	442
267	3.04 (3H, s), 3.10 (1H, dd, J=12.9Hz, 10.8Hz), 3.23 (1H, m), 3.53-3.58 (1H, m), 3.59 (3H, s), 3.68-3.72 (1H, m), 3.99 (1H, m), 4.15-4.20 (1H, m), 4.77 (1H, dd, J=10.2Hz, 1.6Hz), 7.03 (1H, s), 7.21-7.43 (5H, m), 8.15 (1H, d, J=5.1Hz), 8.89 (1H, d, J=5.4Hz), 9.27 (1H, s) (CDCl ₃)	443
268	2.73 (6H, s), 3.11 (1H, dd, J=10.6Hz, 12.9Hz), 3.35 (1H, td, J=12.6Hz, 3.3Hz), 3.55-3.41 (2H, m), 3.61 (3H, s), 4.03 (1H, td, J=11.7Hz, 2.1Hz), 4.20 (1H, dd, J=11.4Hz, 2.1Hz), 4.83 (1H, dd, J=10.5Hz, 1.8Hz), 6.72 (1H, s), 7.61 (2H, d, J=8.4Hz), 7.81-7.84 (4H, m), 8.81 (2H, m) (CDCl ₃)	456
269	2.73 (6H, s), 3.11 (1H, dd, J=10.6Hz, 12.9Hz), 3.35 (1H, td, J=12.6Hz, 3.3Hz), 3.55-3.41 (2H, m), 3.61 (3H, s), 4.03 (1H, td, J=11.7Hz, 2.1Hz), 4.20 (1H, dd, J=11.4Hz, 2.1Hz), 4.83 (1H, dd, J=10.5Hz, 1.8Hz), 7.36 (1H, s), 7.62 (2H, d, J=8.4Hz), 7.83 (2H, d, J=8.4Hz), 8.12 (1H, d, J=1.2Hz), 8.88 (1H, d, J=5.1Hz), 9.29 (1H, d, J=1.2Hz) (CDCl ₃).	457
270	0.68 (1H, m), 1.15 (3H, d, J=3.4Hz), 1.25 (2H, m), 1.44 (1H, m), 3.09 (1H, t, J=11.7Hz), 3.29 (1H, t, J=11.1Hz), 3.52-3.64 (2H, m), 3.57 (3H, s), 3.98 (1H, dd, J=10.4Hz, 11.0Hz), 4.16 (1H, d, J=11.3Hz), 4.69 (1H, d, J=9.9Hz), 6.70 (1H, s), 7.35 (2H, d, J=8.1Hz), 7.55 (2H, d, J=7.4Hz), 7.63 (1H, br.s), 7.79 (2H, d, J=4.9Hz), 8.71 (2H, d, J=4.9Hz) (CDCl ₃).	446

Compound No.	¹ H-NMR δ	MS(M+1)
271	0.69 (1H, m), 1.14 (3H, d, J=3.4Hz), 1.25 (2H, m), 1.44 (1H, m), 3.09 (1H, t, J=11.7Hz), 3.29 (1H, t, J=11.1Hz), 3.52-3.64 (2H, m), 3.57 (3H, s), 3.98 (1H, dd, J=10.4Hz, 11.0Hz), 4.16 (1H, d, J=11.3Hz), 4.69 (1H, d, J=9.9Hz), 7.27 (1H, s), 7.36 (2H, d, J=7.5Hz), 7.55 (1H, br.s), 7.56 (2H, d, J=7.5Hz), 8.14 (1H, d, J=4.7Hz), 8.86 (1H, d, J=5.0Hz), 9.27 (1H, s) (CDCl ₃).	447
272	1.61-1.94 (8H, m), 2.69 (1H, t, J=8.1Hz), 3.09 (1H, dd, J=10.8Hz, 12.8Hz), 3.25 (1H, td, J=3.0Hz, 12.0Hz), 3.52-3.64 (2H, m), 3.57 (3H, s), 3.98 (1H, td, J=12.0Hz, 2.1Hz), 4.15 (1H, dd, J=12.0Hz, 1.5Hz), 4.70 (1H, dd, J=10.8Hz, 2.1Hz), 6.70 (1H, s), 7.32 (1H, br.s), 7.35 (2H, d, J=8.4Hz), 7.56 (2H, d, J=8.4Hz), 7.78 (2H, d, J=4.8Hz), 8.71 (2H, d, J=4.8Hz) (CDCl ₃)	460
273	1.61-1.95 (8H, m), 2.69 (1H, t, J=8.1Hz), 3.09 (1H, dd, J=10.8Hz, 12.8Hz), 3.25 (1H, td, J=3.0Hz, 12.0Hz), 3.51-3.63 (2H, m), 3.58 (3H, s), 3.99 (1H, td, J=12.0Hz, 2.1Hz), 4.16 (1H, dd, J=12.0Hz, 1.5Hz), 4.70 (1H, dd, J=10.8Hz, 2.1Hz), 7.27 (1H, s), 7.31 (1H, br.s), 7.36 (2H, d, J=8.4Hz), 7.57 (2H, d, J=8.4Hz), 8.14 (1H, dd, J=5.4Hz, 1.5Hz), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	461
274	0.69 (2H, m), 1.32 (2H, m), 1.72 (3H, s), 3.09 (1H, dd, J=10.8Hz, 13.4Hz), 3.30 (1H, td, J=7.0Hz, 12.0Hz), 3.52-3.64 (2H, m), 3.57 (3H, s), 4.01 (1H, td, J=11.4Hz, 2.1Hz), 4.15 (1H, d, J=12.0Hz), 4.69 (1H, d, J=9.48Hz), 6.70 (1H, s), 7.37 (2H, d, J=8.4Hz), 7.53 (1H, br.s), 7.55 (2H, d, J=8.4Hz), 7.79 (2H, d, J=4.5Hz), 8.71 (2H, dd, J=4.5Hz, 1.5Hz) (CDCl ₃)	446
275	0.69 (2H, m), 1.32 (2H, m), 1.49 (3H, s), 3.09 (1H, dd, J=10.8Hz, 12.8Hz), 3.27 (1H, td, J=7.0Hz, 12.0Hz), 3.51-3.62 (2H, m), 3.55 (3H, s), 4.02 (1H, td, J=12.5Hz, 2.3Hz), 4.17 (1H, dd, J=12.0Hz, 1.9Hz), 4.70 (1H, dd, J=10.5Hz, 2.1Hz), 7.35 (1H, s), 7.37 (2H, d, J=6.7Hz), 7.51 (1H, br.s), 7.54 (2H, d, J=6.7Hz), 8.14 (1H, dd, J=5.4Hz, 1.5Hz), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.1Hz) (CDCl ₃)	447
276	1.56 (6H, s), 3.03 (1H, br.s), 3.10 (1H, dd, J=10.7Hz, 13.0Hz), 3.30 (1H, td, J=2.9Hz, 12.2Hz), 3.53-3.65 (2H, m), 3.57 (3H, s), 3.99 (1H, td, J=11.4Hz, 1.9Hz), 4.16 (1H, dd, J=11.5Hz, 1.8Hz), 4.71 (1H, dd, J=10.4Hz, 2.0Hz), 6.70 (1H, s), 7.38 (2H, d, J=8.5Hz), 7.63 (2H, d, J=8.5Hz), 7.80 (2H, d, J=5.9Hz), 8.70 (2H, d, J=6.2Hz), 8.80 (1H, br.s) (CDCl ₃)	450
277	1.57 (6H, s), 2.16 (1H, br.s), 3.10 (1H, dd, J=10.7Hz, 13.0Hz), 3.30 (1H, td, J=2.9Hz, 12.2Hz), 3.52-3.64 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=11.4Hz, 1.9Hz), 4.16 (1H, dd, J=11.5Hz, 1.8Hz), 4.71 (1H, dd, J=10.4Hz, 2.0Hz), 7.25 (1H, s), 7.39 (2H, d, J=8.4Hz), 7.63 (2H, d, J=8.4Hz), 8.14 (1H, d, J=5.4Hz), 8.75 (1H, br.s), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	451

Compound No.	¹ H-NMR δ	MS(M+1)
278	2.97-3.04 (1H, m), 3.20-3.25 (1H, m), 3.33 (1H, br.s), 3.48 (3H, s), 3.70-3.82 (2H, m), 3.86-3.94 (1H, m), 4.07-4.11 (1H, m), 4.86 (1H, dd, J=1.2Hz, 10.2Hz), 7.02 (1H, s), 7.58 (2H, d, J=6.8Hz), 7.97 (2H, d, J=6.8Hz), 8.20 (1H, dd, J=1.2Hz, 4.2Hz), 8.99 (1H, d, J=4.2Hz), 9.29 (1H, d, J=1.2Hz) (CDCl ₃)	394
279	1.45 (3H, s), 1.47 (3H, s), 3.08-3.37 (3H, m), 3.19 (3H, s), 3.48 (3H, s), 3.58-3.67 (2H, m), 3.58 (3H, s), 4.00 (1H, td, J=11.5Hz, 1.8Hz), 4.76 (1H, dd, J=10.5Hz, 2.1Hz), 6.70 (1H, s), 7.24 (2H, d, J=8.3Hz), 7.43 (2H, d, J=8.3Hz), 7.80 (2H, d, J=6.1Hz), 8.72 (2H, d, J=6.1Hz) (CDCl ₃)	478
280	1.45 (3H, s), 1.47 (3H, s), 3.08-3.37 (4H, m), 3.20 (3H, s), 3.38 (3H, s), 3.59 (3H, s), 4.01 (1H, t, J=11.5Hz), 4.20 (1H, d, J=11.8Hz), 4.75 (1H, d, J=10.6Hz), 7.25 (2H, d, J=7.9Hz), 7.36 (1H, s), 7.44 (2H, d, J=7.8Hz), 8.15 (1H, d, J=5.1Hz), 8.88 (1H, d, J=4.8Hz), 9.27 (1H, s) (CDCl ₃)	479
281	1.20 (6H, s), 3.11 (1H, dd, J=10.5Hz, 12.9Hz), 3.30-3.37 (1H, m), 3.32 (3H, s), 3.54 (1H, m), 3.60 (3H, s), 3.71 (1H, d, J=12.9Hz), 4.01 (1H, td, J=11.7Hz, 2.1Hz), 4.20 (1H, dd, J=11.8Hz, 2.1Hz), 4.37 (1H, br.s), 4.80 (1H, dd, J=10.2Hz, 1.8Hz), 6.71 (1H, s), 7.29 (2H, d, J=8.4Hz), 7.49 (2H, d, J=8.4Hz), 7.79 (2H, d, J=6.0Hz), 8.73 (2H, d, J=6.0Hz) (CDCl ₃)	464
282	1.21 (6H, s), 3.11 (1H, dd, J=10.5Hz, 12.9Hz), 3.30-3.37 (1H, m), 3.32 (3H, s), 3.50 (1H, m), 3.60 (3H, s), 3.71 (1H, d, J=12.9Hz), 4.01 (1H, td, J=11.7Hz, 2.4Hz), 4.20 (1H, dd, J=11.8Hz, 2.1Hz), 4.37 (1H, br.s), 4.80 (1H, dd, J=10.2Hz, 1.8Hz), 7.25 (2H, d, J=8.1Hz), 7.31 (1H, s), 7.49 (2H, d, J=8.1Hz), 8.13 (1H, d, J=5.0Hz), 8.88 (1H, d, J=5.1Hz), 9.28 (1H, s) (CDCl ₃)	465
283	0.84-0.88 (2H, m), 1.09-1.12 (2H, m), 1.52 (1H, m), 3.10 (1H, dd, J=12.9Hz, 10.5Hz), 3.27-3.46 (1H, m), 3.52-3.56 (1H, m), 3.57 (3H, s), 3.69 (1H, dd, J=12.9Hz, 1.8Hz), 3.97 (1H, m), 4.15-4.18 (1H, m), 4.74 (1H, dd, J=10.5Hz, 2.1Hz), 6.70 (1H, s), 7.13 (1H, m), 7.33-7.37 (2H, m), 7.57 (1H, s), 7.80(2H, dd, J=4.5, 1.5Hz), 7.81 (1H, s), 8.72 (2H, dd, J=4.5Hz, 1.5Hz) (CDCl ₃)	432
284	0.86-0.91 (2H, m), 1.08-1.12 (2H, m), 1.50 (1H, m), 3.11 (1H, dd, J=13.2Hz, 10.8Hz), 3.31 (1H, m), 3.50-3.54 (1H, m), 3.58 (3H, s), 3.70 (1H, m), 3.96 (1H, m), 4.17 (1H, dd, J=11.7Hz, 2.4Hz), 4.76 (1H, dd, J=10.5, 2.1Hz), 7.15 (1H, m), 7.31-7.40 (4H, m), 7.85 (1H, s), 8.17 (1H, dd, J=6.0Hz, 1.2Hz), 8.90 (1H, d, J=5.4Hz), 9.28 (1H, s) (CDCl ₃)	433

Compound No.	¹ H-NMR δ	MS(M+1)
285	0.82-0.86 (2H, m), 1.07-1.10 (2H, m), 1.52 (1H, m), 2.81 (1H, dd, J=12.3Hz, 10.2Hz), 3.31 (1H, m), 3.54-3.58 (1H, m), 3.61 (3H, s), 3.80-3.83 (1H, m), 3.84 (3H, s), 4.00 (1H, m), 4.18 (1H, m), 5.05 (1H, d, J=8.1Hz), 6.69 (1H, s), 6.85 (1H, d, J=8.7Hz), 7.32 (1H, m), 7.53-7.57 (2H, m), 7.82 (2H, dd, J=4.5, 1.5Hz), 8.72 (2H, dd, J=4.5, 1.5Hz) (CDCl ₃)	462
286	0.83-0.86 (2H, m), 1.07-1.10 (2H, m), 1.52 (1H, m), 2.81 (1H, dd, J=12.6Hz, 10.2Hz), 3.31 (1H, m), 3.52-3.57 (1H, m), 3.63 (3H, s), 3.78-3.82 (1H, m), 3.84 (3H, s), 4.00 (1H, m), 4.19 (1H, m), 5.05 (1H, d, J=8.4Hz), 6.85 (1H, m), 7.32 (1H, m), 7.34 (1H, s), 7.47-7.59 (2H, m), 8.20 (1H, d, J=5.4Hz), 8.87 (1H, d, J=5.4Hz), 9.28 (1H, d, J=1.2Hz) (CDCl ₃)	463
287	2.77 (1H, m), 2.98 (3H, s), 3.36 (1H, m), 3.54-3.59 (1H, m), 3.62 (3H, s), 3.83-3.86 (1H, m), 3.86 (3H, s), 4.03 (1H, m), 4.22 (1H, m), 5.04 (1H, d, J=9.3Hz), 6.44 (1H, s), 6.70 (1H, s), 6.89 (1H, d, J=8.7Hz), 7.30-7.39 (1H, m), 7.32 (1H, m), 7.82 (2H, d, J=5.1Hz), 8.71 (2H, d, J=5.1Hz) (CDCl ₃)	472
288	2.76 (1H, dd, J=12.9Hz, 10.5Hz), 2.98 (3H, s), 3.34 (1H, ddd, J=12.6Hz, 12.6Hz, 3.0Hz), 3.53-3.57 (1H, m), 3.63 (3H, s), 3.81-3.85 (1H, m), 3.87 (3H, s), 4.00 (1H, ddd, J=11.7Hz, 11.7Hz, 2.4Hz), 4.22 (1H, dd, J=11.7Hz, 2.1Hz), 5.04 (1H, dd, J=10.2Hz, 1.8Hz), 6.32 (1H, s), 6.90 (1H, d, J=8.7Hz), 7.26-7.29 (1H, m), 7.35 (1H, s), 7.40 (1H, d, J=2.7Hz), 8.19 (1H, d, J=2.7Hz), 8.87 (1H, d, J=2.4Hz), 9.28 (1H, d, J=0.9Hz) (CDCl ₃)	473
289	2.90-3.00 (1H, m), 3.15-3.20 (1H, m), 3.45 (3H, s), 3.65-3.71 (2H, m), 3.84-3.91 (1H, m), 4.03-4.07 (1H, m), 4.57 (2H, s), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.84 (1H, s), 6.93-7.01 (3H, m), 7.97 (2H, d, J=4.2Hz), 8.70 (2H, d, J=4.2Hz), 10.75 (1H, br.s) (CDCl ₃)	420
290	2.92-3.00 (1H, m), 3.13-3.20 (1H, m), 3.47(3H, s), 3.67-3.74 (2H, m), 3.85-3.92 (1H, m), 4.03-4.07 (1H, m), 4.56 (2H, s), 4.68 (1H, dd, J=1.2Hz, 10.2Hz), 6.94-7.02 (4H, m), 8.20 (1H, dd, J=1.2Hz, 4.2Hz), 9.00 (1H, d, J=4.2Hz), 9.30 (1H, d, J=1.2Hz), 10.75 (1H, br.s) (CDCl ₃)	421
291	1.22-1.62 (2H, m), 1.44-1.46 (2H, m), 3.10 (1H, dd, J=10.7Hz, 13.0Hz), 3.30 (1H, td, J=2.9Hz, 12.2Hz), 3.51-3.63 (2H, m), 3.58 (3H, s), 4.00 (1H, td, J=11.4Hz, 1.9Hz), 4.16 (1H, dd, J=11.5Hz, 1.8Hz), 4.27 (1H, br.s), 4.71 (1H, dd, J=10.4Hz, 2.0Hz), 7.27 (1H, s), 7.39 (2H, d, J=8.5Hz), 7.62 (2H, d, J=8.5Hz), 8.14 (1H, d, J=5.4Hz), 8.84 (1H, br.s), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl ₃)	449

Compound No.	$^1\text{H-NMR } \delta$	MS(M+1)
292	1.15-1.17 (2H, m), 1.37-1.42 (2H, m), 3.10 (1H, dd, J=10.7Hz, 13.0Hz), 3.30 (1H, td, J=2.9Hz, 12.2Hz), 3.49 (3H, s), 3.52-3.64 (2H, m), 3.59 (3H, s), 4.00 (1H, td, J=11.4Hz, 1.9Hz), 4.16 (1H, dd, J=11.5Hz, 1.8Hz), 4.71 (1H, dd, J=10.4Hz, 2.0Hz), 7.27 (1H, s), 7.39 (2H, d, J=8.5Hz), 7.62 (2H, d, J=8.5Hz), 8.14 (1H, d, J=5.4Hz), 8.51 (1H, br.s), 8.86 (1H, d, J=5.1Hz), 9.27 (1H, d, J=1.2Hz) (CDCl_3)	463

Experiment 1: Inhibitory activity of the medicament of the present invention against P-GS1 phosphorylation by bovine cerebral TPK1

A mixture containing 100 mM MES-sodium hydroxide (pH 6.5), 1 mM magnesium acetate, 0.5 mM EGTA, 5 mM β -mercaptoethanol, 0.02% Tween 20, 10% glycerol, 12 μ g/ml P-GS1, 41.7 μ M [γ - 32 P] ATP (68 kBq/ml), bovine cerebral TPK1 and a compound shown in Table (a final mixture contained 1.7% DMSO deriving from a solution of a test compound prepared in the presence of 10% DMSO) was used as a reaction system. The phosphorylation was started by adding ATP, and the reaction was conducted at 25°C for 2 hours, and then stopped by adding 21% perchloric acid on ice cooling. The reaction mixture was centrifuged at 12,000 rpm for 5 minutes and adsorbed on P81 paper (Whatmann), and then the paper was washed four times with 75 mM phosphoric acid, three times with water and once with acetone. The paper was dried, and the residual radioactivity was measured using a liquid scintillation counter. The results are shown in the table below. The test compound markedly inhibited the P-GS1 phosphorylation by TPK1. The results strongly suggest that the medicaments of the present invention inhibit the TPK1 activity, thereby suppress the A β neurotoxicity and the PHF formation, and that the medicaments of the present invention are effective for preventive and/or therapeutic treatment of Alzheimer disease and the above-mentioned diseases.

Table 5

Compound No.	IC ₅₀ (nM)
6	3.4
24	6.4
50	4.8
70	5.1
100	5.2
091	6.1
202	0.43
210	5.4
220	0.48
231	5.8
237	9.7

Experiment 2 : Inhibitory activity on tau phosphorylation in vivo

Test compound was administrated to male CD-1 mice of 5-6 weeks weighing 25-35 g (Charles River Japan, inc.) at 1, 3, 10, 30 mg/kg p.o. (0.5% Tween/H₂O suspension) and after 1h, mice were decapitated and cortex was promptly removed, followed by being frozen in liquid N₂. Cortex was directly homogenized with 2.3% SDS homogenization buffer (62.5 mM Tris-HCl, 2.3% SDS, 1 mM each of EDTA, EGTA and DTT, protease inhibitor cocktail (sigma P2714) containing 0.2 μ M 4-(2-Aminoethyl)benzenesulfonyl fluoride (AEBSF), 13 μ M bestatin, 1.4 μ M E-64, 0.1 mM leupeptin, 30 nM aprotinin, pH 6.8) and centrifuged at 15000 \times g for 15 min at 4°C. Protein concentrations were determined using DC protein assay kit (BIO-RAD). Supernatants were diluted with sample buffer (62.5 mM Tris-HCl, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue, pH6.8) to adjust the protein concentrations around 0.5 - 2 mg/mg and then boiled for 5 min. 10 μ g of samples were applied on 10% SDS-PAGE mini slab gels and transferred onto PVDF membranes. Membranes were incubated with PBS containing 5% non-fat milk for 1h at r.t. and then probed with pS396 anti-body (BIOSOURCE) over night at 4°C. Anti-rabbit IgG HRP-conjugated anti-body (Promega) was used as secondary

anti-body. Membranes were visualized by ECL kit (Amerasham Bioscience) and detected by LAS1000 (Fuji Photo Film).

Formulation Example

(1) Tablets

The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus.

Compound of Example 1	30 mg
Crystalline cellulose	60 mg
Corn starch	100 mg
Lactose	200 mg
Magnesium stearate	4 mg

(2) Soft capsules

The ingredients below were mixed by an ordinary method and filled in soft capsules.


Compound of Example 1	30 mg
Olive oil	300 mg
Lecithin	20 mg

Industrial Applicability

The compounds of the present invention have TPK1 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal advance of TPK1 such as neurodegenerative diseases (e.g. Alzheimer disease) and the above-mentioned diseases.

CLAIMS

1. A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof;



wherein each symbol is as defined below.

X represents CH or N;

R¹ represents a C₁-C₁₂ alkyl which may be substituted;

R² represents a hydrogen atom, a halogen or a C₁-C₆ alkyl which may be substituted;

R' represents a C₁-C₆ alkyl which may be substituted,

a C₂-C₆ alkenyl which may be substituted,

a C₂-C₆ alkynyl which may be substituted,

a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

a heterocyclic group which may be substituted,

a C₁-C₆ alkoxy which may be substituted,

a C₃-C₆ alkenyloxy which may be substituted,

a C₃-C₆ alkynyloxy which may be substituted,

a C₃-C₇ cycloalkyloxy which may be substituted,

a C₃-C₇ cycloalkenyloxy which may be substituted,

a hydroxyl,

an oxo group,

a halogen,

a nitro, or

a cyano;

q represents 0 or an integer of 1 to 3;

Y represents a C₁-C₆ alkyl which may be substituted,

a C₂-C₆ alkenyl which may be substituted,

a C₂-C₆ alkynyl which may be substituted,

a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

a C₁-C₆ alkoxy which may be substituted,

a C₃-C₆ alkenyloxy which may be substituted,

a C₃-C₆ alkynyloxy which may be substituted,

a C₃-C₇ cycloalkyloxy which may be substituted,

a C₃-C₇ cycloalkenyloxy which may be substituted,

a halogen,

a nitro,

a cyano,

an amino,

a C₁-C₆ alkylamino which may be substituted,

a C₃-C₆ alkenylamino which may be substituted,

a C₃-C₆ alkynylamino which may be substituted,

a N,N-di-C₁-C₆ alkylamino which may be substituted,

a N-C₁-C₆ alkyl-N-C₃-C₆ alkenylamino which may be substituted,

a N-C₁-C₆ alkyl-N-C₃-C₆ alkynylamino which may be substituted,

a N,N-di-C₃-C₆ alkenylamino which may be substituted,

a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylamino which may be substituted,

or

a N,N-di-C₃-C₆ alkynylamino which may be substituted,

p represents 0 or an integer of 1 to 4;

R represents

a carboxyl group,

a 2,3-dihydroindolyl,


a perhydroindolyl,

a perhydroisoindolyl,


a perhydroquinolinyl,

a perhydroisoquinolinyl, or

a formula (1) or (2);



(1)



(2)

In the formula (1), R³ represents a hydrogen atom,

a C₁-C₆ alkyl which may be substituted,

a C₃-C₆ alkenyl which may be substituted,

a C₃-C₆ alkynyl which may be substituted,

a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

a C₆-C₁₀ aryl which may be substituted, or

a heterocyclic group which may be substituted;

R⁴ represents an adamantyl,


a C₃-C₇ cycloalkyl which may be substituted,

a C₃-C₇ cycloalkenyl which may be substituted,

a C₆-C₁₀ aryl which may be substituted,

a heterocyclic group which may be substituted, or

a formula (3)



wherein m represents 0 or an integer of 1 to 4,

Z¹ represents a carbonyl group, a thiocarbonyl group or a sulfonyl group,

R²⁰ and R²¹ are the same or different and each represents a hydrogen atom or a C₁-C₆ alkyl;

R⁷ represents a C₁-C₆ alkyl which may be substituted,

a C₃-C₆ alkenyl which may be substituted,

a C₃-C₆ alkynyl which may be substituted,


a C₃-C₇ cycloalkyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
a C₆-C₁₀ aryl which may be substituted,
a heterocyclic group which may be substituted,
a C₁-C₆ alkoxy which may be substituted,
a C₃-C₆ alkenyloxy which may be substituted,
a C₃-C₆ alkynyloxy which may be substituted,
a C₃-C₇ cycloalkyloxy which may be substituted,
a C₃-C₇ cycloalkenyloxy which may be substituted,
a C₆-C₁₀ aryloxy which may be substituted,
a heterocycle-oxy which may be substituted, or
a group represented by -NRa Rb;

wherein Ra and Rb are the same or different and each represents a hydrogen atom,

a C₁-C₆ alkyl which may be substituted,
a C₃-C₆ alkenyl which may be substituted,
a C₃-C₆ alkynyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
a C₃-C₇ cycloalkyl which may be substituted,
a C₆-C₁₀ aryl which may be substituted,
a heterocyclic group which may be substituted,
a C₁-C₆ alkylcarbonyl which may be substituted,
a C₂-C₆ alkenylcarbonyl which may be substituted,
a C₂-C₆ alkynylcarbonyl which may be substituted,
a C₃-C₇ cycloalkylcarbonyl which may be substituted,
a C₃-C₇ cycloalkenylcarbonyl which may be substituted,
a C₆-C₁₀ arylcarbonyl which may be substituted,
a heterocycle-carbonyl which may be substituted,
a C₁-C₆ alkoxy carbonyl which may be substituted,
a C₃-C₆ alkenyloxycarbonyl which may be substituted,
a C₃-C₆ alkynyloxycarbonyl which may be substituted,
a C₃-C₇ cycloalkyloxycarbonyl which may be substituted,

a C₃-C₇ cycloalkenyloxycarbonyl which may be substituted,
a C₆-C₁₀ aryloxycarbonyl which may be substituted,
a C₁-C₆ alkylsulfonyl which may be substituted,
a C₂-C₆ alkenylsulfonyl which may be substituted,
a C₂-C₆ alkynylsulfonyl which may be substituted,
a C₃-C₇ cycloalkylsulfonyl which may be substituted,
a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
a C₆-C₁₀ arylsulfonyl which may be substituted,
a heterocycle-sulfonyl which may be substituted,
an aminocarbonyl,
a C₁-C₆ alkylaminocarbonyl which may be substituted,
a C₃-C₆ alkenylaminocarbonyl which may be substituted,
a C₃-C₆ alkynylaminocarbonyl which may be substituted,
a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a C₆-C₁₀ arylaminocarbonyl which may be substituted,
a heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,

a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
 a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
 a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted, or
 a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
 a N,N-di-heterocycle-aminocarbonyl which may be substituted;
 or Ra and Rb bind to form a nitrogen containing heterocycle which may contain sulfur atom or oxygen atom together with the adjacent nitrogen atom, or R⁷ and R³ may bind to form a cycle, and further Ra or Rb may binds R³ to form a cycle together with the adjacent nitrogen atom, or R⁷ may form a cycle together with Y;
 In the formula (2), Z represents a carbonyl group, a sulfonyl group, or a group represented by -O-W- wherein W represents a C₁-C₆ alkylene group which may be substituted;
 R⁵ and R⁶ are the same or different and each represents a hydrogen atom,
 a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted, or
 a heterocyclic group which may be substituted;
 or R³ and R⁴, or R⁵ and R⁶ may combine with the adjacent nitrogen atom to form a cyclic amino group represented by the formula (4):




wherein R¹⁰ represents a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,
 a C₃-C₆ alkynyl which may be substituted,
 a C₃-C₇ cycloalkyl which may be substituted,
 a C₃-C₇ cycloalkenyl which may be substituted,
 a C₆-C₁₀ aryl which may be substituted,
 a heterocyclic group which may be substituted,
 a C₁-C₆ alkoxy which may be substituted,
 a C₃-C₆ alkenyloxy which may be substituted,
 a C₃-C₆ alkynyloxy which may be substituted,
 a C₃-C₇ cycloalkyloxy which may be substituted,
 a C₃-C₇ cycloalkenyloxy which may be substituted,
 a C₆-C₁₀ aryloxy which may be substituted,
 a hydroxyl,
 an oxo group,
 a halogen,
 a nitro, or
 a cyano;

r represents 0 or an integer of 1 to n+2;

n represents an integer of 1 to 4;

with the proviso that when n represents 2, then r is not 0;


Q represents a bond, an oxygen atom, sulfur atom or a formula:



wherein R²⁴ represents a hydrogen atom,
 a C₁-C₆ alkyl which may be substituted,
 a C₃-C₆ alkenyl which may be substituted,

a C₃-C₆ alkynyl which may be substituted,
a C₃-C₇ cycloalkyl which may be substituted,
a C₃-C₇ cycloalkenyl which may be substituted,
an C₆-C₁₀ aryl which may be substituted,
a heterocyclic group which may be substituted,
a C₁-C₆ alkylcarbonyl which may be substituted,
a C₂-C₆ alkenylcarbonyl which may be substituted,
a C₂-C₆ alkynylcarbonyl which may be substituted,
a C₃-C₇ cycloalkylcarbonyl which may be substituted,
a C₃-C₇ cycloalkenylcarbonyl which may be substituted,
a C₆-C₁₀ arylcarbonyl which may be substituted,
a heterocycle carbonyl which may be substituted,
a C₁-C₆ alkoxy carbonyl which may be substituted,
a C₃-C₆ alkenyloxycarbonyl which may be substituted,
a C₃-C₆ alkynyloxycarbonyl which may be substituted,
a C₃-C₇ cycloalkyloxycarbonyl which may be substituted,
a C₃-C₇ cycloalkenyloxycarbonyl which may be substituted,
a C₆-C₁₀ aryloxycarbonyl which may be substituted,
a C₁-C₆ alkylsulfonyl which may be substituted,
a C₂-C₆ alkenylsulfonyl which may be substituted,
a C₂-C₆ alkynylsulfonyl which may be substituted,
a C₃-C₇ cycloalkylsulfonyl which may be substituted,
a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
a C₆-C₁₀ arylsulfonyl which may be substituted,
an aminocarbonyl,
a C₁-C₆ alkylaminocarbonyl which may be substituted,
a C₃-C₆ alkenylaminocarbonyl which may be substituted,
a C₃-C₆ alkynylaminocarbonyl which may be substituted,
a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a C₆-C₁₀ arylaminocarbonyl which may be substituted,

a heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
a N,N-di-heterocycle-aminocarbonyl which may be substituted;
or Q further represents a formula:



wherein R^{30} and R^{31} are the same or different and each represents a hydrogen atom,

a C_1 - C_6 alkyl which may be substituted,

a C_3 - C_6 alkenyl which may be substituted,

a C_3 - C_6 alkynyl which may be substituted,

a C_3 - C_7 cycloalkyl which may be substituted,

a C_3 - C_7 cycloalkenyl which may be substituted,

a C_6 - C_{10} aryl which may be substituted,

a heterocyclic group which may be substituted,

a C_1 - C_6 alkyloxycarbonyl which may be substituted,

a C_3 - C_6 alkenyloxycarbonyl which may be substituted,

a C_3 - C_6 alkynyloxycarbonyl which may be substituted,

a C_3 - C_7 cycloalkyloxycarbonyl which may be substituted,

a C_3 - C_7 cycloalkenyloxycarbonyl which may be substituted,

a C_6 - C_{10} aryloxycarbonyl which may be substituted,

a C_1 - C_6 alkoxy which may be substituted,

a C_3 - C_6 alkenyloxy which may be substituted,

a C_3 - C_6 alkynyloxy which may be substituted,

a C_3 - C_7 cycloalkyloxy which may be substituted,

a C_3 - C_7 cycloalkenyloxy which may be substituted,

a C_6 - C_{10} aryloxy which may be substituted,

a heterocycl-oxy which may be substituted,

an amino,

a C_1 - C_6 alkylamino which may be substituted,

a C_3 - C_6 alkenylamino which may be substituted,

a C_3 - C_6 alkynylamino which may be substituted,

a C_3 - C_7 cycloalkylamino which may be substituted,

a C_3 - C_7 cycloalkenylamino which may be substituted,

an C_6 - C_{10} arylamino which may be substituted,

a heterocycle-amino which may be substituted,
a N,N-di-C₁-C₆ alkylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₆ alkenylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₆ alkynylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylamino which may be substituted,
a N-C₁-C₆ alkyl-N-heterocycle-amino which may be substituted,
a N,N-di-C₃-C₆ alkenylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylamino which may be substituted,
a N-C₃-C₆ alkenyl-N-heterocycle-amino which may be substituted,
a N,N-di-C₃-C₆ alkynylamino which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylamino which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylamino which may be substituted,
a N-C₃-C₆ alkynyl-N-heterocycle-amino which may be substituted,
a N,N-di-C₃-C₇ cycloalkylamino which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylamino which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylamino which may be substituted,
a N-C₃-C₇ cycloalkyl-N-heterocycle-amino which may be substituted,
a N,N-di-C₃-C₇ cycloalkenylamino which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylamino which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-heterocycle-amino which may be substituted,
a N,N-di-C₆-C₁₀ arylamino which may be substituted,
a N-C₆-C₁₀ aryl-N-heterocycle-amino which may be substituted,
a N,N-diheterocycle-amino which may be substituted,
a C₁-C₆ alkylcarbonyl which may be substituted,
a C₂-C₆ alkenylcarbonyl which may be substituted,

- a C₂-C₆ alkynylcarbonyl which may be substituted,
- a C₃-C₇ cycloalkylcarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylcarbonyl which may be substituted,
- a C₆-C₁₀ arylcarbonyl which may be substituted,
- a heterocycle-carbonyl which may be substituted,
- a C₁-C₆ alkylsulfonyl which may be substituted,
- a C₂-C₆ alkenylsulfonyl which may be substituted,
- a C₂-C₆ alkynylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkylsulfonyl which may be substituted,
- a C₃-C₇ cycloalkenylsulfonyl which may be substituted,
- a C₆-C₁₀ arylsulfonyl which may be substituted,
- an aminocarbonyl,
- a C₁-C₆ alkylaminocarbonyl which may be substituted,
- a C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₁-C₆ alkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ alkynylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
- a N-C₁-C₆ alkyl-N-heterocycle-aminocarbonyl which may be substituted,
- a N,N-di-C₃-C₆ alkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₆ alkynylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
- a N-C₃-C₆ alkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,

a N-C₃-C₆ alkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₆ alkynylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₆ alkynyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₃-C₇ cycloalkylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₃-C₇ cycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₆-C₁₄ dicycloalkenylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₃-C₇ cycloalkenyl-N-heterocycle-aminocarbonyl which may be substituted,
a N,N-di-C₆-C₁₀ arylaminocarbonyl which may be substituted,
a N-C₆-C₁₀ aryl-N-heterocycle-aminocarbonyl which may be substituted, or
a N,N-di-heterocycle-aminocarbonyl which may be substituted.

2. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein R² is a hydrogen atom or a halogen.

3. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein R² is a hydrogen atom.

4. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein R¹ is methyl group.

5. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein q is 0.

6. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein Y is a C₁-C₆ alkyl which may be substituted, a C₁-C₆ alkoxy which may be substituted, a halogen, a nitro, a cyano, an amino, a C₁-C₆ alkylamino which may be substituted or a N,N-di-C₁-C₆ alkylamino which may be substituted.

7. The compound, an optically active isomer thereof, or a pharmaceutical

acceptable salt thereof according to claim 1, wherein R represents a formula (1).

8. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein R represents a formula (2).

9. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 7, wherein R⁴ represents a formula (3).

10. The compound, an optically active isomer thereof, or a pharmaceutical acceptable salt thereof according to claim 1, wherein R¹ is methyl group, R² is hydrogen atom, and p is 0.

11. A compound according to claim 1 selected from the group consisting of:
 2-(2-(4-((4-Pyrrolidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-((4-Piperidin-1-yl)piperidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-(N-Cyclohexyl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-(4-(2-Hydroxyethyl)piperazin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-((3-Pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-(3-N-acetyl-N-methylaminopyrrolidin-1-yl)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
 2-(2-[4-(3-Hydroxyazetidin-1-yl)phenyl]morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,
 N-(4-(4-(1-Methyl-6-oxo-4-(pyridin-4-yl)-1,6-dihydropyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,
 N-(4-(4-(1,6-Dihydro-1-methyl-6-oxo-4,4'-bipyrimidin-2-yl)morpholin-2-yl)phenyl)-acetamide,
 2-(2-(4-(2-Pyridylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,
 2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-Cyclopropylcarbonylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-Tetrahydrofuran-3-ylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

2-(2-(4-(N-Tetrahydrofuran-3-yl-N-methylamino)phenyl)morpholin-4-yl)-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one,

N-{4-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,

N-{4-[(2S)-4-(1-Methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}-2-pyrrolidin-1-ylacetamide,

N2,N2-Dimethyl-N1-{4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}glycinamide,

Methyl {4-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,

Ethyl {4-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}carbamate,

N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide,

N-{4-Methoxy-3-[(2S)-4-(1-methyl-6-oxo-1,6-dihydro-4,4'-bipyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide, and

N-{3-[(2S)-4-(1-Methyl-6-oxo-4-pyridin-4-yl-1,6-dihydropyrimidin-2-yl)morpholin-2-yl]phenyl}acetamide,

an optically active isomer thereof, or a pharmaceutically acceptable salt thereof.

12. A medicament comprising as an active ingredient a substance selected from the group consisting of the compound represented by the formula (I) and an optically active isomer thereof, or a pharmaceutically acceptable salt thereof according to claim 1.

13. A tau protein kinase 1 inhibitor selected from the group consisting of the compound represented by the formula (I) and an optically active isomer thereof, or a pharmaceutically acceptable salt thereof according to claim 1.

14. The medicament according to claim 12 which is used for preventive

and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity.

15. The medicament according to claim 12 which is used for preventive and/or therapeutic treatment of a neurodegenerative disease.

16. The medicament according to claim 15, wherein the disease is selected from the group consisting of Alzheimer disease, ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism, dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

17. The medicament according to claim 12, which is used for preventive and/or therapeutic treatment of a disease selected from the group consisting of non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and a virus-induced tumor.

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/JP2005/017080

A. CLASSIFICATION OF SUBJECT MATTER
C07D413/04 C07D413/14 A61K31/5377 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/027080 A (MITSUBISHI PHARMA CORPORATION; SANOFI-SYNTHELABO; UEHARA, FUMIAKI; ARI) 3 April 2003 (2003-04-03) cited in the application page 5, line 11 - page 8, line 7; compounds B138-B140, B259, B260, B275	1-17
X	WO 03/037888 A (MITSUBISHI PHARMA CORPORATION; SANOFI-SYNTHELABO; UEHARA, FUMIAKI; ARI) 8 May 2003 (2003-05-08) cited in the application page 5, line 11 - page 8, line 7; compounds B138-B140, B274, B275, B283, B288, B289	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

28 November 2005

05/12/2005

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Usuelli, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2005/017080

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03027080	A	03-04-2003	BR 0212893 A	03-08-2004
			CA 2460177 A1	03-04-2003
			CN 1555367 A	15-12-2004
			EP 1427709 A1	16-06-2004
			HU 0401898 A2	28-12-2004
			JP 2005510472 T	21-04-2005
			NO 20041604 A	17-06-2004
			US 2005130967 A1	16-06-2005
WO 03037888	A	08-05-2003	BR 0212892 A	03-08-2004
			CA 2460121 A1	08-05-2003
			CN 1556804 A	22-12-2004
			EP 1427720 A1	16-06-2004
			HU 0401900 A2	28-12-2004
			JP 2005510506 T	21-04-2005
			NO 20041600 A	16-06-2004
			US 2005090490 A1	28-04-2005